

Professor R L Powles CBE, MD BSc FRCP FRCPath

BIBLIOGRAPHY

1967 - PRESENT

1. Powles, R.L., and Malpas, J.S. Guillain-Barren associated with chronic lymphatic leukaemia. *Brit Med J* 1967; 3: 286-287.
2. Powles, R.L., Shinebourne, E., and Hamer, J. Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy. *Thorax* 1969; 24 (5); 616-618.
3. Powles, R.L., Smith, C., Kohn, J., and Hamilton Fairley, G. Method of removing abnormal protein rapidly from patients with malignant paraproteinaemias. *Brit Med J* 1971; 3: 664-667.
4. Powles, R.L., Balchin, L.A., Hamilton Fairley, G., and Alexander, P. Recognition of leukaemia cells as foreign before and after autoimmunisation. *Brit Med J* 1971;1: 486-489.
5. Powles, R.L., Balchin, L.A., Currie, G.A., and Alexander, P. Specific autostimulating factor released by lymphocytes. *Nature* 1971; 231, (5299): 161-164.
6. Powles, R.L. Uses of the NCI/IBM cell separator. *Brit J Haem* 1971; 21, 3: 361-362.
7. Powles, R.L. Recognition of leukaemic cells as foreign before and after autoimmunization. *Year Book of Cancer*. Pub: Year Book Medical Publishers Inc., Chicago, USA. 1972. 16: 349.
8. Alexander, P., and Powles, R.L. The possible occurrence in vivo of the autostimulating factor (ASF) for lymphocytes. *March of Dimes, National Foundation original article series, birth defects: the long-term lymphocyte in human genetics*. 1973; 9: 111-128.
9. Crowther, D., Powles, R.L., Bateman, C.J.T., Beard, M.E.J., Gauci, C.L., Wrigley, P.F.M., Malpas, J.S., Hamilton Fairley, G., and Bodley Scott, R. Management of adult acute myelogenous leukaemia. *Brit Med J* 1973; 1: 131-137.
10. Gauci, C.L., Crowther, D., Powles, R.L. Thioguanine in the treatment of leukaemia. In: *Leukaemien und maligne lymphome*. Pub: Urban and Schwarzenberg, Munchen, Berlin and Wein, 1973; 124.
11. Grant, C., and Powles, R.L. The cryopreservation of immunocompetent cells. *Cryobiology* 1973; 10, 4: 290-294.
12. Hamilton Fairley, G., Crowther, D., and Powles, R.L., et al. Circulating lymphoid cells in Hodgkin's Disease. *National Cancer Institute Monograph*, 1973; 36: 95-98
13. Powles, R.L. Immunotherapy of acute myelogenous leukaemia in man. *National Cancer Institute Monograph*, 1973; 39: 243-247
14. Powles, R.L. Immunotherapy for acute myelogenous leukaemia. *Brit J Cancer* 1973; 28 (1): 262-265.
15. Powles, R.L., Immunotherapy. In: *Leukaemien und maligne lymphome*. Pub: Urban and Schwarzenberg, Munchen, Berlin and Wein 1973; 714.
16. Powles, R.L., Crowther, D., Bateman, C.J.T., Beard, M.E.J., McElwain, T.J., Russell, J., Lister, T.A., Whitehouse, J.M.A., Wrigley, P.F.M., Pike, M., Alexander, P., and Hamilton Fairley, G. Immunotherapy for acute myelogenous leukaemia. *Brit J Cancer* 1973; 28: 365-376.

17. Powles, R.L., Balchin, L.A., Smith, C., and Grant, C.K. Some properties of cryopreserved acute leukaemia cells. *Cryobiology* 1973; 10 (4): 282-289.
18. Powles, R.L. The treatment of acute myelogenous leukaemia in adults using chemotherapy and immunotherapy. *Year Book Cancer Res.*, (Amsterdam), 1973, 22: 45-50.
19. Powles, R.L. Immunotherapy for acute myelogenous leukaemia. In: *Proceedings of the 10th Canadian Cancer Research Conference, 1973*. Pub: University of Toronto Press; 1974:130-135.
20. Powles, R.L., McElwain, T.J., Alexander, P., Crowther, D., Hamilton Fairley, G., and Pike, M. Immunotherapy of acute myeloblastic leukaemia in man. In: *Recent results in Cancer Res.*, Ed. G. Mathe and R. Weiner. Pub: Springer-Verlag, Berlin-Heidelberg-New York 1974; 47: 449-454.
21. Begent, R.H., Birch, J.A., Clink, H.M., Hockley, A., Jameson, B., Kay, H.A.M., Klouda, P.T., Lawler, S., Lawson, D.S., Lynch, S.J., McElwain, T.J., Powles, R.L., Russell, J.A., Summersgill, B. Bone marrow aplasia after infectious hepatitis treated by bone marrow transplantation. *Brit Med J* 1974; 1: 363-364.
22. Powles, R.L. Active specific immunotherapy for acute myelogenous leukaemia. In: *The role of immunological factors in viral and oncogenic processes*. Pub: Johns Hopkins Medical Journal 1974; Suppl 3: 333-341.
23. Powles, R.L. Immunotherapy for acute myelogenous leukaemia. *Irish Journal of Medical Science* 1974; July Suppl: 10-19.
24. Atkinson, K., Wells, D.G., Clink, H.McD., Kay, H.E.M., Powles, R.L., and McElwain, T.J. Adult acute leukaemia. *Brit. J. Cancer* 1974; 30: 272-278.
25. Powles, R.L. Immunotherapy for acute myelogenous leukaemia using irradiated and unirradiated leukaemia cells. *Cancer* 1974; 34 (4): 1558-1562.
26. Powles, R.L. Tumour associated antigens in acute leukaemia. In: *Advances in acute leukaemia*. Ed: Cleton, F.J., Crowther, D., and Malpas, J.S. Pub: ASP-Biological and Medical Press B.V. (North Holland Division) 1974; 115-141.
27. Powles, R.L., Lister, T.A., Oliver, R.T.D., Russell, J., Smith, C., Kay, H.E.M., McElwain and Hamilton Fairley, G. Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy. *Brit Med J* 1974; 4: 375-379.
28. Powles, R.L. Treatment of acute leukaemia. In: *Progress in chemotherapy (Antibacterial antiviral antineoplastic)*. Ed: G.K. Daikos, Athens 1974; 3.
29. Powles, R.L., Lister, T.A., Crowther, D., McElwain, T.J., Alexander, P., Fairley, G.H. Immunotherapy for acute myelogenous leukaemia. In: *Comparative Leukaemia Research 1973*, Ed: Y. Ito and R.M. Dutcher, Univ. of Tokyo Press 1995; 737-749.
30. Powles, R.L., Crowther, D., Bateman, C.J.T., Beard, M.E.J., McElwain, T.J., Russell, J., Lister, T.A., Whitehouse, J.M.A., Wrigley, P.F.M., Pike, M., Alexander, P., and Hamilton Fairley, G. Immunotherapy for acute myelogenous leukaemia. In: *Proceedings XIth*

- International Cancer Congress, Pub: Excerpta Medica, Ed: P. Bucalossi, V. Veronesi and N Cascinelli, 1975; 6: 401-412.
31. Powles, R.L., et al. Immunotherapy for acute myelogenous leukaemia. *Bibliotheca Haematologica* (Basel), 1975; 40: 739.
 32. Russell, J.A., Powles, R.L. Neuropathy due to cytosine arabinoside. *Brit Med J* 1975; 4: 652-653.
 33. Klouda, P.T., Lawler, S.D., Powles, R.L., Oliver, R.T.D., and Grant, C.K. HLA antibody response in patients with acute myelogenous leukaemia treated by immunotherapy. *Transplantation* 1975; 19 (3): 245-249.
 34. Powles, R.L., Russell, J., and Chapuis, B. Immuno-therapie des leucemies myeloblastiques. *Med et Hyg.* 1975; 33 606-607.
 35. Oliver, R.T.D., Lister, T.A., Russell, J., and Powles, R.L., Leucopheresis in the management of patients with acute leukaemia. Leucocytes: separation, collection and transfusion. Ed: Goldman, J.M., and Lowenthal, R.M. Pub: Academic Press Limited 1975; 471-476.
 36. Sell, K., Ben-David, A., Ness-Ziona, and Strong, D.M. (Powles, R.L., a contributor). Lymphocyte and target cell cryopreservation. In: *Transplantation proceedings*. Pub: Grune and Stratton, 1975; VII: 1, (Supple 1).
 37. Powles, R.L., Russell, J., Oliver, T., Lister, T.A., Hamilton Fairley, G., and Alexander, P. Immunotherapy for acute myelogenous leukaemia. A possible mechanism of action. In: *Proceedings XIth International Cancer Congress*. Published by Excerpta Medica 1996. Ed: P. Bucalossi, V. Veronesi and N. Cascinelli.
 38. Powles, R.L. Immunotherapy for acute myelogenous leukemia: A possible mechanism of action. In: *Erkrankungen der myelopoese-leukamiekongress*. Pub: Urban and Schwarzenberg. Ed: A. Stacher and P. Hocker 1976; 258-260.
 39. Powles, R.L., and Toy, J.L. The effect of immuno-therapy on survival of patients with acute myelogenous leukaemia after relapse. *Haematologia* 1976; 10 (1): 5-9.
 40. Russell, J.A., and Powles, R.L. White cell therapy. In: *Clinics in Haematology*, Pub: W.B. Saunders Co. Ltd., London. Ed: J. Cash, 1976; 5 (1): 81-93.
 41. Powles, R.L. Immunotherapy in the management of acute leukaemia. *Annotation, Brit J Haem* 1976; 32, 2: 145-149.
 42. Powles, R.L. Immunologic manoeuvres in the management of acute leukaemia. In: *Medical Clinics of North America* 1976; 463-472.
 43. Powles, R.L., and Russell, J.A. The place of immunological methods of treatment in the management of acute leukaemia. In: *Modern Trends in Human Leukaemia (Part II)*. Pub: Lehmanns-Verlag. Ed: Rolf Neth, R Gallo, K Mannweiler and William C. Mahoney, 1976; 297-304.

44. Russell, J.A., and Powles, R.L. A practical guide to granulocyte transfusion therapy. *J Clin Path* 1976; 29: 369-379.
45. Powles, R.L., and Russell, J.A. The place of immuno-logical methods of treatment in the management of acute leukaemia. In: *75 frontiers on leukaemia total care*. Ed: J Astaldi, Rome, 1976.
46. Russell, A., Chapuis, B., and Powles, R.L. Various uses of BCG and allogeneic acute leukaemia cells to treat patients with acute myelogenous leukaemia. *Cancer Immunol and Immunother* 1976; 1: 87-91.
47. Russell, J.A., Powles, R.L., and Oliver, R.T.D. Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. *Brit Med J* 1976; 1: 1508.
48. Powles, R.L., Russell, J.A. Toy, J.L., Mand Chapuis, B. New methods of assessing treatment success in acute myelogenous leukaemia. In: *BCG in Cancer Immunotherapy*. Pub: Grune and Stratton. Ed: Gilles Lamoureux, R. Turcotte, and V. Portelance, 1976; 279-284.
49. Toy, J.L., and Powles, R.L. Multiple myeloma. *Nursing Mirror*, September 30th 1976: 50-53.
50. Smith, I.E., Powles, R.L., and McElwain, T.J. (1976). Causes of early death in acute leukaemia. *Lancet* 1976; ii: 574-575.
51. Powles, R.L. Pitfalls in analysis of survival in clinical trials. *Biomedicine* 1976; 24: 327-328.
52. Chapuis, B., Cocks, P., and Powles, R.L. In vitro proliferative growth of acute myeloid leukaemia (AML) cells cryopreserved for active specific immunotherapy. *Cryo-immunology*, Pub: INSERM 1976; 62: 347-354.
53. Smith, I.E., Powles, R.L., et al. Early deaths in acute myelogenous leukaemia. *Cancer* 1977; 39: 1710-1717.
54. Russell, J.A., and Powles, R.L. Studies involving the use of chemotherapy and immunotherapy in the management of patients with acute myelogenous leukaemia. *Proceedings of the international meeting on immuno-proliferative disease*. Minerva Medica, 1977; 68: 3528-3532.
55. Cocks, P., Powles, R.L., Chapuis, B., Alexander, P. Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia. *Brit J Cancer* 1977; 35: 273-279.
56. Gordon, M.Y., Powles, R.L., and Douglas, I.D.C. Colony forming ability of marrow from patients receiving immunotherapy during chemotherapy induced remission in acute myeloid leukaemia. *J Clin Path* 1977; 30: 70-75.
57. Powles, R.L., Russell, J., Lister, T.A., Oliver, T., Whitehouse, J.M.A., Malpas, J., Chapuis, B.B., Crowther, D., and Alexander, P. Immunotherapy for acute myelogenous leukaemia:

- A controlled clinical study 2.5 years after entry of the last patient. *Brit J Cancer* 1977; 35: 265-272.
58. Chapuis B, Summersgill BM, Cocks P, Howard P, Lawler SD, Alexander P and Powles RL. Test for cryopreservation efficiency of human acute myelogenous leukaemia cells relevant to clinical requirements. *Cryobiology* 1977; 14: 637-648.
 59. Powles RL. Should we be bone marrow grafting? *Cancer Topics* 1977; 1 (5): 5-7.
 60. Powles RL and Toy JL. Blood cell separators. *Brit J Haem* 1977; 53 (4): 668.
 - 60(a) Atkinson K, Clink H, Lawler S, Lawson DN, McElwain TJ, Peckham MJ, Powles RL, Mann J R Jnr, Cameron AH, Arthuk K. Encephalopathy following bone marrow transplantation. *European Journal of Cancer* , 1977; 13: 623-625
 61. Russell JA, Toy JL and Powles RL. Plasma exchange in malignant paraproteinaemias. *Exp Haemat* 1977; 5: 105-116.
 62. Powles RL. Boosting Immune Defences. *General Practitioner*, 18 March 1977: 30.
 63. Powles RL, Russell JA, Selby PJ, Prentice HG, Jones DR, McElwain TJ and Alexander P. Maintenance of remission in acute myelogenous leukaemia by a mixture of BCG and irradiated leukaemia cells. *Lancet* 1977; ii 1107 -1110.
 64. The Royal Marsden Hospital Bone Marrow Transplantation Team. Failure of syngeneic bone marrow graft without pre-conditioning in post-hepatitis marrow aplasia. *Lancet* 1977;ii 742-744.
 65. Powles RL, Russell J, Oliver T, Whitehouse JMA, Chapuis B, Malpas J, Crowther D and Alexander P. Immunotherapy for acute myelogenous leukaemia. Analysis of a controlled clinical study 2.5 years after entry of the last patient. Pub: Raven Press. Ed: W Terry. *Immunotherapy of Cancer: Present status of trials in man.* 1978; 315-327.
 66. Powles RL. A biological approach to the management of acute leukaemia in man. In: *Immunological Engineering*, Pub: MTP Press Ltd, Jirsch DW, 1978: 1-34.
 67. Powles RL. Immunotherapy. In: *Oncology for Nurses and Health Care Professionals*. Pub: George Allen and Unwin. Ed: Robert Tiffany. 1978; 1: 293-325.
 68. Chapuis B, Powles RL and Alexander P. Inability to demonstrate lytic antibodies to autologous leukaemia cells in the sera from remission patients with acute myelogenous leukaemia treated with active specific immunotherapy. *Clinical and Experimental Immunology* 1978; 32: 253-258.
 69. Russell JA and Powles RL. The relationship between serum viscosity, hypervolaemia and clinical manifestations associated with circulating paraprotein. *Brit J Haem* 1978; 39: 163-175.
 70. Alexander P and Powles RL. Immunotherapy of human acute leukaemia. *Clinics in Haematology* 1978; 7, 2:275-294.

71. Russell JA, Fitzharris BM, Corringham R, Darcy DA and Powles RL. Plasma exchange vs. peritoneal dialysis for removing Bence Jones protein. *Brit Med J* 1978; 2: 1397.
72. Powles RL and Payne P. The use of the NAG random number generating routines in simulated survival studies. *Biomedicine, Special Issue*, 1978; 28: 53-55.
73. Powles RL, Barrett AJ, Clink H, Kay HEM, Sloane J, McElwain TJ (1978). Cyclosporin A for the treatment of graft versus host disease in man. *Lancet* 1978 ii: 1327-1331.
74. Bakowski MT, Prentice HG, Lister TA, Malpas JS, McElwain TJ and Powles RL. Limited activity of ICRF-159 in advanced acute leukaemia. *Cancer Treat. Rep.* 1979; 63: 1; 127-129.
75. Kay HEM, Powles RL, Sloane JP and Farthing JG. (1979). Cyclosporin A in human bone marrow grafts. MUNICH.
76. Barratt A, Barrett AJ, Powles RL. Total body irradiation and marrow transplantation for acute leukaemia. The Royal Marsden Hospital Experience. *Pathologie Biologie* 1979; 27 (6): 357-359.
77. The Westminster Hospital, Hammersmith Hospital and Royal Marsden Hospital Bone Marrow Transplant Teams. Report compiled by AJ Barrett. Allogeneic bone marrow transplantation for severe aplastic anaemia - The London Experience. *Clin and Lab Haem* 1979; 1: 95-107.
78. Kay HEM, Powles RL, Sloane JP and Farthing MG. (1979). Cyclosporin A in human bone marrow grafts. ST. MORITZ.
79. Palu G, Selby P, Powles RL and Alexander P. Spontaneous regression of human acute myeloid leukaemia xenografts and phenotypic evidence for maturation. *Brit J Cancer* 1979; 40: 731-735.
80. Russell J, Palu G, Selby P and Powles RL. The use of cultured cells for immunotherapy of acute myelogenous leukaemia. In: *Adjuvant Therapy of Cancer II*. Ed: SE Jones and SE Salmon, New York, Pub: Grune and Stratton, 1979; 199-203.
81. Powles RL, Selby P, Palu G, Morgenstern G, McElwain TJ, Clink HM and Alexander P. The nature of remission in acute myeloblastic leukaemia. *Lancet* 1979; ii: 674-676.
82. Powles RL. The application of immunotherapy to the treatment of cancer. *Pharmac Ther* 1979; 4: 281-306.
83. Powles RL. Immunotherapy of ANLL. In: *Therapy of acute leukaemia. Proceedings of 2nd International Symposium Rome, 7-10th December 1977*. Ed: F Mandelli, Pub: Lombardo, 1979; 777-781.
84. Selby PJ, Powles RL, Jameson Beryl, Kay HEM, Watson JG, Thornton R, Morgenstern G, Clink HM, McElwain TJ, Prentice HG, Corringham R, Ross MG, Hoffbrand AV and Brigden D. Parenteral acyclovir therapy for herpesvirus infections in man. *Lancet* 1979; ii: 1267-1270.85.

85. Palu G, Powles RL, Selby P, Summersgill BM and Alexander P. Patterns of maturation in short-term culture of human acute myeloid leukaemic cells. *Brit J Cancer* 1979; 40: 719-730.
86. Cuckle H, Galton DAG and Peto R. Report prepared for the Medical Research Council's Working Party on Leukaemia In Adults on the Sixth trial (Chemotherapy) Chemotherapy for acute myeloid leukaemia in adults. (Dr R Powles RL being a member of the Working Party.) *Brit J Cancer* 1979; 39: 69-86.
87. McElwain TJ, Clink HM, Jameson B, Kay HEM and Powles RL. Central nervous system involvement in acute myelogenous leukaemia. In: CNS complications of malignant disease. Ed: JMA Whitehouse and HEM Kay. Pub: MacMillan, 1979; pp 91-96.
88. Powles RL, Palu G and Raghavan D. Curability of acute leukaemia. In: Topical Reviews in Haematology. Ed: S Roath, Pub: John Wright and Sons Ltd, London, 1980; pp 186- 219.
89. SLOANE J and Powles RL. Graft versus host disease in recipients of syngeneic bone marrow. *Lancet* 1980 i: 253.
90. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett, A, Jameson Beryl, Sloane J, Lawler SD, Kay HEM, Lawson D, McElwain TJ and Alexander P. Cyclosporin A to prevent GVHD in man after allogeneic bone marrow transplantation. *Lancet* 1980; i: 327-329.
91. SLOANE JP, Farthing MJG and Powles RL. Histopathological changes in the liver after allogeneic bone marrow transplantation. *Journal of Clin Path* 1980; 33: 344-350.
92. Powles RL, Morgenstern G, Clink HM, Hedley D, Bandini G, Lumley H, Watson JG, Lawson D, Spence D, Barrett A, Jameson B, Lawler S, Kay HEM, McElwain TJ. The place of bone marrow transplantation in acute myelogenous leukaemia. *Lancet* 1980; i: 1047-1050.
93. Kay HEM, Powles RL, Lawler SD, Clink HM. Cost of bone marrow transplants in acute myeloid leukaemia. *Lancet* 1980; i: 1067-1069.
94. Powles RL. Acute leukaemia in adults. *Medicine*, 1980; 29: 1482-1485.
95. Chessells JM and Powles RL. Acute leukaemia. *Medicine*, 1980; 29: 1477-1478.
96. Selby PJ, Jameson Beryl, Watson JG, Morgenstern G, Powles RL, Kay HEM, Thornton R, Clink HM, McElwain TJ, Prentice HG, Ross MG, Corringham R, Hoffbrand AV, Brigden D. Traitment parenteral par l'acyclovir des infections a herpes virus chez l'homme. *Le Journal International de Medecine* 1980; 2, 8: 709-714.
97. Barrett AJ, Blanco A, Powles RL. An in vivo counterpart of HLA restricted H-Y killing. *Transplantation* 1980; 29 (4): 335- 37.
98. Tobias JS, Morgenstern G, Bloom HJG, Powles RL. Doxorubicin in pregnancy. *Lancet* 1980; i: 776.
99. Powles RL and Morgenstern GR. Bone marrow transplants in leukaemia. *Lancet* 1980; ii: 200.

100. Palu G, Watson JG and Powles RL. L'acicloguanosina nel trattamento delle infezioni da virus erpetici nell'uomo. Atti della Soc. Italiana di Microbiol. XIX Congresso Nazionale. 1980. Catania 5-8 giugno.
101. Powles RL. Mismatch bone marrow transplantation in leukaemia. Abstract Brit. Soc. Haem. November 1980. Brit J Haem 1991; 47 (4) 627
102. Powles RL. Cyclosporin A. Cancer Topics 1980, 2 11; 2-3.
103. Powles RL. Recent trends in the treatment of acute leukaemia. Indian Journal of Cancer Chemo 1980; 3 (1): 1-2.
104. Morgenstern G, and Powles RL. Allogeneic bone marrow transplantation for acute myeloid leukaemia in first remission. Haematology and Blood Transfusion, 26. Modern Trends in Human Leukemia IV, Ed: Neth, Gallo, Graff, Mannweiler, Winkler. Pub: Springer Verlag. Berlin Heidelberg, 1981; 26: 139-142.
105. Powles RL. The management of acute leukaemia. Postgraduate Doctor - Middle East 1981; 4 (5): 224-231.
106. Powles RL. Bone marrow transplantation for acute myeloid leukaemia. Lyon Medical, 30 October 1981; 235-236.
107. Jones DR, Powles RL, Machin D, Sylvester RJ. On estimating the proportion of cured patients in clinical studies. Biometrie-Praximetrie 1981; 21: 1-11.
108. Barrett A, Depledge MH, Morgenstern G, Powles RL, Sloane JP and Watson G. Late effects of total body irradiation in man. In: Proceedings of EULEP Symposium, Munich, August 1981.
109. Powles RL. and Morgenstern G. Cyclosporin A for matched and mismatched bone marrow transplantation in man. In: Transplantation and Clinical Immunology, Proceedings 13th International Course, Lyon. Ed: JL Touraine, J Traeger, H Betuel, et al. Excerpta Medica, Amsterdam, 1981; XIII: pp 41-43.
110. Morgenstern GR, Lumley H, Watson JG and Powles RL. Cyclosporin A prophylaxis following matched and mismatched grafts. In: Proceedings of the 5th European Symposium on Bone Marrow Transplantation, Courchevel, March 1981. Bone Marrow Transplantation in Europe. Ed: Touraine, Gluckman, Griscell. Pub: Excerpta Medica, Amsterdam, 1981; II: 156-159.
111. Lumley H, Powles RL, Morgenstern GR, Clink HM and McElwain TJ. Pseudosyngeneic transplantation as a treatment for recurrent leukaemia following allogeneic bone marrow transplantation. In: Proceedings of the 5th European Symposium on Bone Marrow Transplantation, Courchevel, March 1981. Bone Marrow Transplantation in Europe. Ed: Touraine, Gluckman, Griscelli. Pub: Excerpta Medica, Amsterdam, 1981; II: 8-10.

112. Watson JG, Morgenstern GR, Powles RL and the Royal Marsden Hospital Marrow Transplant Team. Marrow transplantation in leukaemia: The Royal Marsden Hospital recent experience. In: Proceedings of the 5th European Symposium on Bone Marrow Transplantation, Courchevel, March 1981. Bone Marrow Transplantation in Europe Vol. II. Ed: Touraine, Gluckman, Griscelli, Pub: Excerpta Medica, Amsterdam, 1981: pp 8-10.
113. Forbes Penelope, Dobbie D, Powles RL and Alexander P. Maturation of human peripheral blood leukaemic cells in short term culture. *Hematology and Blood Transfusion*, Vol. 26. Modern Trends in Human Leukaemia IV. Ed: Neth, Gallo, Graaf, Mannweiler, Winkler. Pub: Springer Verlag, Berlin Heidelberg, 1981.
114. Watson JG, Powles RL, Clink HM, Jameson B, Kay HEM, Lumley H, Morgenstern GR. Acute myeloid leukaemia: comparison of support required during initial induction of remission and marrow transplantation in first remission. *Lancet* 1981; ii: 957-959.
115. Watson JG, Jameson Beryl, Powles RL, McElwain TJ, Lawson DN, Judson I, Morgenstern GR, Lumley Hilary, Kay HEM. Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia. *Lancet* 1982; i: 6-9.
116. Powles RL and Morgenstern GR. Allogeneic bone marrow transplantation using mismatched family donors. In: "Cyclosporin A" Proceedings of an International Conference on cyclosporin A. Ed: D White, R Powles, P McMasters and A Davis. Pub: Elsevier, 1982: 539-543
117. Powles RL and Morgenstern GR. Cyclosporin A to prevent graft versus host disease in man following HLA/MLC matched allogeneic bone marrow transplantation. In: "Cyclosporin A" Proceedings of an International Conference on cyclosporin A. Ed: D White, R Powles, P McMasters and A Davis. Pub: Elsevier, 1982:485-489
118. Hedley D, Powles RL, and Morgenstern GR. Toxicity of Cyclosporin A in patients following bone marrow transplantation. In: "Cyclosporin A" Proceedings of an International Conference on cyclosporin A. Ed: D White, Powles RL, P McMasters and A Davis. Pub: Elsevier, 1982; 553-558
119. Attridge SR, Powles RL, Hedley D and Bunnett MA. Serum Cyclosporin A levels in bone marrow transplant patients. In: "Cyclosporin A" Proceedings of an International Conference on cyclosporin A. Ed: D White, R Powles, P McMasters and A Davis. Pub: Elsevier, 1982: 545-551.
120. Powles TJ, Coombes RC, Depledge M, Muindi J and Powles RL. Prostaglandin administration to patients with cancer. *Prostaglandins & Cancer; First International Conference*. Pub: Alan R Liss Inc. Ed: T Powles , R Buckman, K Honn, P Ramwell, 1982: 825-830.
121. Guyotat D, Morgenstern GR, Powles RL. Cyclosporin A as prophylaxis against graft-versus-host disease. *Brit Med J* 1982; 285: 1424.
122. Powles RL, Watson JG, Morgenstern GR, Kay HEM. Bone marrow transplantation in leukaemia remission. *Lancet* 1982; i: 336-337.

123. Powles RL, Morgenstern GR, Leigh M, Filshie J, Platt J and Lumley H. Cyclosporin A following matched and mismatched family allogeneic bone marrow transplants. In: *Modern Trends in Human Leukaemia V*. Ed: Neth. Pub: Springer Verlag, 1982; 28: 17-17-3.
124. Powles RL and McElwain TJ. Introduction: Leukaemia and lymphoma. In: *Seminars in Haematology*. Guest Eds: Powles RL and McElwain. Pub: Grune and Stratton, NY, 1982; XIX, 3:153-154.
125. Watson JG, Jameson B, and the Royal Marsden Hospital Bone Marrow Transplant Team. Infection after bone marrow transplantation. *Experimental Haem*, 1982; 10 (Suppl 10): 1.
126. Barratt A, Depledge MH, The Royal Marsden Hospital & ICR Sutton, Bone Marrow Transplant Team. Total body irradiation: Some factors affecting outcome. *Experimental Haem* 1982; 10 (Suppl 10): 56-63.
127. Lumley HS, Powles RL, Morgenstern GR and Clink HM. Matched allogeneic sibling bone marrow transplantation for acute myeloid leukaemia in first remission. *Experimental Haem* 1982; 10 (Suppl 10): 70-71.
128. Depledge MH, Barrett A, Morgenstern, GR, Sloane JP, Powles RL. Pulmonary oedema with leaky endothelia syndrome. *Experimental Haem* 1982; 10, Suppl 10: 113.
129. Farthing MJG, Clark ML, Sloane JP, Powles RL and McElwain TJ. Liver disease after bone marrow transplantation. *Gut* 1982; 23: 465-474.
130. Kay HEM, Lumley H, Clink HM and Powles RL. Ratio of blood and marrow derived cells in bone marrow transplantation. *J Clin Path* 1982; 35: 492-495.
131. Morgenstern GR, Powles RL, Robinson Bridget and McElwain TJ. Cyclosporin interaction with ketoconazole and melphalan. *Lancet* 1982; ii: 1342.
132. Barratt A, Jacobs A, Kohn J, Raymond J and Powles RL. Changes in serum amylase and its isoenzymes after whole body irradiation. *Brit Med J* 1982; 285: 170-171.
133. Powles RL, Morgenstern GR, Leigh M, Filshie J, Platt J and Lumley H. Cyclosporin A following matched and mismatched family allogeneic bone marrow transplants. *Proceedings of Int. Symp. Amsterdam, June 1982, Bone marrow transplantation and cyclosporin*. Ed: Bekkum and Wagemaker. *Actua Sandoz* 1983; 4: 55-60.
134. Barratt A, Depledge MH, and Powles RL. Interstitial pneumonitis following bone marrow transplantation after low dose rate total body irradiation. *International J. Radiation Oncology, Biology & Physics* 1983; 9: 1029-1033.
135. Depledge MH, Barrett A and Powles RL. Lung function after bone marrow grafting. *International J of Radiation Oncology, Biology and Physics* 1983; 9: 145-151.
136. Chessells J and Powles RL. Acute leukaemia. *Medicine International* 1983, Issue 26: 1207-1208.
137. Powles RL, Acute leukaemia in adults. *Medicine International* 1983, Issue 26, 1211-1213.

138. Sloane JP, Depledge MH, Powles RL, Morgenstern GR, Trickey BS and Dady PJ. Histopathology of the lung after bone marrow transplantation. *J Clin Path* 1983; 36: 546-554.
139. Kay HEM, Watson JG, Jameson Beryl, Morgenstern GR and Powles RL. Infections after bone marrow transplantation using Cyclosporine. *Transplantation* 1983; 36 (5): 491-495.
140. Powles RL and McElwain TJ. Concluding Remarks: Lymphomas III. In: *Seminars in Haematology*. Guest Editors: Powles and McElwain. Pub: Grune and Stratton, NY 1983, 2, (1): 57-58.
141. Powles RL, Morgenstern GR, Kay HEM, McElwain TJ, Clink HM, Dady PJ, Barrett A, Jameson B, Depledge MH, Watson JG, Sloane J, Leigh M, Lumley H, Hedley D, Lawler SD, Filshie J and Robinson B. Mismatched family donors for bone marrow transplantation as treatment for acute leukaemia. *Lancet* 1983; i: 612-615.
142. Leigh M, Powles RL, Morgenstern GR, Hughes RG, Mackenzie JC, Lumley HS and Depledge M. Bone marrow transplantation for acute leukaemia using matched and mismatched family members. *Proceedings of the 9th Annual Meeting of the EBMT Group*, Ed: Heimpel, Heit and Heim. *Experimental Haem* 1983; 2 (Suppl 13); 14.
143. Mackenzie JC, Lumley HS, Hughes RG, Leigh M, Clink HM, Kay HEM, Powles RL. Haemolytic uraemic syndrome in bone marrow transplantation. In: *Proceedings of the 9th Annual Meeting of the EBMT Group*, Ed: Heimpel, Heit and Heim. *Experimental Haem* 1983; 2 (Suppl 13): 18.
144. Crawford DH, Powles RL, Iliescu V, Hawkins RE, Edwards JMB. Epstein Barr virus infection of B cells from bone marrow transplant patients. In: *Proceedings of the 9th Annual Meeting of the EBMT Group*, Ed: Heit and Heim. *Experimental Haem* 1983; 2 (Suppl 13): 113-116.
145. Powles RL, Morgenstern G, Crofts M, Evans B and The Royal Marsden Hospital Bone Marrow Transplant Team. Mismatched family bone marrow transplantation as treatment for acute leukaemia. In: *Recent Advances in Bone Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series*, Ed: Robert Peter Gale. Pub: Alan Liss Inc, NY, 1983; VII: Article No 753.
146. Powles RL, Bone Marrow Transplantation. Editorial in *Cancer Topics* 1983; 4, No 7: 73.
147. Favrot M, Janossy G, Tidman N, Blacklock Hilary, Lopez Lisa, Bofill Margarita, Lampert I, Morgenstern G, Powles RL, Prentice HG and Hoffbrand AV. T-cell regeneration after allogeneic bone marrow transplantation. *Clin Exp Immunol* 1983; 54: 59-72.
148. McElwain TJ and Powles RL. High dose intravenous melphalan for plasma cell leukaemia and myeloma. *Lancet* 1983; 2: 822-824.
149. Powles RL, Evans B, Pedrazzini A, Crofts M, Hill P and Westensee W. Cyclosporin - A model for the testing of bio-immunological reaction modifiers in man. Ed: P Reizenstein. *Med Onc and Tumour Pharmacother* 1984; 1: No 2: 137-139.

150. Powles RL, Pedrazzini A, Crofts M, Clink H, Millar J, Bhattia G and Perez. Mismatched family bone marrow transplantation. *Seminars in Haematology* 1984; 21 (3): 182-187.
151. Powles RL, Goss G, Pedrazzini A, Crofts M, Clink H, Millar J, Khan B, Perez D. Mismatched bone marrow transplantation. In: *Cancer Chemotherapy and Selective Drug Development*. Ed: Harrap K, Davies W and Calvert H. Pub: Martinus Nijhoff, Boston, 1984.
152. Crofts MAJ, Powles RL and Millar J. Relapses following bone marrow transplant for acute leukaemia: response to treatment and survival. *Exp Haematol* 1984; 12 (Suppl 15): 31.
153. Sloane JP, Thomas JA, Imrie SF, Easton DF, Powles RL. Morphological and immunohistological changes in the skin in allogeneic bone marrow recipients. *J Clin Pathol* 1984; 37: 919-930.
154. Powles RL. Graft versus host disease after marrow transplantation. *Lancet* 1984; 1: 491-492.
155. Powles RL. Long term remissions in acute myelogenous leukaemia. *Lancet* 1984; 1: 800-801.
156. Selby P and Powles RL. Herpes virus infections in immuno-compromised patients with acyclovir. In: *Proceedings of the Symposium on New Trends in Antimicrobial and Anticancer Chemotherapy*. Pub: Czechoslovak Society of Chemotherapy, Prague, 1984: 182.
157. Selby P, Powles RL, Stolle K, Stern H. Acyclovir for cytomegalovirus infection. *Brit Med J* 1984; 289: 253.
158. Selby P, Powles RL, Blake S, Stolle K, Mbidde EK, McElwain TJ, Hickmott E, Whiteman PD, Fiddian AP. Amino (Hydroxyethoxymethyl) Purine: A new well-absorbed prodrug of acyclovir. *Lancet* 1984; ii: 1428-1430.
159. Thomas JA, Wakeling WF, Imrie SF, Sloane JP, Powles RL, Lawler SD. Chimerism in Skin of Bone Marrow Transplant Recipients. *Transplantation* 1984; 38 (5): 475-478.
160. Goss G and Powles RL. (1985). Bone Marrow Grafting in Leukaemia. *Clinics in Immunology and Allergy* 1985; 5 (1): 121-139.
161. Goss GD, Powles RL, Barrett A, Millar J, Gore M, Porta F, Pimentel P, Bagnulo S, Hernandez F. Melphalan plus total body irradiation versus cyclophosphamide plus total body irradiation prior to bone marrow transplant in acute myeloid leukaemia in first remission. *Exp Hematol* 1985; 13 (Suppl 17): 12-13.
162. Crawford D, Mulholland N, Iliescu V and Powles RL. EB virus infection and immunity in bone marrow transplant patients. *Exp Hematol* 1985; 13 (Suppl 17): 71.
163. Powles RL, Goss GD, Barrett A, Millar J, Gore M, Porta F, Pimentel P, Bagnulo S, Hernandez F. Monoclonal antibody purging of bone marrow using CamPath 1 and UCHL1 for matched and mismatched family allogeneic bone marrow transplantation. *Exp Hematol* 1985; 13 (Suppl 17): 112-113.

164. Sloane JP, Lwin KY, Gore ME, Powles RL, Smith JF. Disturbance of blood-brain barrier after bone marrow transplantation. *Lancet* 1985; ii, 280-281.
165. Favorot MC, Tidman N, Powles RL, Prentice G, Hoffbrand AV, Janossy G. T-cell reconstitution after bone marrow transplantation. *Quo Vadis Satellite Symposium of the International Conference on Analytical Cytology and Flow Cytometry* 1982; 283-284.
166. Medical Research Council Working Party on Leukaemia in Adults (prepared by MacLennan ICM & J Cusick). Objective evaluation of the role of Vincristine in induction and maintenance therapy for myelomatosis. *Br J Cancer* 1985; 52 153-158.
167. Clutterbuck RD, Hills CA, Hoey P, Alexander P, Powles RL, Millar JL. Studies on the development of human acute myeloid leukaemia xenografts in immune-deprived mice: Comparison with cells in short-term culture. *Leukaemia Research* 1985; 9 (12); 1511-1518.
168. Powles RL, Goss GD, Millar J, Maitland J, Borthwick-Clark, Al-Jundi A. Prevention of Graft versus Host Disease following Allogeneic Bone Marrow Transplantation. *Tokai J Exp Clin Med* 1985, 10 (No 2,3); 133-138.
169. Ernst P, Maraninchi D, Jacobsen N, Kolb, H-J, Bordigoni P, Ljungman P, Bandini G, Parker AC, Volin L, Powles RL, Gorin NG, Rio B. Marrow transplantation for non-Hodgkin's lymphoma: a multi-centre study from the European Co-Operative Bone Marrow Transplant Group. *Bone Marrow Transplantation* 1986; 1: 81-86.
170. Baker MC, Lawler SD, Harris H, Barrett A, Powles RL. Radiation damage in patients treated with total body irradiation, bone marrow grafting and cyclosporin. *Radiation Research* 1986; 105 413-424
171. Zuiable A, Borthwick-Clarke C, Maitland J, Clink H, Powles RL. Hodgkin's disease in an adult with acute lymphoblastic leukaemia. *Postgraduate Medical Journal* 1986: 62; 487-488.
172. Pollard C M, Lakhani A, Powles RL, Perren T, Helenglass G, Zuiable A, Tooze J. Bone marrow transplantation using Busulphan/Cyclophosphamide conditioning as first line treatment for acute megakaryoblastic leukaemia. *Lancet* 1986; 2: 1343.
173. Chan L C, Karhi K K, Rayter S I, Heisterkamp N, Eridani S, Powles RL, Lawler S D, Groffen J, Foulkes J G, Greaves M F, Wiedemann L M. A novel abl protein is expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. *Nature* 1986 325 (6105); 635-637.
174. Bone Marrow Autotransplantation in Man. Report of an International Cooperative Study. *Lancet* 1986: 960-962.
175. Elliott CJ, Sloane JP, Sanderson KV, Vincent M, Shepherd V and Powles RL. The histological diagnosis of cutaneous graft versus host disease: relationship of skin changes to marrow purging and other clinical variables. *Histopathology* 1987; 11: 145-155.
176. Lawler S.D., Harris H., Millar J., Barrett A. & Powles RL. Cytogenetic follow up studies of recipients of T-cell depleted allogeneic bone marrow. *British Journal of Haematology* 1987; 65, 143-150.

177. Mansi J L, Selby P J, Carter R L, Powles RL, McElwain T J. Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes. *Post Graduate Medical Journal* (1987), 63: 447-449.
178. Pollard CM, Powles RL, Miller JL, Shepherd V, Milan S, Lakhani A, Zuiable A, Treleavan J, Helenglass G. Leukaemic relapse following Campath-1 treated bone marrow transplantation for leukaemia. *Lancet* 1986; 2: 1343.
179. Pollard CM, Powles RL, Miller JL, Shepherd V, Milan S, Lakhani A, Zuiable A, Treleavan J, Helenglass G. Leukaemic relapse after Campath-1 treated bone marrow transplantation for leukaemia. *Lancet* 1986; 2: 1404.
180. Lawler SD, Jones EH, Jackson S and Powles RL. Lymphocytotoxic antibodies in leukaemic patients treated by bone marrow transplantation. *Transplantation*, 1985; 39: 263-265.
181. Milne A, Braithwaite J, Pollard C, Zuiable A, Treleavan JG, Powles RL. The role of ABO incompatibility in allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 1987; 2 (Suppl 1) 289.
182. Nandi AC, Miller JL, Miller B, Pollard CM, Zuiable A, Treleavan J, Powles RL. The effect of methyl prednisolone manipulation of bone marrow on engraftment and prevention of graft versus host disease. *Bone Marrow Transplantation* 1987; 2 (Suppl 1) 174.
183. Lakhani A, Gore M, Powles RL. Management of an acute abdomen following high-dose cytosine arabinoside. *Postgraduate Medical Journal* 1987; 63: 413-414.
184. McCready VR, Leach MO, Treleavan J, Hind A, Sharp J, R, Powles RL. The development of ³¹P NMR spectroscopic techniques for the study of bone marrow metabolism. *Bone Marrow Transplantation*, 1987; 2 (Suppl 1) 231.
185. Zuiable A, Hill G, Lakhani, Powles RL, Treleavan J G, Milan S. Timing of relapse after bone marrow transplantation for acute myeloid leukaemia. *Bone Marrow Transplantation* 1987; 2 (Suppl 1) 30.
185. Powles RL. Bone marrow transplantation for leukaemia. Published by Churchill Livingstone, Ed. Morris J. Brown. In *Advanced Medicine* 21 1986; 337-390.
187. Lakhani AK, Helenglass G, Powles RL, Zuiable AG, Pollard C, Treleavan J. Allogeneic Bone Marrow Transplantation in first remission acute myeloid leukaemia - a study of 98 patients. *Bone Marrow Transplant* 1987; (2 Suppl 1) :27
188. Lakhani AK, Zuiable AG, Pollard CM, Milne A, Treleavan J, Powles RL. Paraplegia after intrathecal Mitozanthrone. *Lancet* 1986; 2: 1393.
189. Nicholls J, Maitland J, Nandi A, Zuiable, Powles RL. Ovarian function following BMT. *Bone Marrow Transplant* 1986; 1 (Suppl 1) 221.
190. Porta F, Montagna D, Powles RL. Natural killer and T specific cytotoxic activities after allogeneic bone marrow transplantation: case report. *Bone Marrow Transplantation* 1986; 1 (Suppl 1); 154.

191. Khokharm T, Lawler S D, Powles RL, Miller J. Determination of cellular origin after BMT using autosomal heteromorphisms and the 3.4Y DNA probe. *Bone Marrow Transplant* 1987; 2 (Suppl 1); 233.
192. Conte R, Tazzari P L, Giovanardi L, Sacchi R, Bandini G, Gobbi D, Raspadori D, Bontadini A, Ricci P, Powles RL, Tura S. Autologous mixed lymphocyte reaction in long term bone marrow transplant recipients. *Bone Marrow Transplantation* 1987; 2 (Suppl 1) 292.
193. Zuiable A, Helenglass G, Lakhani A, Powles RL, Nandi A, Miller J, Milne A, Treleaven J. Allogeneic versus autologous bone marrow transplantation for acute lymphoblastic leukaemia. *Bone Marrow Transplantation* 1987; 2 (Suppl 1); 28.
194. Zuiable A, Maitland J, Nandi A, Clink HM, Powles RL. Intrathecal mitozantrone for resistant leukaemia. *Lancet* 1985, 2; 167-173.
195. Levy JG, Logan PM, Whitney S, Malcolm AJ, Naiman S, Powles RL, Crawford D and S Naiman. Demonstration of a leukaemia associated antigen (CAMAL) in peripheral blood leucocytes of bone marrow transplant patients prior to relapse. *Transplantation* 1986; 40 (2): 167-173.
196. Selby PJ, McElwain TJ, Nandi A, Perren TJ, Powles RL, Tillyer CR, Osborne RJ, Slevin ML, Malpas JM. Multiple Myeloma treated with high dose intravenous melphalan. *Brit J Haem* 1987; 66: 55-62.
197. Powles RL. Bone Marrow Transplantation and Radiation Accidents. *Lancet* 1986; 2: 862.
198. Chan Li C, Chen Po-Min, Powles RL, Saragas E, Wiedemann L, Lefen J, Greaves M. Molecular lesion in chronic granulocytic leukaemia is highly conserved despite ethnic and geographical variation. *Leukaemia* 1987; 1 (6) 486-490
199. Orr RM, Davies LC, Stock JA, Taylor GA, Powles RL, Harrap KR. Inhibition of human leukaemic thymidylate kinase and L1210 Ribonucleotide reductase by dinucleotides of Adenosine and Thymidine and their phosphonate analogues. *Biochem. Pharmac* 1988; 37 (4); 673-677.
200. Hill G, Helenglass G, Powles RL, Perren & Selby P. Mediastinal emphysema in marrow transplant recipients. *Bone Marrow Transplant* 1987; 2: 315-320.
201. Crawford DH, Mulholland N, Iliescu V, Hawkins R and Powles RL. Epstein Barr virus infection and immunity in bone marrow transplant recipients. *Transplantation* 1986; 2: 50-54.
202. Selby P, Powles RL, Jameson B, Stolle K, Tryhorn Y, Stern H. Treatment of cytomegalovirus pneumonitis after bone marrow transplantation with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine. *Lancet* 1986; 1: 1377-1378.
203. Lakhani A, Hill G, Helenglass G, Treleaven J and Powles RL. Management of post-transplant relapse of acute non-lymphocytic leukaemia (ANLL). XIII Annual Meeting European 7): Abstract.

204. Khokhar MT, Lawler SD, Powles RL, Millar JL. Cytogenetic studies using Q-band polymorphisms in patients with AML receiving marrow from like sex-donors. *Hum Genet* 1987; 76: 176-180.
205. Helenglass G, Powles RL, McElwain TJ, Lakhani A, Milan S, Gore M, Nandi A, Zuiable A, Perren T, Forgeson G, Treleaven J, Hamilton C, Millar J. Melphalan and TBI versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling BMTs for acute myeloblastic leukaemia in first remission. *Bone Marrow Transplant* 1988; 3: 21-29.
206. Helenglass G, Lakhani A, Powles RL, Nandi A, Zuiable A, Gore M, Forgeson G, Treleaven J, Milliken S, Millar J. Bone marrow transplantation - The Marsden Experience. *Haematological Oncology* 1987; 5: 245-254.
207. Barrett A, Nicholls J & Gibson B. Late effects of total body irradiation. *Radiotherapy and Oncology* 1987; 9: 131-135.
208. Jones EH, Lawler SD, Powles RL. One haplotype matched bone marrow grafts: An investigation using the HLA system as a marker of cellular origin. *Disease Markers*, 1988; 6: 47-56.
209. Powles RL, Milan S, Millar J, McElwain TJ, Zuiable A, Aboud H, Treleaven J, Gallagher C, Milliken S, Helenglass G, DeLord C, Nandi A. A controlled trial of Melphalan/TBI versus cyclophosphamide/TBI for matched sibling BMT for 1st remission AML. *Bone Marrow Transplantation* 1988; 3 (1); 146-147.
210. Milliken S, Helenglass G, Powles RL. Fluconazole pharmacokinetics following oral dosage in leukaemic patients receiving autologous BMT. *Bone Marrow Transplantation* 1988; 3 (1): 324-5.
211. Milliken S, Lakhani A, Powles RL. Bone Marrow Transplantation. In *Oncology for Nurses and Health Care Professionals*. Publ. Harper & Row, London. Eds. Tiffany R. and Pritchard P. 1989; Vol 1; 320-345.
212. Sloane JP, Elliott CJ, Powles RL. HLA-DR expression in epidermal keratinocytes after allogeneic bone marrow transplantation: Relationship to histology, rash, marrow purging and systemic GVHD. *Transplantation* 1988; 46 (6) 840-844.
213. Ryalls MR, Brook CGD, Meller ST, and Powles RL. Changes in hormone secretory dynamics in children receiving TBI and allo/autograft for leukaemia. *Bone Marrow Transplantation* 1988; 3 (1); 310.
214. Weimbren N, Forgeson G, Helenglass G, Jameson B, Powles RL. Unusual presentation of pseudomonas infection. *BMJ* (1988), 297: 1034-1035.
215. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long term oral acyclovir after allogeneic bone marrow transplantation. *Am J Med* 1988; 85: 99.

216. Powles RL, Milliken S, Helenglass G, Treleavan J, Pinkerton R, Zuiable A, Nandi A, Aboud H, and Millar J. The use of Melphalan in conjunction with total body irradiation as treatment for acute leukaemia. *Transplantation Proc* 1989; 21: 2955-2997.
217. Khokhar MT, Lawler SD, Reeves BR, & Powles RL. Simultaneous application of immunolabelling and in-situ hybridization to detect the origin of B- & T-Lymphocytes in a case of ALL after bone marrow transplantation. *Bone Marrow Transplantation* 1989; 4; 363-366.
218. Milliken S, Powles RL, Jones A, & Helenglass G. Pharmacokinetics of oral Fluconazole in autologous bone marrow transplantation recipients given TBI and high dose melphalan. *Transplantation Proceedings* 1989; 21 (1); 3067-3069.
219. Milliken S, Powles RL, Ettinger N, Gallagher C, Jameson B, Tryhorn Y, Stern H, Selby P. Ganciclovir in the treatment of cytomegalovirus pneumonitis in bone marrow transplant recipients. *Transplantation Proceedings* 1989; 21 (1); 3110-3111.
220. Helenglass G, Davies H, Khokhar MT, Lawler SD, Powles RL. Reconstitution with donor cells following chemotherapy for relapse post allograft. *Bone Marrow Transplant* 1988; 72: 5 (1): 391a.
221. Helenglass G, Milliken S, Powles RL. Factors influencing engraftment in cyclosporin (CyA) treated recipients of allogeneic bone marrow transplants. *Blood* 1987; 70: 5 (1); 295a, 1034.
222. Helenglass G, Milliken S, Powles RL. Factors influencing speed of engraftment following matched allogeneic bone marrow transplantation. *J. Cellular Biochemistry* 1988; 12 (117): 89.
223. Lawler S, Davies H, Khokhar MT, Williams G & Powles RL. Cytogenetic studies of leukaemia recurrence in recipients of bone marrow allografts. *Cancer Genetic and Cytogenetic* 1990; 47 (2): 249-263.
224. Gore M, Powles RL, Lakhani A, Milan S, Maitland J, Goss G, Nandi A, Perren T, Forgeson G, Treleavan J, Zuiable A, Porta F. Treatment of relapsed and refractory acute leukaemia with high dose cytosine arabinoside (ARA-C) and etoposide. *Cancer Chemother Pharmacol* 1989; 23: 373-376.
225. Selby PJ, Powles RL, Easton D, Perren TJ, Stolle K, Jameson B, Fiddian AP, Tryhorn Y and Stern H. The prophylactic role of intravenous and long term oral acyclovir after allogeneic bone marrow transplantation. *Brit. J Cancer* 1989; 59: 434-438.
226. Helenglass G, Talbot D, Jameson B, Powles RL. Possible role of person to person transmission of listeria infection in immunocompromised patients. (Letter) *Lancet* 1989; 2: 851.
227. Clutterbuck R, Clarke D, Powles RL, & Millar J. Growth of xenografted human bone marrow: comparison with haemopoietic reconstitution in patients after allogeneic bone marrow transplant and response to granulocyte macrophage colony stimulating factor. *Leukaemia* 1989; 3 (9): 637-642.

228. Milliken S, Gore M, Powles RL, Harding M, Jameson B, Talbot D, McElwain T. Fluconazole versus polyenes as oral anti-fungal prophylaxis in autologous and allogeneic bone marrow recipients. *Bone Marrow Transplant* 1989 4 (2): 27.
229. Ryalls MR, Meller S, Powles RL. Growth and endocrine sequelae of BMT for childhood leukaemia. *Bone Marrow Transplantation* 1989; 4 (2): 28.
230. Andolina M, Agosti E, de Manzini A, Zanazzo GA, Bittolo M, Porta F, Powles RL, and Millar J. Haploidentical bone marrow transplantation (BMT) for end stage leukaemia in children. *Bone Marrow Transplantation* (1989) 4: 2: 40.
231. Helenglass G., Powles RL, Millar J, Shepherd V, Nandi AC, Zuiable A, Milan S, Treleaven J, Milliken S, Aboud H. Bone Marrow purging with campath 1 in autologous transplantation for acute lymphocytic leukaemia (ALL). *Bone Marrow Transplant* 1989; 4 (2): 60.
232. Pinkerton R, Ryalls MR, Meller ST, McElwain TJ & Powles RL. High dose melphalan/TBI in childhood leukaemia - does increased efficacy outweigh toxicity. *Bone Marrow Transplant* 1989; 4 (2): 77.
233. Kwong YL, Clutterbuck RD, Newman A, Millar JL, Powles RL. In vitro interactions between recombinant human interleukin-1 (IL1), interleukin-3 (IL3) and granulocyte-macrophage colony stimulating factor (GM CSF). *Bone Marrow Transplant* 1989; 4: 100-
234. Nandi A, Powles RL, Aboud H, Zuiable A, Helenglass G, Treleaven J, Milliken S, Millar J. Autologous bone marrow transplantation in relapsed acute myeloid leukaemia. *Bone Marrow Transplant* 1989; 4: 108
235. Clutterbuck RD, Powles RL, & Millar JL. The response of human myeloid leukaemia xenografts to human recombinant tumour necrosis factor. *Br J Cancer* 1989; 59: 841-843.
236. Kwong YL, Millar JL, Powles RL. Recovery of circulating haemopoietic reconstitution after autologous and allogeneic Bone Marrow Transplantation. *Bone Marrow Transplantation* 1989; 4: 575-578.
237. Ettinger N, Selby P, Powles RL, Milliken S, Jameson B, Gallagher C, Tryhorn Y, Stern H. Cytomegalovirus pneumonia: The use of ganciclovir in marrow transplant recipients. *J Antimicrobial Chemo* 1989; 24; 53-62.
238. Zuiable A, Aboud H, Nandi A, Powles RL & Treleaven J. Extramedullary disease initially without bone marrow involvement in acute promyelocytic leukaemia. *Clin Lab Haem* 1989; 2 (3) 288-289.
239. Zuiable AG, Aboud H, Coulson I, Treleaven JG, Powles RL. Razoxane and T-cell lymphoma (letter). *Brit J Derm* 1989 121 (1): 149.
240. Powles RL. The Antileukaemic action of Bone Marrow Transplantation. In *Reunion de la Associaion Espanola de Hematologia y Hemoterapia*. Ed. A Torres-Gomez, published by Graficas milla, Cordoba 1989; 97-99.

241. Helenglass G, Treleaven J, Parikh P, Aboud H, Smith C, Powles RL. Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. *Bone Marrow Transplant* 1990; 5 (4): 247-251.
242. Adams JA, Gordon A, Jiang Y Z, McDonald D, McCarthy DM, Zuiable A, Treleaven J, Powles RL, and Barrett. Thrombocytopenia after bone marrow transplantation for leukaemia - changes in megakaryocyte growth and growth promoting activity. *British Journal of Haematology* 1990; 75: 195-201.
243. Milliken S and Powles RL. Antifungal prophylaxis in bone marrow transplantation. *Reviews of Infectious Diseases* 1990; 12: 1 (Suppl 3) 374-379.
244. Clutterbuck R, Newman A, Powles RL, Kwong YL, Millar J, Shepherd V, Smith C. Failure to immortalize human AML cells using human recombinant GM-CSF in vitro and in-vivo. *Bone Marrow Transplant* 1989; 4: (4) 40-41.
245. Cust, M, Whitehead M, Powles RL. The Psychosexual and endocrine consequences of ovarian failure following BMT with TBI as treatment for leukaemia. *British Congress of Obstetrics and Gynaecology, July 1989. British Medical Journal* 1990; 300: 1494-7.
246. Cust M, Whitehead M, Powles RL, Hunter M, & Milliken S. Consequences and treatment of ovarian failure following total body irradiation for leukaemia. *British Medical Journal* 1989; 299: 1494-1497.
247. Milliken S, Powles RL, Parikh P, Whitehead M, Mayes I, Prentice A, Falconer A, Aboud H, Helenglass G, Nandi A, Talbot D, Treleaven J. Successful pregnancy following BMT for leukaemia. *Bone Marrow Transplant* 1990; 5: 135-37.
248. Talbot D, Powles RL, Sloane J, Rose J, Treleaven J, Aboud H, Helenglass G, Parikh P, Smith C, Rowley M, Cavanagh J, Milliken S, Hewetson M & Norton J. Cyclosporine-induced GVHD following autologous bone marrow transplantation in acute myeloid leukaemia. *Bone Marrow Transplantation*. 1990, 6, 17-20.
249. Powles RL, Parikh P, Helenglass G, Aboud H, Smith C, Sharrock C, Mrazek I, Shepherd V, Milliken S, Treleaven J, Feary S, Meller S, Lawler S. Bone marrow transplant from father to son and subsequent regraft from son to father. *Lancet* 1990; 335: 999.
250. Parikh P, Powles RL, Treleaven J, Helenglass G,, Gore M, Rose J, Talbot D, Milan S, Smith C, Pinkerton CR, Aboud H, Cavanagh J, Rowley M, McElwain TJ and Hewetson M. High dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study. *Brit J of Cancer* 1990; 62: 830-833.
251. Lobo P, Powles RL, Hanrahan A, Reynolds D. Acute Myeloblastic Leukaemia -A model for assessing value for money for new treatment programmes. Submitted to *British Medical Journal* 1991; 302 (6772): 323-27
252. Smith C, Milliken S, Powles RL, Da Costa F, Gore M, Benjamin S, Talbot D, Ellis L, Large J, Jameson B. Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients. *Brit J Haematology* 1990 76: Suppl 2, 6-9.

253. Schroeder H, Pinkerton R, Powles RL, Meller S, Tait D, McElwain T. High dose melphalan and total body irradiation with autologous marrow rescue in childhood lymphoblastic leukaemia after relapse. *Bone Marrow Transplantation* 1991; 7: 11-15.
254. Powles RL, Smith C, Tiley C, Findlay M, O'Brien M. The antileukaemic action of melphalan and total body irradiation in bone marrow transplantation. *Organ Transplantation by G M Abouna, M.S.A. Kumar, A.G. White (Editors); Kluwer Academic Publishers* 1990; Chapter 59: 443-446.
255. Powles RL, Smith CL, Milan S et al. Autologous bone marrow transplantation as treatment for bad risk first remission acute lymphoblastic leukaemia. *Organ Transplantation by G M Abouna, M.S.A. Kumar, A.G. White (Editors); Kluwer Academic Publishers* 1990 Chapter 57; 429-35.
256. Powles RL, Smith CL, Milliken S. Antifungal prophylaxis with Fluconazole in bone marrow transplantation. *Organ Transplantation, by G M Abouna, M.S.A. Kumar, A.G. White Eds), Kluwer Academic Publishers* 1990; Chapter 60: 447-51.
257. Powles RL, Smith CL, Tiley C, Findlay M, O'Brien M. The antileukaemic action of melphalan and total body irradiation in bone marrow transplantation. *Hematology Reviews and Communications* 1990; 4: 23-26.
258. Milliken S. and Powles RL. *Oxford Textbook of Oncology. Chapter: Bone Marrow Transplantation for Leukaemia* 1995; Vol 2 Section 14:4 (Oxford University Press).
259. Aboud H, Treleaven J, O'Brien M, Powles RL. An Adult with common ALL (C-ALL) presenting with skin infiltration. *Brit J Derm* 1991;124: 84-85.
260. Powles RL, Gordon-Smith E C., Smith C, Milan S, Treleaven J, Millar J L, McElwain T J, and several others. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double blind placebo-controlled trial. *Lancet* 1990; 336: 1417-1420.
261. Powles RL. Bone Marrow Transplantation and graft-versus-host-disease. Article for *Current Opinions in Immunology: Current Biology* 1990; 2 (6); 870-875.
262. R Chopra, AH Goldstone, AK McMillan, R Powles, AG Smith, HG Prentice, C Reid, R Marcus, A Bell, D Milligan, D. McCarthy, G. Morgernstern, D Barnard. Successful treatment of AML beyond first remission with ABMT using Bu/Cy and unpurged marrow - the British Autograft Group (BAG) Experience. *Journal of Clinical Oncology* 1991; 9: 1840-1847.
263. Ringdon O, Blume KG, Chao NJ, Powles RL, Tiley C, Ringdon O. Methotrexate and/or CSA for BMT in early leukaemia. *International Bone Marrow Transplant Registry Writing Committee. Clinical Transplants* 1990; Editor Paul I. Terasaki.
264. Tiley C & Powles RL. Bone Marrow transplantation - The Marsden Experience. *Clinical Transplants* 1990, Editor Paul Terasaki. Published UCLA Tissue Typing Laboratory 1991; (Chapter 18): 165-173

265. Powles RL, Milliken S. The prophylaxis of fungal infections. *The Journal of Antimicrobial Chemotherapy* 1991; 28 (Suppl. A); 97-103.
266. Baruch J, Benjamin S, Treleaven J, Wilcox AH, Barron JL, Powles RL. Male Sexual function following bone marrow transplantation. *Bone Marrow Transplantation* 1991; 7: 2: 52.
267. Visani G, Gamberi P, Greenberg R, Powles RL et al. The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomised controlled trial. *Bone Marrow Transplant* 1991; 7 (2): 81.
268. Powles RL, Treleaven J, Miller J, Gordon-Smith E, Tiley C, Findlay M, Teo C, Duncombe A, and Robinson G. How do allogeneic bone marrow transplants cure leukaemia? The role of graft versus host disease. *Bone Marrow Transplant* 1991; 7 (2): 9-10.
269. Powles RL, Treleaven J, Millar J, Gordon-Smith EC, Tiley C, Findlay M, Teo C, Duncombe A, & Robinson G. Human recombinant GM-CSF in allogeneic BMT for leukaemia: double-blind placebo controlled trial. *Bone Marrow Transplantation* 1991, 7; 2: 85-86.
270. Herve P, Racadot E, Wijdenes J, Powles R et al. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti-IL-2 R antibody. *Bone Marrow Transplantation* 1991, 7; 2: 149.
271. Tiley C, Powles RL, Teo CP, Treleaven J, Findlay J, Hewetson M. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor. *Bone Marrow Transplantation* 1991; 7 (2): 151.
272. Zuiable A, Treleaven J, Powles RL, et al. Acute myeloid leukaemia following matched allogeneic BMT for T cell lymphoblastic lymphoma. *Leukaemia & Lymphoma* 1992; 5: 431-433
273. Bradley R, Millar J, Bertoncetto I, and Powles RL. Antagonism of the inhibitory effects of transforming growth factor- β on colony formation of mouse bone marrow cells in vitro by increasing concentrations of growth factors. *Annals of the New York Acad Sci* 1991; 628: 52-58.
274. Millar JL, Powles RL, Bradley TR. Reducing the normal circulating hematopoietic inhibitor level using cytotoxic drugs or silver nitrate. A Comparison with the effect of Interleukin-I. *Annals of the New York Academy of Sciences*, 1991, 628: 185-187.
275. Powles RL, Goldstone A, Stevens R, Dawson A. Cooperation between United Kingdom and Soviet Union. *British Medical Journal* 1991; 302: 1468.
276. De Lord C, Clutterbuck R, Tiley J, Ormerod M, Gordon-Smith T, Millar J, Powles RL. Growth of primary human acute leukaemia in severe combined immunodeficient mice. *Exp Haematol* 1991; 19: 991-993.
277. Wasan H, Mansi JL, Benjamin S, Powles RL, Cunningham D. Myeloma & Benign intracranial hypertension - a new association. *British Medical Journal* 1992; 304: 685

278. Wasan H, Mansi JL, Benjamin S, Powles RL, Cunningham D. Myeloma & Benign intracranial hypertension - (authors reply) *British Medical Journal* 1992; 304: 1245-124
279. Tiley C, Powles RL, Catalano J, Treleaven J, Eshelby J, Hewetson M, Tait D, Cunningham D. Results of a double-blind placebo controlled study of Ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. *Leukaemia & Lymphoma* 1992; 7: 317-321
280. Gupta P, Tiley C, Treleaven J, Millar J, Catalano J, Powles RL. No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation. Preliminary Report. *Bone Marrow Transplant* 1992; 9: 491-493
281. Ringdon O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan FE and Bortin MM. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukaemia? *Blood* 1993; 81 (4) 1094-1101.
282. Millar B, Bell J, Millar J, Treleaven J, Montes J, Joffe J, Powles RL, McElwain T. Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: Its augmentation by GM-CSF in vivo and Interleukin 4 in vitro. *Exp Haematol* 1992; 20: 209-215.
283. Robinson G, Matutes E, Swansbury J, Toon M, Findlay M, Powles RL, Catovsky D. Biphenotypic leukaemia associated with chromosomal translocation. *Brit J Haem (year)*; 77 (1) 66.
284. Tiley C, Grimwade D, Findlay M, Treleaven J, Height S, Catalano J, Powles RL. Tumour Lysis Following Hydrocortisone Prior to a Blood Product Transfusion in T-Cell Acute Lymphoblastic Leukaemia. *Leukaemia and Lymphoma* 1992; 8: 143-146
285. Parikh P, Powles RL, Advani S. Changing strategies to enhance the antileukaemic effect of bone marrow transplantation. *Bombay Hospital Journal* 1992; 34 (1) 1992.
286. Powles RL, Mehta J. Systemic fungal infections : Major problems in cancer patients. *Indian Journal of Cancer* 1994; 33-36
287. Llungman P, Printice G, Gluckman E, Powles RL, Milpeid N, Rananda J, Mandelli F. For the European Acyclovir in CMV prophylaxis group. The effect of intravenous acyclovir followed by oral acyclovir on CMV infections following BMT. A randomized double-blind controlled trial, in Michelson S, Plotkin SA, (Eds). *Multidisciplinary approach to understanding Cytomegalovirus disease. Proceeding of 4th International Cytomegalovirus Workshop, New York NY Expcerta Medica, 1993.*
288. Tiley C, Powles RL. The role of bone marrow transplantation in the management of acute myeloid leukaemia. Chapter in *Bone Marrow Transplantation in Practice*, J.Treleaven/J. Barratt (Eds) Published by Churchill Livingstone, 1992; Chapter 2: 11-18
289. De Lord C, Clutterbuck R, Powles RL, Min T, Titley J and Millar J. Human Philadelphia-positive chronic myeloid leukaemia: a potential model for anti-sense therapy. *Exp Haematol*; 1993; 21: 826-828

290. Mehta J, Powles RL, Treleaven J, Shields M, Agrawal S, and Allard S. Cimetidine-induced myelosuppression after bone marrow transplantation. *Leuk Lymphoma* 1994; 13: 179-181.
291. Rassam SMB, Turker A, Powles RL, Smith AG, Newland AC, Erskine JG, Pearce RM, and Goldstone AH. Idarubicin for remission induction of acute myeloid leukaemia. United Kingdom Multicentre Experience. *Seminars in Oncology* 1993 20 (6)
292. Rowbottom AW, Norton J, Riches PG, Hobbs JR, Powles RL, and Sloane JP. Cytokine gene expression in skin and lymphoid organs in human graft versus host disease. *J Clin Path* 1993; 46: 341-45
293. Mehta J, Powles RL. Successful management of acute emesis in patients receiving highly or moderately emetogenic chemotherapy. *Postgrad Doctor Caribbean* 1993; 9:123-127.
294. Rege K, Powles RL, Norton J, Mahendra P, Mitchell P, Agrawal S, Mehta J, Treleaven J. An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma. *Leukaemia & Lymphoma* 1993; 11: 305-307.
295. Powles RL and Mehta J. The future of bone marrow transplantation. *Clinical Bone Marrow Transplantation*. Cambridge University Press. (K Atkinson Ed.) 1994; Chapter 92: 736-740.
296. Mitchell PLR, Powles RL, Treleaven J, Rege K, Mehta J, Jameson B. Topical Phenoxythanolamine for pseudomonas infection in neutropenic patients. *Journal of Hospital Infection*, March 1993; 25: 53-56.
297. Mehta J, Powles RL. Successful management of acute emesis in patients receiving highly or moderately emetogenic chemotherapy. *Postgrad Doctor Middle East* 1993; 16: 446-451
298. Mehta J, Powles RL. Acute Leukaemias: In: Horwich A, Ed. *Textbook of Clinical Oncology*. Publ. Chapman and Hall. Chapter 20; 261-273 (1995)
299. Prentice G, Gluckman E, Powles RL, Llungman P, Milpied NJ, Fernandez Ranada JM, Mandelli F, Kho P, Bell AR. Impact of longterm acyclovir on cytomegalovirus infections and survival after autologous bone marrow transplantation: The Lancet Study Group: (year) 343 No. 8900 pp. 749-753.
300. Davidson A, Childs J, Tait D, Powles RL. CNS complications due to the cumulative effect of cranial irradiation and TBI in children receiving bone marrow transplantation for acute lymphocytic leukaemia. Abstract: International Society of Paediatric Oncology XXIII Meeting. Rhodes, October 1-4, 1991.
301. Powles RL, Treleaven J, Gorman C, Milan S. Long-term follow-up of BMT from mismatched family donors for AML in first CR. *Blood*, 1992; 80 (Suppl 1): 530a.
302. Mehta J, Powles RL, Treleaven J, Tiley C, Jameson B, Gorman C and Lakhani A. Idarubicin (IDR), high-dose Ara-C and VP-16 for induction of remission in untreated primary AML under 50 years. *Blood* 1992; 80 (Suppl 1): 113a.

303. Mehta J, Powles RL, Treleaven J, Tiley C, Gorman C, and Milan S. Idarubicin (IDR), High dose Ara-C and VP-16 for remission induction in therapy related secondary ANLL. *Blood* 1992; 80 (suppl 1) 455a.
304. Ljungman Per de Witte T, Verdonck L, Gahrton G, Freycon F, Gravett P, McCann S, Morgenstern HG, Nikoskelainen J, Powles RL, Proctor SJ, Volin L, Zwaan F, Gratwohl A. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. *Br J Haem* 1993; 83: 61-66
305. Tiley C, Powles RL, Treleaven J, Catovsky D, Milan S, Teo CP, Catalano J, C, Mehta J, Shields M, Gupta P, Richards S, Millar J, Gorman C. Feasibility and efficacy of maintenance chemotherapy combined with autologous bone marrow transplantation for treatment of first remission acute lymphoblastic leukaemia. *Bone Marrow Transplant* 1993; 12:449-455
306. Mehta J, Powles RL, Shepherd V, Dainton M, Treleaven J. Transplantation of autologous peripheral blood stem cells mobilized using GM-CSF for acute leukaemia with myelofibrosis. *Leuk Lymphoma* 1993; 11:157-158
307. Powles RL, Mehta J. Systemic fungal infections: Major problems in cancer patients. *Indian J Cancer* 1994; 31: 180-184
308. Mehta J, Powles RL, Treleaven J, Horton CAP, Meller S, Pinkerton CR, Milan S, Catovsky D. Management of acute promyelocytic leukaemia: The Royal Marsden Hospital Experience. Abstract Book of the International Symposium on Acute Promyelocytic Leukaemia (78), Rome, 11-12 November, 1993.
309. De Lord C, Clutterbuck R, Powles RL, Morilla R, Hanby A, Titley J, Min T, Millar J. Growth of primary human acute lymphoblastic and myeloblastic leukaemia in SCID mice. *Leuk Lymphoma* 1994; 16:157-165
310. Tiley C; Powles RL; Dyer M; Min T; Luckit J; Zellant A; Catovsky D. Primary chemotherapy resistant acute promyelocytic leukemia with cromosomal translocation T(3-8)(P25-Q12). *Experimental Hematology* 1992, Vol 20, No 6 p 788.
311. Millar BC; Bell JBG; Millar JL; Bradley TR; Powles RL. Effect of transforming growth factor-beta-1 on interleukin-4 and granulocyte colony-stimulating factor stimulation of human bone marrow cells. *Exp Hematol* 1992; 20 (6): 763
312. Mahendra P, Barfoot RK, Bell JBG, Goldman JM, Powles RL, Millar JL, Millar BC. Proliferation of chronic myeloid leukemic (CML) cells induced by granulocyte colony-stimulating factor (G-CSF) is inhibited by transforming growth factor-beta-1 (TGF-BETA-1) invitro. *Exp Hematology* 1992; 20 (6) 755.
313. De Lord C, Clutterbuck RD, Titley JC, Ormerod MG, Millar JL, Powles RL. Engraftment of severe combined immunodeficient mice with human leukaemia. *Exp Haematol* 1991; 19: 530
314. Clutterbuck R, Powles RL, Millar J. Comparison of the growth of xenografted human bone marrow with the growth of xenografted AML cells and marrow repopulating capacity following transplantation into allogeneic recipients. Chapter in Book "Leukemias" Fleisher (Ed), Springer-Verlag Berlin Heidelberg (Publisher) 1993; 205-209

315. De Lord C, Clutterbuck RD, Titley JC, Ormerod MG, Gordon Smith E, Millar JL, Powles RL. Transplantation of severe combined immunodeficient (SCID) mice with myeloid and lymphoid leukaemias. *Exp Haematol* 1992; 20: 722
316. Newman A, Clutterbuck R. et al. Selective inhibition of primary acute myeloid leukaemia cell growth by Lovastatin. *Leukemia* 1994; 8 (2) 274-280,
317. Powles RL. Leukaemia and BMT. Proceedings of the 17th International Congress of Life Assurance Medicine, 1993 203-204.
318. Height S, Dainton M, Matutes E, Kearney L, Swansbury J, Dyer M, Zalent A, Treleaven J, Powles RL and Catovsky D. Acute Myelomonocytic Leukaemia with (t:10-11)(p13q23). Heterogeneity of breakpoints involving 11q23 and association with activation of recombinase. *Blood* 1993; 82, 10 (Suppl 1) 35a
319. Clutterbuck RD, Newman A, Powles RL, Kwong YL, Shepherd V, Smith C. Failure to immortalize human AML cells using human recombinant GM-CSF in vitro and in vivo. *Bone Marrow Transplant* 1989; 4 (Suppl 4): 40-43 MISSING
320. Mehta J, De Lord C, Treleaven J, Powles RL. G-CSF-mobilised peripheral blood progenitors can tolerate maintenance chemotherapy after autografting for adult ALL. Abstract Book: III International Symposium on Peripheral Blood Stem Cell Autografts, Bordeaux, (11-13 October 1993).
321. Rawal BK, Booth JC, Fernando S, Butcher PD, Powles RL. Quantification of cytomegalovirus (CMV) DNA in blood specimens from bone marrow transplant recipients by the polymerase chain reaction. *Journal of Virological Methods* 1994 47: 189-202
322. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied NJ, Ranada JMF, Mandelli F, Kho P, Kennedy, L, Bell AR (the European Acyclovir for CMV Prophylaxis Study Group). Impact of long term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. *The Lancet* 1994, 343 (8900) 749-753.
323. Mehta J, Powles RL, Treleaven J, Rege K, Mitchell P, Morton C, Luckitt J, Agrawal S, Allard S, De Lord C, Wilson K. A radiation-free preparative regimen for matched unrelated bone marrow transplantation combined with a low marrow cell dose may result in an increased incidence of graft failure. *Br. J Haematol* 1993; 84 (Suppl 1): 50.
324. Hirst W, Agrawal S, Parikh PM, Allard S, Mehta J, Powles RL, Treleaven J, Mufti GJ. The effect of trilineage dysplasia on engraftment in allogeneic bone marrow transplantation for primary acute myeloid leukaemia. *Br. J Haematol* 1993; 84 (Suppl 1): 27.
325. Mehta J, Powles RL, Mitchell P, Rege K, De Lord C, Treleaven J. Graft failure after bone marrow transplantation from unrelated donors using busulfan and cyclophosphamide for conditioning. *Bone Marrow Transplant* 1994; 13: 583-587. Missing
326. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute myeloid leukaemia cell growth by Simvastatin. *Leukaemia* 1994; 8: 2023-2029 Missing

327. Perry A, Mehta J, Iveson T, Treleaven J, Powles RL. Guillain-Barré syndrome after bone marrow transplant 1994; 14: 165-167.
328. Mehta J, Singhal S, Powles RL. Approach to the febrile neutropenic patient. I: General principles of management. Post Grad Doctor Middle East 1994; 17: 327-333
329. Mehta J, Singhal S, Powles RL. Approach to the febrile neutropenic patient. II: Antimicrobial therapy and prophylaxis. Postgrad Doctor Middle East 1994; 17: 392-399
330. Mehta J, Powles RL, Treleaven J, Iveson T, Singhal S, Zomas A, De Lord C, Elebute M, Philpott N, Tait D, Catovsky D. Melphalan-total body irradiation (M-TBI) and allogeneic bone marrow transplantation (BMT) for chronic lymphocytic leukaemia (CLL) and promyelocytic leukaemia (PLL). Br J Haematol 1994; 86 (Suppl 1): 81.
331. Ringdon O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlion RE, Deeg HJ, Dicke K, Masaoka T, Powles RL. Methotrexate cyclosporin, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukaemia? Blood 1993; 81: 1094-1101.
332. Cunningham D, Powles RL, Malpas JS, Milan S, Meldrum S, Viner C, Montes A, Hickish T, Nicholson M, Johnson P, Mansi J, Treleaven J, Raymond J, Gore ME. A randomised trial of maintenance therapy with Intron-A following High dose melphalan and ABMT in myeloma. Proceedings American Society Clinical Oncology 12: 1232, 1993
333. Philpott N, Mehta J, Treleaven J, Powles R. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukaemia. Leuk Lymphoma 1994; 15: 127-130
334. Mehta J, Powles RL, Treleaven J, Horton C, Milan S, Catovsky D. Allogeneic Bone Marrow Transplantation for primary resistant acute leukaemia. Blood 1993; 82 (Suppl 1): 637a.
335. Mehta J, Powles RL, Treleaven J, Horton C, Meller S, Pinkerton R, Milan S, Catovsky D. Bone Marrow Transplantation for Acute Promyelocytic Leukaemia. Blood 1993; 82 (Suppl 1): 637a.
336. Mehta J, Powles RL, Franklin R, Banner N, Radley-Smith R, Halil O, Mason M, Smith J, Taylor P, Sloane JP, Khaghani A, Yacoub M. Attempted Establishment of Systemic Microchimerism by Infusion of Donor Marrow in a Heart Allograft Recipient with Pompe's Disease. Blood 1993; 82 (Suppl 1): 651a.
337. Mehta J, Powles RL, De Lord C, Ivson T, Wroe S, Mitchell P, Philpott N, Luckitt J, Shepherd V, Millar B, Treleaven J. Maintenance Chemotherapy with 6-MP and MTX after High-Dose Melphalan and G-CSF mobilised peripheral blood stem cell transplantation for adult ALL. Blood 1993; 82 (Suppl 1); 638a.
338. Mehta J, Powles RL, Treleaven J, Milan S. Busulfan-melphalan conditioning prior to bone marrow transplantation for poor risk leukaemia. Euro J Cancer 1993; 29a (Suppl 6): S152
- 338a. Morton C, Cabral S, Mehta J, Powles R. Peripheral blood stem cell transplantation (PBSCT): a nursing and patient perspective. Eur J Cancer 1993; 29a (Suppl 6): S252

- 339 Powles RL, Parikh P, Antrum J, Marlow C, Milan S, Hewetson M, Mehta J. Transplantation Events and Activity Template (TEAT) for assessing cost effectiveness. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 72.
- 340 Mehta J, Powles RL, Gorman C, Milan S, Treleaven J. Outcome of unpurged ABMT for AML in first CR after remission induction with high-dose ARA-C and VP-16. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 33.
- 341 Mehta J, Powles RL, Treleaven J, Gorman C, Milan S. Long term follow-up of unmanipulated mismatch BMT for AML. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 26. MISSING
- 342 Mehta J, Powles RL, Shepherd V, Dainton M, Cabral S, Proctor S, Jeremiah J, Treleaven J. Autologous peripheral blood stem cell (PBSC) transplant for acute leukaemia with myelofibrosis. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 33. MISSING
- 343 Allard S, Agrawal S, Mehta J, Luckitt J, Treleaven JG, Powles RL, Catovsky D. Bone marrow transplantation for Ph1+ acute lymphoblastic leukaemia. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 40. MISSING
- 344 Agrawal S, Mehta J, Powles RL, Gorman C, Milan S, Treleaven J. Treatment of AML with high dose ARA-C and VP-16 followed by allogeneic BMT in first CR. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 January 1993, p. 27. MISSING
- 345 Agrawal S, Mufti G, Powles RL, Parikh PM, Allard S, Hurst W, Treleaven J, Mehta J. The effect of trilineage on engraftment in allogeneic BMT in first CR. Proceedings of the 19th Annual Meeting of the European Group for Bone Marrow Transplantation (EBMT), Garmisch-Partenkirchen, 17-21 Jan 1993, p. 35 MISSING
346. Mitchell P, Mehta J, Treleaven J, Horton C, Powles RL. Chemotherapy (CT) only preparation allows more rapid neutrophil recovery than CT with TBI in autologous bone marrow transplantation (ABMT) of patients with acute myeloid leukaemia (AML). Bone Marrow Transplantation 1994 (Suppl): 118.
- 346a Mehta J, Powles R, Singhal S, Horton C, Milan S, Treleaven J. Autologous bone marrow or peripheral blood stem cell transplantation with maintenance chemotherapy for acute lymphoblastic leukemia. Ann Oncol 1994 5 (Suppl 8): 127
347. Mitchell P, Powles RL, Cabral S, Proctor H, Shepherd V, Dainton M, Pinkerton C. Peripheral Blood Stem Cells (PBSC) used to augment autologous bone marrow transplantation (ABMT) in children. Bone Marrow Transplant; 1994 (Suppl): 118.

348. Fernandez JM, Shepherd V, Millar J, Powles RL & Pinkerton CR. When is the optimum time to harvest peripheral blood stem cells in children following standard dose chemotherapy. *Med. Ped. Oncol.*, 1993; 21: 465-469.
349. Cunningham D, Powles RL, Viner C, Meldrum M, Gore M, Selby P, Malpas J. High dose chemotherapy and autologous bone marrow transplantation in multiple myeloma. Fourth International Workshop on Multiple Myeloma, Rochester, USA. Oct 1993. MISSING
350. Cunningham D, Powles RL, Malpas JS, Milan S, Meldrum M, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Mansi J, Treleaven J, Raymond J, Gore ME. A randomised trial of maintenance therapy with intron following high dose melphalan and ABMT in myeloma. *Myeloma Today* 1993; 1: 4
351. Cunningham D, Powles RL, Malpas JS, Milan S, Meldrum M, Montes AN, Hickish T, Nicholson M, Johnson P, Mansi J, Treleaven J, Raymond J, & Gore ME. A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. *The British Journal of Cancer* 1993; 67 (Suppl XX): 30
352. Mahendra P, Barfoot RK, Bell G, Treleaven JG, Powles RL, Millar J, Millar C. TGF β ₁ and IL-4 Have opposing effects on the proliferation of chronic phase chronic myeloid leukaemic cells stimulated by G-CSF In Vitro. *Leuk Lymphoma* 1994; 12: 449-455
353. Fife K, Milan S, Westbrook K, Powles RL, Holmes-Sellors P, & Tait D. Risk factors for requiring cataract surgery following TBI. *Radiotherapy & Oncology* 1994; 33: 93-98
354. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicholson M, Meldrum M, Viner C, Milan S, Selby PJ, Norman A, Raymond J and Powles RL. High-dose melphalan for multiple myeloma: Long Term Follow Up Data: *Journal of Clinical Oncology* 1994; 12 (4) 764-768
355. Cunningham D, Paz-Ares L, Milan S, Powles RL, Nicholson M, Hickish T, Selby P, Treleaven J, Viner C, Malpas J, Slevin M, Findlay M, Raymond J and Gore ME. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. *Journal of Clinical Oncology* 1994, 12 (4) 759-763
356. Powles RL, Mehta J. The Future of Bone Marrow Transplantation: Chapter 92, *Clinical Bone Marrow Transplantation*: K Atkinson Ed. Publ. Cambridge 1994; 736-40
357. Lampe H, Dearnaley DP, Price A, Mehta J, Powles RL, Nicholls J, Horwich A. High dose Carboplatin and etoposide for salvage therapy of germ cell tumours. *Eur J Cancer* 1995; 31a (5): 717-723.
358. Rege K, Mehta J, Treleaven J, Meller ST, Mitchell P, Milan S, Powles RL. Fatal pneumococcal infections following allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 1994, 14: 903-906.
359. Mehta J, Horton C, Milan S, Powles RL. Hyperbilirubinemia after ABO-mismatched allogeneic bone marrow transplantation (BMT). *Br J Haematol* 1994; 86 (Suppl 1): 81
360. Powles RL, Mehta J, Norman A, Iveson T, Cunningham D, Viner C, O'Brien M, Gore M, Malpas J. High dose chemotherapy followed by marrow or blood stem rescue and

- interferon-a for multiple myeloma in first remission or stable plateau. Second Clinical Conference of the International Myeloma Foundation, Singapore, 2-5 March 1994, Abst. No. 6. MISSING
- 361 Powles RL, Mehta J. Overcoming problems of rejection in mismatched and unrelated donor transplants. Abstract Book of a Symposium on Marrow Transplantation in Children: Current Results and controversies, Hilton Head Island, South Carolina, 3-5 March 1994. MISSING
- 362 Singhal S, Mehta J, Powles RL. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. *Blood* 1994; 84: (suppl 1) 489a MISSING
- 363 Singhal S, Mehta J, Powles RL. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. *Blood* 1994; 84: 2055 MISSING
- 364 Mehta J, Singhal S, Powles RL. Approach to the febrile neutropenic patient Part II: antimicrobial therapy and prophylaxis. *Postgraduate Doctor Middle East* 1995; Volume 11: 100-107
- 365 Mehta J, Powles RL, Horton C, Milan S, Treleaven J, Tait D, Catovsky D. Bone marrow transplantation for primary refractory acute leukaemia. *Bone Marrow Transplantation* 1994, 14: 415-418
- 366 Mitchell P, Mehta J, Cunningham D, Raje N, Powles RL. Intron A maintenance therapy in myeloma following high dose melphalan (HDM) and either autologous bone marrow (ABMT) or peripheral blood stem cell transplantation. *Proceedings of Clinical Oncology Society of Australia, Adelaide* (1994). MISSING
- 367 Height SE, Dainton MG, Kearney L, Swansbury GJ, Matutes E, Dyer MJS, Treleaven JG, Powles RL, Catovsky D. Acute Myelomonocytic Leukemia with t(10;11)(p13;q23): Heterogeneity of Breakpoints at 11q23 and Association With Recombinase Activation. *Genes, Chromosomes & Cancer* 1994; 11: 136-139)
- 368 Bell JBG, Barfoot R, Iveson T, Powles RL, Millar BC. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b. *Br J Cancer* 1994; 70: 646-651.
- 369 Powles RL, Parikh P M, Treleaven J, Mehta J, Milan S, Shepherd V, Morton C, Advani S H. G-CSF mobilised peripheral blood stem cell transplantation (PBSCT) for acute lymphoblastic leukemia (ALL) followed by maintenance chemotherapy with 6MP/MTX. *Proceedings of the 16th International Cancer Congress of the UKCC, New Delhi, 30 October - 5 November 1994*, p.281 MISSING
- 370 Parikh PM, Powles RL, Advani SH, Milan S, Mehta J, Antrum J, Morton C, Shepherd V, Treleaven J, Catovsky D. Peripheral blood stem cell transplantation for multiple myeloma. *Proceedings of the 16th International Cancer Congress of the UICC, New Delhi, 30 October - 5 November 1994*; 276 MISSING
- 371 Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles RL. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. *Blood* 1995; 85: 1147-1148.

- 372 Mitchell P, Clutterbuck R, Powles R, De Lord C, Titley J, Millar J. Interleukin-4 (IL-4) improves survival and suppresses human ALL xenografts in scid mice, confirming invitro growth inhibition. *Blood* 84 (10) Supplement: 48a (abstract 179)
- 373 Mitchell P, Clutterbuck R, Powles RL, Bharucha C, Morilla R, Hiorns L, Treleaven J and Millar J. A scid mouse-human cord blood chimera will engraft adult acute myeloid leukaemia (AML) without growth factor support. *Blood* 1994; 84 (10) 48a MISSING
- 374 Mehta J, Powles RL, Treleaven J, Singhal S, Horton C, Milan S, Catovsky D. High dose ARA-C and VP16 with or without idarubicin for induction of remission in untreated primary acute myeloid leukemia. *Blood* 1994;(84)10: 145a (abstract 567). MISSING
- 375 Powles RL, Mehta J, Singhal S, Williams H, Matthey F, Lumley H, Pollard C, Samaratunga, Lakhani A, Treleaven J. Sequential high dose therapy of adult acute lymphoblastic leukemia with blood stem cell autografting and maintenance chemotherapy in first remission reserving allografting for second remission. *Blood* 1994; 84 (Supplement 1) 213a (Abstract 836) MISSING
- 376 Mehta J, Horton C, Powles RL, Milan S, Treleaven J. Elevated bilirubin after allogeneic bone marrow transplantation: effect of donor-recipient ABO blood group incompatibility. *Blood* 1994; 84 (Supplement 1) p.488a, abstract 1936. MISSING
- 377 Singhal S, Powles RL, Mehta J, Treleaven J, Horton C, Carrington D, Tryhorn Y, Milan S, Jameson B. A short course of preemptive ganciclovir for cytomegaloviremia after allogeneic bone marrow transplantation. *Blood* 1994, 84 (Supplement 1) p.489a abstract 1943 MISSING
- 378 Powles RL, Cunningham D, Malpas JS, Raje N, Milan S, Singhal S, Mehta J, Viner C, Treleaven J, Raymond J. A randomised trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma. *Blood* 1994; 84 (Supplement 1) p535a, abstract 2127 MISSING
- 379 Mitchell P, Clutterbuck R, Powles RL, De Lord C, Titley J and Millar J. Human leukaemias engrafted into scid mice - a model for in vivo testing of cytotoxic therapy. *Blood* 1994; 84 (1): 622a
- 380 Mehta J, Powles RL, Singhal S, Chang J, Smith J, Treleaven J. Cytokine-mediated immunotherapy with or without donor cells for acute leukemia relapsing after allogeneic bone marrow transplantation. *Blood* 1994; 84 (Supplement 1) p 714a, abstract 2842. MISSING
- 381 Mehta J, Powles RL, Treleaven J, Singhal S, Horton C, Tait D, Milan S, Meller S, Pinkerton C, Chang J, Hamblin M, O'Driscoll A, Zomas A, Catovsky D. Melphalan versus cyclophosphamide with total body irradiation as conditioning for allogeneic bone marrow transplantation in first remission acute myeloid leukemia. *Blood* 1994 (Supplement 1) p. 714a, abstract 2843
- 382 Powles RL, Mehta J, Singhal S, Treleaven J, Horton c, Tait D, Milan S, Meller S, Pinkerton C, Catovsky D. Autografting for acute myeloid leukemia in first remission: evaluation of a

- conditioning regimen containing melphalan and identification of modifiable treatment related prognostic factors. *Blood* 1994 (Supplement 1) p. 718a, abstract 2859. MISSING
- 383 Raje N, Powles RL, Mehta J, Singhal S, Milan S, Horton S, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Blood* 1994 (Supplement 1) p719a, abstract 2862. MISSING
- 384 Singhal S, Powles RL, Mehta J, Milan S, Horton C, Treleaven J, Raje N, Barton C, Viner C, Cunningham D. Second autografts for relapsed multiple myeloma. *Blood* 1994 (Supplement 1) p2871 abstract 2871. MISSING
- 385 Mehta J, Powles RL, Cabral S, Morilla R, Shepherd V, Treleaven J, Catovsky D. Comparison of COBE spectra and haemonetics MCS-3P cell separates for harvesting peripheral blood stem cells. *Blood* 1994; (Supplement 1) p737a, abstract 2935. MISSING
- 386 Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles RL. Oral Pilocarpine Hydrochloride for the Treatment of Refractory Xerostomia associated With Chronic Graft-Versus-Host-Disease. *Blood* 1995; 85 (4): 1147 -1148.
- 387 Powles RL, Mehta J, Norman A, Iveson I, Cunningham D, Viner C, O'Brien M, Gore M, Malpas J. High-Dose Melphalan with Bone Marrow or Peripheral Blood Stem Cell Transplantation Followed by Interferon- for Multiple Myeloma. *Annals of Oncology*, ESMO, 19th Congress of the European Society for Medical Oncology, Nov 18-22 1994
- 388 Raje N, Powles RL, Mehta J, Singhal S, Milan S, Horton C, Viner C, Treleaven J. Peripheral Blood Stem Cell Transplantation in Multiple Myeloma. *Bone Marrow Transplantation*, Volume 15, Supplement 2, March 1995 abstract 142, p S30. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 389 Cabral S, Powles RL, Mehta J, Morilla R, Shepherd V, Treleaven J, Catovsky D. Comparison of COBE Spectra and Haemonetics MCS-3P cell separators for harvesting peripheral blood stem cells. *Bone Marrow Transplantation*, Volume 15, Supplement 2, March 1995. Abstract 201, p S44. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 390 Mehta J, Powles RL, Treleaven J, Singhal S, Tait D, Milan S, Horton C, Millar J. Autografting for Adult Acute Lymphoblastic Leukaemia: The Role of Post-Transplant Maintenance Chemotherapy. *Bone Marrow Transplantation*, Volume 15, Supplement 2, March 1995. Abstract 235, p S53. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 391 Powles RL, Singhal S, Mehta J, Tait D, Milan S, Horton C, Treleaven J. A Package of Treatment Options for the Total Therapy of Acute Myeloid Leukaemia. *Bone Marrow Transplantation*, Volume 15, Supplement 2, March 1995. Abstract 270, p S62. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 392 Mitchell PLR, Mehta J, Horton C, Treleaven J, Powles RL. Relapsed acute Myeloid Leukaemia - Results of High Dose Therapy with Autologous Bone Marrow Transplantation (ABMT). *Bone Marrow Transplant* 1995; 15 (2) S65.

- 393 Mehta J, Powles RL, Singhal S, Chang J, Willis A, Treleaven J. Interferon-Mediated Immunotherapy for Acute Leukemia Relapsing After Allogeneic BMT. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 294, p S68. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 394 Mehta J, Powles RL, Singhal S, Horton C, Tait D, Milan S, Treleaven J. Melphalan-total Body Irradiation and Unpurged Autografting for Acute Myeloid Leukemia: impact of Consolidation Therapy on Outcome. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 295, p S68. (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 395 Singhal S, Powles RL, Mehta J, Milan S, Horton C, Raje N, Viner C, Treleaven J, Cunningham D. Kinetics of Paraprotein Disappearance after Autografting for Myeloma. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 473, p S113 (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 396 Singhal S, Powles RL, Mehta J, Milan S, Horton C, Treleaven J, Raje N, Viner C, Cunningham D. Second Autografts for Relapsed Multiple Myeloma. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 474, p S113 (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 397 Chang J, Powles RL, Mehta J, Treleaven J, Jameson B, Willis A. Retrospective study of listeria monocytogenes infection in bone marrow transplant recipients. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 519, p S125 (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 398 Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles RL. Oral pilocarpine for refractory xerostomia associated with chronic graft-versus-host disease. Bone Marrow Transplantation, Volume 15, Supplement 2, March 1995. Abstract 588, p S142 (EBMT, 21st Annual Meeting of the EBMT and 11th Meeting of the Nurses Group, Davos, Switzerland (March 19 - 23 1995))
- 399 Powles RL, Mehta J, Treleaven J, Singhal S, Chang J, Willis A, Horton C, Milan S, Tait D, Catovsky D. Melphalan or cyclophosphamide and total Body irradiation prior to allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. Bone Marrow Transplant 1995; 15 (suppl 2) S149
- 400 Gluckman, HG Prentice, Powles RL, P Ljungman, NJ Milpied, R Camara, F Mandelli for the European Acyclovir for CMV Prophylaxis Study Group, Hôpital Saint Louis, Paris, France. Double-Blind Randomised Study of the Effect of Long-Term Acyclovir (ACV) on Cytomegalovirus (CMV) Infection and Survival After Bone Marrow Transplant (BMT).
- 401 Singhal S, Mehta J, Powles RL, Treleaven J, Horton C, Carrington D, Tryhorn Y, Jameson B. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995; 15: 777-781

- 402 Mehta J, Powles RL, Singhal S, Treleaven J. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. *Bone Marrow Transplantation* 1995; 15: 652-653
- 403 Barlogie B, Anderson K, Berenson J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles RL, Reece D, Reiffers J, Salmond S, Tricot G, Vesole D. Transplants for multiple myeloma. *Bone Marrow Transplantation*, 1995 Volume 15 (Supplement 1); 234-246
- 404 Zoman A, Mehta J, Powles RL, Treleaven J, Iveson T, Singhal S, Jameson B, Paul B, Brincat S, Catovsky D. Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukaemia. *Bone Marrow Transplant* 1994; 14: 799-803.
- 405 Powles RL, Mehta J, Singhal S, Horton C, Tait D, Milan S, Pollard C, Lumley H, Matthey F, Shirley J, Williams H, Samaratunga I, Lakhani A, Millar J and Treleaven J. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. *Bone Marrow Transplant* 1995; 16: 241-247
- 406 Stewart A, Powles RL, Hewetson M, Mehta J, Antrum J, Richardson C. Costs of antifungal prophylaxis after Bone Marrow Transplantation: Model comparing oral fluconazole, liposomal mphotericin and oral polyenes. *Pharmaco Economics* 1995; 8; 350-361
- 407 Mehta J, Powles RL, Singhal S, Horton C, Tait D, Milan S, Meller S, Pinkerton R, Treleaven J. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. *Bone Marrow Transplantation* 1995; Vol. 16; pp.499-507.
- 408 Chang J, Powles RL, Mehta J, Paton N, Treleaven J, Jameson B. Listeriosis in bone marrow transplant recipients: Incidence, clinical features, and treatment. *Clin Infect Dis* 1995; 21: 1289-1290
- 409 Mehta J, Powles RL, Horton C, Milan S, Singhal S, Treleaven J. The relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. *Bone Marrow Transplant* 1995; 15; 853-858
- 410 Singhal S, Powles RL, Milan S, Raje N, Viner C, Treleaven J, Raymond J, Cunningham D, Mehta J. Kinetics of paraprotein clearance after autografting for multiple myeloma. *Bone Marrow Transplant* 1995; 16: 537-540.
- 411 Mehta J, Powles RL, Cabral S, Shepherd V, Singhal S, Morilla R, Treleaven J, Comparison of Cobe Spectra and Haemonetics MCS-3P cell separates for harvesting peripheral blood stem cells. *Bone Marrow Transplant.* 1995; 16: 707-709
- 412 Mehta J, Powles RL, Singhal S, Tait D, Swansbury J and Treleaven J. Cytokine-mediated immunotherapy with or without donor leucocytes for poor risk acute myeloid leukaemia relapsing after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 1995; 16: 133-137

- 413 Steele JPC, Mitchell PLR, Clutterbuck RD, Powles RL, Catovsky D, Morilla R, Cayuela J, Sigaux F, Dyer M, Zani W, Heward J, Jaydayel D and Millar J. T-cell acute lymphoblastic leukaemia (T-ALL). Engraftment in SCID mice. *Blood* 1995; 86 (1): 768a MISSING
- 414 Dunlop L, Powles RL, Treleaven J, Swansbury GJ, Singhal S, Mehta J. Bone Marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia. *Bone Marrow Transplant* 1996; 17: 365-369
- 415 Singhal S, Powles RL, Treleaven J, Pollard C, Lumley H, Mehta J. Allogeneic bone marrow transplantation for primary myelofibrosis *Bone Marrow Transplantation* 1995; 16: 743-746.
- 416 Chang J, Powles RL, Singhal S, Jameson B, Treleaven J, Mehta J. Foscarnet for cytomegalovirus infection after allogeneic bone marrow transplantation. *Clin Infect Dis* 1996; 22: 583-584
- 417 Mehta J, Mijovic A., Powles RL, Pagliuca A, Singhal S, Czepulkowski B, Swansbury GJ, Treleaven J. and Mufti GJ. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukaemia. *Bone Marrow Transplant*: 1996; 17: 25-29.
- 418 Powles RL. Role of IFN Alpha in Residual Disease in Multiple Myeloma. *hematology and oncology*. Abstract 1995 Genval, Brussels 16th June 1995. Schering Plough.
- 419 Mehta J, Powles RL, Singhal S, Horton C, Treleaven. Outcome of autologous rescue after failed engraftment of allogeneic marrow. *Bone Marrow Transplant* 1996 17, 213-217
- 420 Mehta J, Powles RL, Treleaven J, Singhal S, Horton C, Catovsky. Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia. *Br J Haematol* 1995: 89 (Suppl 1): 66
- 421 Mehta J, Powles RL, Singhal S, Shepherd V, Cabral S, Treleaven J. Peripheral blood stem cell harvesting in acute lymphoblastic leukemia: the effect of G-CSF dose and harvest schedule on cell yields. *Br J haematol* 1995: 89 (Suppl 1):19
- 422 Mehta J, Powles RL, Singhal S, Willis A, Chang J, Horton C, Tait D, Milan S, Treleaven J. Melphalan-total body irradiation and allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. *Br J Haematol* 1995: 89 (Suppl 1): 16
- 423 Powles R, Singhal S, Mehta J, Tait D, Catovsky D, Treleaven J. Total therapy of acute myeloid leukemia: Outcome evaluation of a package of treatment options. *Br J Haematol* 1995; 89 (Suppl 1): 66
- 424 Singhal S, Powles RL, Treleaven J, Lumley H, Pollard C, Mehta J. Allogeneic bone marrow transplantation for primary myelofibrosis. *Br J Haematol* 1995: 89 (Suppl 1): 17
- 425 Powles RL, Singhal S, Mehta J, Tait D, Milan S, Treleaven J. Total Therapy of acute lymphoblastic leukemia. *Br J Haematol* 1995: 89 (Suppl 1):66
- 426 Singhal S, Powles RL Mehta J, Horton C, Meller S, Pinkerton CR, Milan S, Treleaven J. Effect of cell dose on transplant-related mortality after autografting for acute myeloid leukemia. *Br J Haematol* 1995: 89 (Suppl 1): 19

- 427 Powles RL, Mufti GJ, Mehta J, Pagliuca A, Mijovic A, Swansbury J, Czepulkowski B, Singhal S, Treleaven J. Harvesting peripheral blood stem cells after myelosuppressive chemotherapy in chronic myeloid leukaemia. *Br J Haematol* 1995; 89 (Suppl 1):38
- 428 Powles RL, Raje NS, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. *Br J Haematol* 1995; (Suppl 1):83
- 429 Raje N, Powles RL, Mehta J, Singhal S, Milan S, Horton C, Viner C, Treleaven J. Peripheral Blood Stem Cell Transplantation in Multiple Myeloma. *Br J Haematol* 1995; 89 (Suppl 1); 84
- 430 Powles R L, Raje N, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Single centre results of total therapy including autografts in previously untreated myeloma. *Br J Haematol* 1995; 89 (Suppl1): 53
- 431 Dunlop LC, Mehta J, Treleaven J, Powles RL. Results of bone marrow transplantation in Philadelphia chromosome positive acute lymphoblastic leukaemia. *Br J Haem* 1995; 89 (Suppl 1): 18
- 432 Clutterbuck R, Newman A, Powles RL, Catovsky D & Millar J. Differential sensitivity of leukaemic and normal bone marrow progenitor cells to simvastatin. *Brit J Haem* 1995; 89 (Suppl 1): 60
- 433 Mitchell P, Clutterbuck R, Powles RL, De Lord C, Titley J, Morilla R, Hiorns L, Van Rhee F, Catovsky D and Millar J. Engraftment leukaemia in scid mice and treatment of antisense oligodeoxynucleotides (ODNs) targeting BCR-ABL. *Br J Haematol* 1995; 89 (1) 47
- 434 Mehta J, Powles RL, Singhal S, Chang J, Willis A, Treleaven J. Interferon-mediated immunotherapy for acute leukemia relapsing after allogeneic BMT. *Bone Marrow Transplant* 1995; 15 (Suppl 2) S68
- 435 Powles RL, Parikh PM, Treleaven J, Mehta J, Milan S, Shepherd V, Morton C, Advani SH. G-CSF mobilised peripheral blood stem cell transplantation (PBSCT) for acute lymphoblastic leukaemia (ALL) followed by maintenance chemotherapy with 6 MP/MTX. Proceedings of the 16th Cancer Congress of the UICC, New Delhi, 30 October-5 November 1994: p. 281 MISSING
- 436 Chang J, Powles RL, Singhal S, Jameson B, Treleaven J, Mehta J. Foscarnet for cytomegalovirus infection after allogeneic bone marrow transplantation. *Br J Cancer* 1995; 71 (suppl 24): 69
- 437 Newman A, Clutterbuck RD, DeLord C, Powles RL, Catovsky D, and Millar JL. The Sensitivity of leukemic bone marrow to simvastatin is lost at remission: A potential purging agent for autologous bone marrow transplantation. *J. Investig Med* 1995; 43: 269-274
- 438 Mehta J, Powles RL, Singhal S, Matthey F, Prendiville J, Glynne P, Treleaven J. T-cell depleted allogeneic bone marrow transplantation from an HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. *Bone Marrow Transplant* 1996; 17; 881-885

- 439 Singhal S, Powles RL, Mehta J, Rattenbury H, Treleaven J. Oral pilocarpine for refractory xerostomia associated with chronic graft-versus-host disease. *Bone Marrow Transplant* 1995; 15 (Suppl 2): S142
- 440 Nelson PN, Rawal BK, Boriskin YS, Mathers KE, Steel HM, Powles RL, Tryhorn YS, Butcher PD and Booth JC. A polymerase chain reaction (PCR) to detect a spliced 'late' transcript of human cytomegalovirus (CMV) in the blood of bone marrow transplant recipients. *J. Virological Methods* 1996; 56: 139-148
- 441 J Mehta, Powles RL, Singhal S, Horton C, Milan S, Tait D, Treleaven J. Sequential high-dose therapy of adult acute lymphoblastic leukemia: role of maintenance chemotherapy after peripheral blood stem cell transplantation in first remission. "Autologous Marrow and Blood Transplantation" (Proceeding of the Seventh International Symposium, Arlington, Texas, 1994). p.135-144
- 442 Mitchell PLR, Clutterbuck R, Powles RL, DeLord C, Titley J, Catovsky D and Millar JL. Human Interleukin-4 (IL-4) Suppresses Human Acute Lymphoblastic Leukaemia (ALL) Engrafted into SCID Mice and Improves Their Survival. *"Acta Haematologica"* 1995; 93:169
- 443 Pattison RM, O'Donnell MA, Powles RL, Moss ALH. A painful knee in an immunocompromised patient. *Postgrad Med J.* 1996 72: 00-00.
- 444 Powles RL, N Raje, C Horton, J Mehta, S Singhal, T Hickish, C Viner, S Milan, J Treleaven, D Cunningham. Comparison of Interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. *Leuk Lymphoma* 1995; 18: 179-184.
- 445 Mitchell PLR, Clutterbuck RD, Powles RL, Steele J, DeLord C, Titley J, Morilla R, Hiorns L, Catovsky DL, Millar JL. Modelling patient treatment in the immunodeficient mouse: conventional and novel therapy of acute B-lineage leukaemias engrafted into scid mice. *Exp Haematol* 1995; 23: 931-
- 446 Millar B, Bell JBG, Powles RL. Lymphocyte recovery and clinical response in multiple myeloma patients receiving Interferon Alpha 2 beta after intensive therapy. *Br J Cancer* 1996: 73; 236-240.
- 447 Mehta J, Powles RL, Singhal S, Jameson B, Treleaven J. Amphotericin B Lipid Complex (ABLCL) for fungal sepsis in high-risk immunocompromised patients. *Can J Infect Dis* 1995; 6 (Suppl C): 365C.
- 448 Singhal S, Powles R, Mehta J, Cabral S, Treleaven J. Mobilization of peripheral blood stem cells in healthy donors using G-CSF. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
449. Singhal S, Powles R, Mehta J, Treleaven J. Allogeneic bone marrow transplantation for primary myelofibrosis. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
- 450 Singhal S, Mehta J, Powles RL, Treleaven J. Effect of G-CSF dose and harvest schedule on peripheral blood stem cell yields. *Can J Infect Dis* 1995; 6 (Suppl C):370C.

451. Singhal S, Powles RL, Mehta J, Treleaven J. Immunotherapy of relapsed leukemia after allogeneic bone marrow transplantation. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
452. Raje N, Powles RL, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):307C.
453. Raje N, Powles RL, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):307C.
454. Raje N, Powles RL, Horton C, Mehta J, Singhal S, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):371c.
455. Mehta J, Powles RL, Singhal S, & Treleaven J. Idarubicin, High Dose Cytarabine and VP-16 for remission induction in acute myeloid leukaemia. *Can J Infect Dis* 1995; 6 (Suppl C): 305c
456. Powles RL, Cunningham D, Malpas JS, Raje N, Milan S, Singhal S, Mehta J, Viner C, Treleaven J. A randomised trial of maintenance therapy with Intron-A following high-dose melphalan in myeloma - an update. *Can J Infect Dis* 1995; 6 (Suppl C):307c.
457. Powles RL, Raje N, Mehta J, Singhal S, Hickish T, Viner C, Horton C, Milan S, Treleaven J, Cunningham. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplant for myeloma patients who have responded to induction therapy. *Leuk Lymphoma* 1996; 21: 421-427. MISSING
458. Powles RL, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C, Treleaven J. Maintenance Therapy for Remission in Myeloma with Intron-A following High Dose Melphalan and either an Autologous Bone Marrow Transplantation or Peripheral Stem Cell Rescue. *Stem Cell* 1995; 13 (suppl 2): 114-117. MISSING
459. Mehta J, Powles RL, Singhal S, Horton C, Tait D, Treleaven J. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after Cyclophosphamide-Total Body Irradiation and Cyclosporine: Long-term follow-up. *Blood* 1995; 86 (Supplement 1): 93a No. 360 MISSING
460. Singhal S, Powles RL, Treleaven J, Horton C, Meller S, Pinkerton CR, Mehta J. Central nervous system relapse after Bone Marrow Transplantation for Acute Leukemia in First Remission. *Blood* 1995; 86 (Supplement 1): 98a No. 379
461. Singhal S, Powles RL, Treleaven J, Mehta J. Immunotherapy of Acute Leukemia Relapsing after Allogeneic Bone Marrow Transplantation. *Blood* 1995; 86 (Supplement 1): 98a No. 380
462. N. Raje, Powles RL, S. Milan, T. Hickish, J. Mehta, S. Singhal, C. Viner, J. Treleaven, D. Cunningham. Induction Treatment with Vamp/C-Vamp Infusional Chemotherapy in Previously untreated Myeloma. *Blood* 1995; 86 (Supplement 1): 186a No. 731
463. Powles RL, Raje N, Milan S, Mehta J, Singhal S, Hickish T, Viner C, J. Treleaven J, Cunningham D. Impact of Induction Chemotherapy followed by High Dose Treatment in previously untreated Myeloma: A Single Centre Experience. *Blood* 1995; 86 (suppl 1): 186a No. 732

- 464 Powles RL, Raje N, Milan S, Hickish T, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic Factors in Multiple Myeloma. *Blood* 1995; 86 (suppl 1): 186a No. 733
- 465 S. Singhal, R. Powles, D. Cunningham, C. Horton, J. Treleaven, N. Raje, C. Viner, J. Mehta. Repeat Autografts for Relapsed Myeloma. *Blood* 1995; 86 (Supplement 1): 207a No. 814
- 466 Mehta J, Powles RL, Singhal S, Horton C, Treleaven J. Consolidation Therapy of Adult Acute Lymphoblastic Leukemia: Role of Sequential Auto and Allografting. *Blood* 1995; 86 (Supplement 1) 384a No. 1526 MISSING
- 467 Mehta J, Powles RL, Singhal S, Milan S, Treleaven J. GM-CSF After Allogeneic Bone Marrow Transplantation for Hematologic malignancies: 5-Year Follow-up. *Blood* 1995; 86, (Suppl 1); 385 1527
- 468 J. Mehta, Powles RL, S. Singhal, C. Horton, J. Treleaven. Autologous Hematopoietic Rescue after Primary Failure of Alloengraftment. *Blood* 1995; 86: 10 (Suppl 1) 392a No. 1555
- 469 Powles RL, Singhal S, Treleaven J, Hayward T, Ellis C, Mehta J. The First patients to have received cyclosporine for graft-versus-host disease prophylaxis after Bone Marrow Transplantation: 15-Year Follow-up. *Blood* 1995; 86: 10 (supplement 1) 394a No. 1565
- 470 Singhal S, Powles RL, Treleaven J, Rattenbury H, Mehta J. Pilocarpine for xerostomia after Bone Marrow Transplantation. *Blood* 1995; 86: 10 (Supplement 1) 400a No. 1588
- 471 Treleaven J, Powles RL, Singhal S, Swansbury GJ, Millar B, Shepherd V, Bell J, Min T, Cabral S, Mehta J. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia. *Blood* 1995; 86: 10 (Supplement 1) 405a No. 1608
- 472 Singhal S, Powles RL, Treleaven J, Horton C, Hamblin M, Zomas A, Prendiville J, Saso R. Idarubicin high dose cytarabine and etoposide for induction of remission in acute myeloid leukaemia. *Blood* 1995; 86: 10 (Supplement 1) 513a No. 2039
- 473 Mehta J, Powles RL, Singhal S, Horton C, Prendiville J, Glynne P, Zomas A, Hamblin M, Saso R, Mackay H, Treleaven J. Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia. *Blood* 1995; 86: 10 (Supplement 1) 513a No. 2041
- 474 Mehta J, Kelsey SM, Chu P, Powles RL, Singhal S, Hazel D, Newland AC, Treleaven JG. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. *Blood* 1997; 86: 10 (Supplement 1) 513a No. 2042
- 475 Powles RL, Singhal S, Horton C, Treleaven J, Mehta J. Total therapy of adult acute myeloid leukemia: Evaluation of bone marrow transplantation. *Blood* 1995; 86: 10 (Supplement 1), 518a No. 2062
- 476 C. Anasetti, A. Lin, A. Nademanee, E. Gluckman, H. Messner, P. Beatty, T. Chauncey, N. Jacobsen. A Phase II/III Randomized, double-blind, Placebo-controlled Multicenter Trial of Humanized Anti-Tac for prevention of Acute graft-versus-host Disease (GVHD) in

- recipients of Marrow Transplants from unrelated Donors. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 621a No. 2472
- 477 Mehta J, Powles RL, Hamblin M, Zomas A, Singhal S, Glynne P, Prendiville J, Swansbury GJ, Min T, Saso R, Mackay H, Treleaven J. Bleeding diathesis 4 weeks into the course of tretinoin therapy in promyelocytic leukemia. *Blood* 1995, 86: 10 (Supplement 1), 770a No. 3068
- 478 Mitchell PLR, Clutterbuck RD, Powles RL, Catovsky DL, Morilla R, Cayuela J, Sigaux E, Dyer M, Zani V, Heward J, Jaydayel D and Millar JL. T-cell acute lymphoblastic leukemia (T-ALL): Engraftment in SCID mice. *Blood* 1995; 86: 10 (Supplement 1) 1995 782a No. 3114
- 479 Treleaven J, Powles RL, Singhal S, Saso R, Zomas A, Hamblin M, Mackay H, Mehta J. Addition of CCNU to daunorubicin-cytarabine (3+7) for remission induction in acute myeloid leukemia patients over 50 Years. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 784a No. 3124
- 480 Raje N, Powles RL, Hickish T, Milan S, Horton C, Mehta J, Singhal S, Treleaven J, Cunningham D. Beta 2 Microglobulin levels in Patients of Myeloma following high dose treatment and interferon maintenance. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 841a No. 3351
- 481 Raje N, Powles RL, Hickish T, Horton CAP, Milan S, Mehta J, Singhal S, C. Viner C, Treleaven J, Cunningham D. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden Experience. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 841a No. 3352
- 482 Glynne P, Powles RL, Steele J, Singhal S, Prendiville J, Horton C, Treleaven J, Mehta J. Long-term Renal Dysfunction after Autologous Bone Marrow Transplantation. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 947a No. 3775
- 483 Mehta J, Powles RL, Singhal S, Prendiville J, Glynne P, Zomas A, Hamblin M, Saso R, Mackay H, Swansbury Treleaven J, Catovsky D. Allogeneic Bone Marrow Transplantation for Chronic Lymphocytic Leukemia. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 958a No. 3821
- 484 Mehta J, Powles RL, Singhal S, Horton C, Pinkerton CR, Meller S, Treleaven J. Factors affecting engraftment after unpurged autografting in acute leukemia. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 958a No. 3822
- 485 Mehta J, Singhal S, Powles RL, Horton C, Milan S, Treleaven J. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: The effect of donor-recipient ABO incompatibility. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 959a No. 3823
- 486 Powles RL, Treleaven J, Horton C, Jameson B, Mehta J. Cytomegalovirus after autografting. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 966a No. 3853

- 487 Singhal S, Powles RL, Treleaven J, Horton C, Jameson B, Mehta J. Temporal pattern of cytomegalovirus infection after allogeneic bone marrow transplantation. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 966a No. 3854.
- 488 Treleaven J, Powles RL, Singhal S, Horton C, Tait D, Meller S, Pinkerton CR, Mehta J. Melphalan and total body irradiation as a conditioning regimen for autologous bone marrow transplantation in acute myeloid leukaemia. *Blood* Vol 86, No 10, Supplement 1, November 15, 1995, Pg 968a No. 3861.
- 489 Tanner SF, Clarke J, Leach LO, Mesbhai MH, Nicolson V, Powles RL and Husband J. MRI in the evaluation of late bone marrow changes following bone marrow transplantation. *The British Journal of Radiology* 1996; 69: 1145-1151,
- 490 Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. *Br J Haem* 1997; 96: 314-321.
- 491 Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, & Dyer MJS. Deletions and re-arrangement of CDKN2 in lymphoid malignancy. *Blood* 1995; 85: 893-901
- 492 Mehta J, Powles RL, Singhal S, Swansbury J, Millar J, Shepherd V, Bell J, Min T, Cabral S, & Treleaven J. High dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukaemia: *Leuk Lymphoma* 1996; 23: 107-111.
- 493 Singhal S, Powles RL, Treleaven J, Horton C, Meller S, Pinkerton CR, Mehta J. Central nervous system relapse after Bone Marrow Transplantation for Acute Leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1): S38.
- 494 Mehta J, Singhal S, Powles RL, Horton C, Hamblin M, Zomas A, Saso R, Treleaven J. Transfusion requirements after bone marrow transplantation from HLA-Identical siblings: The Effect of donor-recipient ABO incompatibility. *Bone Marrow Transplantation* 1996; 18: 151-156.
- 495 Mehta J, Powles RL, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-TBI and allogeneic bone marrow transplantation for acute leukaemia first remission. *Bone Marrow Transplant* 1996; 17 (Suppl 1): 22
- 496 Philpot NJ, Elebute MO, Powles RL, Treleaven JG, Gore M, Dainton MG, Min T, Swansbury GJ, and Catovsky D. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. *British J Haem* 1996; 93:884-887
- 497 Hamblin M, Powles RL, Treleaven J, Saso R, Singhal S, Middleton G, Kulkarni S, Cabral S & Mehta J. Defibrotide for refractory thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation. *Blood* 1996; 88 (suppl 1) 60b MISSING
- 498 Mehta J, Singhal S, Powles. Peripheral blood stem cell transplantation. In Shankar PS, Ed. *Medicine Update Volume V Madras*, Association of Physicians of India, 1995; 285-292 MISSING

- 499 Mehta J, Powles RL, Treleaven J, Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukaemia. *Bone Marrow Transplant* 1996; 18: 319-324.
- 500 Calabrese G, Min T, Stuppia L, Powles RL, Swansbury JG, Morizio E, Pelia R, Donti E, Fioritoni G, and Palka G. Complex chromosome translocations of standard t(8;21) and t(15;17) arise from a two-step mechanism as evidenced by fluorescence In Situ Hybridization analysis. *Cancer Genet Cytogenet* 1996; 91: 40-45
- 501 Mehta J, Singhal S, Powles RL. Approach to the febrile neutropenic patient II: Antimicrobial therapy and prophylaxis. *Postgrad D Middle East* 1995; 16: 446-451
- 502 Mehta J, Singhal S, Powles RL. Approach to the febrile neutropenic patient. I: General principles of management. *Postgrad Doctor Caribbean* 1995; 11:100-107
- 503 Mehta J, Powles RL, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Prendiville J, Glynne P, Allford S, Mackay H, Treleaven J. Idarubicin, high dose cytarabine and etoposide for induction of remission in acute leukaemia. *Semin Hematol* 1996; 33 (Suppl 3): 18-23.
- 504 Mehta J, Powles RL, Singhal S, Treleaven J. Idarubicin, high dose cytarabine and VP-16 for remission induction in acute myeloid leukaemia. *Can J Infect Dis* 1995; 6 (Suppl C):305C
- 505 Mehta J, Powles RL, Singhal S, Jameson B, Treleaven J. Amphotercin B Lipid Complex (ABLC) for fungal sepsis in high-risk immunocomprised patients. *Eur J Cancer* 1995; 31A (Suppl 5): S255.
- 506 Singhal S, Powles RL, Cabral S, Treleaven J, Mehta J. G-CSF (Filgrastim) for mobilization of stem cells in healthy donors. *Eur J Cancer* 1995;31A (Suppl 5):S123.
- 507 Mehta J, Singhal S, Treleaven J, Horton C, Tait D. Powles RL. Long-term follow-up of allogeneic marrow transplantation for acute myeloid leukemia after cyclophosphamide total body irradiation and cyclosporine. *Eur J Cancer* 1995; 31A (Suppl 5) S236.
- 508 Singhal S, Powles RL, Treleavan J, Long S, Shepherd V, Millar B, Bell J, Mehta J. Comparison of marrow and blood stem cell yields in a double blind, randomised study of allogeneic marrow versus blood stem cell transplantation. Abstract: Proceedings of the 6th Biennial Sandoz-Keystone Symposium on Bone Marrow Transplantation; Keystone Colorado, Jan 15-21, 1996:(409).
- 509 Mehta J, Powles RL, Singhal S, Horton C, Treleaven J. Role of sequential auto and allografting in adult acute lymphoblastic leukaemia. Abstract: Proceedings of the 6th Biennial Sandoz-Keystone Symposium on Bone Marrow Transplantation: Keystone Colorado, Jan 15-21, 1996: (306)
510. Mehta J, Powles RL, Singhal S, Jameson B, Treleaven J. Amphotericin B Lipid Complex (ABLC) for fungal sepsis in high-risk immunocompromised patients. *Eur J Cancer* 1995; 31A (Suppl 5):S255.
- 511 Singhal S, Powles RL, Cabral S, Treleaven J, Mehta J. G-CSF (Filgrastim) for mobilization of stem cells in healthy donors. *Eur J Cancer* 1995; 31A (Suppl 5):S123.

- 512 Mehta J, Singhal S, Treleaven J, Horton C, Tait D, Powles RL. Long-term follow-up of allogeneic marrow transplantation for acute myeloid leukemia after cyclophosphamide-total body irradiation and cyclosporine. *Eur J Cancer* 1995; 31A (Suppl 5):S236.
- 513 Powles RL, Singhal S, Horton C, Treleaven J, Mehta J. Total therapy of acute myeloid leukemia. *Eur J Cancer* 1995; 31A (Suppl 5):S162.
- 514 Singhal S, Powles RL, Cunningham D, Hickish T, Middleton G, Raje N, Viner C, Mehta J. Second autografts for relapsed myeloma. *Eur J Cancer* 1995; 31A (Suppl 5): S168.
- 515 Mehta J, Powles RL, Singhal S, Tait D, Hjiyiannakis P, Prendiville J, Gynne P, Horton C, Treleaven J. Allogeneic bone marrow transplantation for acute myeloid leukemia after melphalan and total body irradiation. *Eur J Cancer* 1995; 31A (Suppl 5):S236-S237.
- 516 Mehta J, Singhal S, Treleaven J, Horton C, Powles RL. Sequential high-dose therapy of adult acute lymphoblastic leukemia. *Eur J Cancer* 1995; 31A (Suppl 5):S170.
- 517 Singhal S, Powles RL, Treleaven J, Prendiville J, Glynne P, Mehta J. Immunotherapy for acute leukwmi relapsing after alloneic bone marrow transplantation. *Eur J Cancer* 1995; 31A (Suppl 5):S237.
- 518 Middleton GW, Mehta J, Miller BC, Bell JA, Raje N, Hickish T, Shepherd V, Powles RL. Comparison of two stem cell mobilization and harvesting regiments for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM). *Eur J Cancer* 1995 31A (Suppl 5): S53-S54.
- 519 Raje N, Powles RL, Horton C, Middleton G, Hickish T, Mehta J, Singhal S, Morton C, Porter H, Viner C, Treleaven J. Peripheral blood transplants followed by maintenance interferon in myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S170-S171.
- 520 Powles RL, Raje N, Hickish T, Middleton G, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Single centre results of therapy including autografts in previously untreated myeloma. *Eur J Cancer* 1995; (Suppl 5): S167
- 521 Raje N, Powles RL, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S167
- 522 Mehta J, Powles RL, Singhal S, Zomas A, Saso R, Hamblin M, Mackay H, Horton C, Treleaven J. Transfusion requirements after allogeneic bone marrow transplantation: The effect of donor-recipient ABO incompatibility. *Bone Marrow Transplant* 1996, Vol 17 (Suppl 1), page 42.
- 523 Mehta J, Powles RL, Singhal S, Treleaven J, Prendiville J, Allford S, Matthey F, Tait D, Saso R, Hamblin M, Zomas A, Mackay H, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia. *Bone Marrow Transplant* March 1996, Vol 17,(Suppl 1), page 66.
- 524 Treleaven J, Powles RL, Singhal S, Horton C, Tait D, Prendiville J, Hamblin M, Saso R, Zomas A, Mackay H, Allford S, Meller S, Pinkerton CR, Mehta J. Allografting for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and

- cyclosporine: Long-term follow-up. *Bone Marrow Transplant* March 1996. Vol 17 (Suppl 1.), page 24.
- 525 Singhal S, Powles RL, Treleaven J, Saso R, Long S, Rowland A, Shepherd V, Millar B, Bell J, Field M, Morton C, Cabral S, Newman A, Mehta J. Comparison of cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 117
- 526 Singhal S, Powles RL, Treleaven J, Horton C, Jameson B, Mehta J. Temporal pattern of CMV infection after allogeneic bone marrow transplantation. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 95.
- 527 Mehta J, Powles RL, Singhal S, Horton C, Atra A, Pinkerton CR, Meller S, Treleaven J. Factors affecting engraftment after autografting for acute leukemia. *Bone Marrow Transplant* 1996, Vol 17: Suppl 1 pp. S136
- 528 Mehta J, Powles RL, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T, and Singhal S. Long term follow up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukaemia in first complete remission after cyclophosphamide total body irradiation and cyclophosphamide. *Bone Marrow Transplant* 1996; 18: 741-746.
- 529 Singhal S, Powles RL, Treleaven J, Tattenbury H, Tait D, Mehta J. Pilocarpine for xerostomia after bone marrow transplantation. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 39.
- 530 Mehta J, Powles RL, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and autologous bone marrow transplantation for acute myeloid leukemia in first remission. *Bone Marrow Transplantation* 1996; 18:119-123
- 531 Treleaven J, Powles RL, Singhal S, Horton C, Tait D, Prendiville J, Allford S, Mehta J. Sequential high-dose therapy of adult acute lymphoblastic leukemia. *Bone Marrow Transplant* March 1996, Vol 17 (Suppl 1), pp. 142.
- 532 Singhal S, Powles RL, Horton C, Treleaven J, Hamblin M, Zomas A, Saso R, Prediville J, Mackay H, Mehta J. Melphalan-total body irradiation and unpurged autografting for acute leukemia beyond first remission. *Bone Marrow Transplant* March 1996, Vol 17 (Suppl 1), page 79.
- 533 Mehta J, Powles RL, Singhal S, Prendiville J, Allford S, Zomas A, Saso R, Hamblin M, Mackay H, Treleaven J. Adoptive immunotherapy of acute leukemia relapsing after allogeneic bone marrow transplantation. *Bone Marrow Transplant* March 1996, Suppl 1, Vol 17, page 10.
- 534 Mehta J, Chu P, Powles RL, Singhal S, Jameson B, Treleaven J. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 64.
- 535 Powles RL, Singhal S, Treleaven J, Horton C, Tait D, Mehta J. Total therapy of acute myeloid leukaemia: Evaluation of bone marrow transplantation. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 24

- 536 Mehta J, Powles RL, Singhal S, Horton C, Treleaven J. Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants. *Bone Marrow Transplant* March 1996, Volume 17, Suppl 1, page 22
- 537 Mehta J, Powles RL, Singhal S, Horton C, Treleaven J. Early identification of patients at risk of death due to infection, hemorrhage or graft failure after allogeneic bone marrow transplantation. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page S37.
- 538 Powles RL, Milan S, Horton C, Singhal S, Treleaven J, Mehta J. A prospective haematology patient database: Structure and description. *Bone Marrow Transplant* March 1996, Vol 17 (Suppl 1), page 55.
- 539 Powles RL, Milan S, Horton C, Singhal S, Treleaven J, Mehta J. A prospective haematology patient database structure & description. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 140.
- 540 Raje N, Powles RL, Eisen T, Milan S, Horton C, Mehta J, Singhal S, Treleaven J, Cunningham D. Beta 2 microglobulin (B2M) levels in patients of myeloma following high dose treatment and interferon maintenance. *Bone Marrow Transplant*, March 1996, Vol 17 (Suppl 1, page 71
- 541 Raje N, Powles RL, Eisen T, Horton CAP, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 71.
- 542 Raje N, Millar BC, Bell JA, Mehta J, Singhal S, Milan S, Shepherd V, Treleaven J, Powles RL. Favourable predictors of rapid engraftment in myeloma following peripheral blood stem transplant (PBSCT). *Bone Marrow Transplant* March 1996 Vol 17 (Suppl 1), page 138.
- 543 Raje N, Powles RL, Horton C. Salvage treatment with VAMP/C-VAMP infusional chemotherapy and high dose melphalan in refractory myelomas. *BMT* 1996 vol 93 suppl 1, pp. 78 abstract No. 303
- 544 Hamblin M, Powles RL, Singhal S, Saso R, Wilson K, Thornton P, Treleaven J, Mehta J. Addition of lomustine (CCNU) to standard daunorubicin-cytarabine (3+7) for induction of remission in acute myeloid leukaemia patients over 50 years. *Br J Haematol* 1996 (Suppl 1):66
- 545 Saso R, Zomas A, Hamblin M, Swansbury GJ, Min T, Singhal S, Powles R, Treleaven J, Mehta J. Sequential transformation of philadelphia-positive acute lymphoblastic leukemia into myelodysplasia and acute myeloid leukemia after autografting with no evolution of the original complex karyotype. *Br J Haematol* 1996; 88 (Suppl 1): 1606
- 546 Middleton G, Mehta J, Powles RL, Singhal S, Swansbury GJ, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia and prolymphocytic leukemia. *Br J Haematol* 1996 (Suppl 1) 93: 44
- 547 Middleton G, Powles RL, Singhal S, Eisen T, Treleaven J, Mehta J. Factors affecting engraftment after unpurged autografting in acute leukemia. *Br J Haematol* 1996 (Suppl 1) 93; 44.

- 548 Eisen T, Powles RL, Singhal S, Middleton G, Treleaven J, Mehta J. Transfusion requirements after bone marrow transplantation from HLA-identical sibling donors. *Br J Haematol* 1996 (Suppl):
- 549 Eisen T, Powles RL, Singhal S, Middleton G, Treleaven J, Mehta J. Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia. *Br J Haematol* 1996 (Suppl 1): 66
- 550 Eisen T, Powles RL, Singhal S, Middleton G, Treleaven J, Mehta J. Long-term follow-up of allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine. *Br J Haematol* 1996 (Suppl) 93: 67
- 551 Singhal S, Powles RL, Horton C, Treleaven J, Mehta J. Melphalan-total body irradiation and autologous transplantation for acute leukemia beyond first remission in adult patients. *Br J Haematol* 1996; (Suppl 1): 93: 45
552. Singhal S, Powles RL, Horton C, Shepherd V, Meller S, Pinkerton CR, Hale G, Waldmann H, Treleaven J, Mehta J. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia. *Br J Haematol* 1996; (Suppl) 93: 37.
- 553 Singhal S, Powles RL, Treleaven J, Horton C, Jameson B, Pinkerton CR, Meller S, Mehta J. Cytomegalovirus infection after autografting for hematologic malignancies: clinical significance and lack of effect on engraftment. *Br J Haematol* 1996; (Suppl 1) 93: 37
- 554 Prentice HG, Gluckman E, Powles RL, Llungman P, Milpied NJ, Camera R, Mandelli F, Kho P, Kennedy L, and Bell AR for the European Acyclovir for CMV prophylaxis Group. Long Term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. *Bone Marrow Transplantation* (1997) 19: 129-133
- 555 Singhal S, Powles RL, Treleaven J, Long S, Rowland A, Mehta J. Comparison of cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Br J Haematol* 1996; (Suppl 1); 93: 37
- 556 Raje N, Powles RL, Milan S, Middleton G, Eisen T, Mehta J, Singhal S, Treleaven J. Autografting in myeloma patients with renal impairment. *Br J Haematol* 1996 (Suppl 1) 93: 79
- 557 Raje N, Powles RL, Eisen T, Middleton G, Field M, Mehta J, Singhal S, Treleaven J, Milan S. A randomised trial of short course consolidation chemotherapy following high dose chemotherapy in multiple myeloma. *Br J Haematol* 1996; (Suppl 1): 93: 79:
- 558 Singhal S, Powles RL, Treleaven J, Horton C, Swansbury J, and Mehta J. Melphalan alone prior to allogeneic BMT from HLA identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. *Bone Marrow Transplant* 1996; 18: 1049-1055
- 559 Glynne P, Powles RL, Steele J, Singhal S, Tait D, Horton C, Prendiville J, Treleaven J, Mehta J. Renal dysfunction beyond one year in survivors of autologous bone marrow transplantation. *Bone Marrow Transplant*, March 1996, Vol 17 (Suppl 1) page 38.

- 560 Singhal S, Powles RL, Treleaven J, Milan J, Prendiville J, Allford S, Hamblin M, Saso R, Zomas A, Mackay H, Mehta J. Long-term follow-up of patients receiving GM-CSF after allogeneic marrow transplantation for hematologic malignancies. *Bone Marrow Transplant* March 1996, Vol 17 (Suppl 1), page 42
- 561 J. Mehta, Powles RL, S. Singhal, A. Zomas, R. Saso, M. Hamblin, H Mackay, J. Treleaven. High-Dose Hydroxyurea and G-CSF to collected philadelphia-negative cells in chronic myeloid leukaemia. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1), page 67.
- 562 Singhal S, Powles RL, D. Cunningham, C. Horton, J. Treleaven, N. Raje, C. Viner, J. Mehta. Repeat Autografts for Relapsed Myeloma. *Bone Marrow Transplant* March 1996, Vol 17, (Suppl 1) page 71.
- 563 Singhal S, Powles RL, Treleaven J, Horton C, Jameson B, Mehta J. Cytomegaloviremia after autografting. *Bone Marrow Transplant* March 1996, Vol 17 (Suppl 1) page 95.
- 564 Powles RL, Singhal S, Treleaven J, Hayward T, Ellis C, Mehta J. The First Patients to have Received Cyclosporine for Graft-Versus-Host Disease Prophylaxis after Bone Marrow Transplantation: 15-Year Follow-up. *Bone Marrow Transplant* 1996; 17: (Suppl 1): 123
- 565 Steele MPC, Mitchell, PLR, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. Engraftment of fresh adult and pediatric acute lymphoblastic leukemias in severe combined immune deficient mice predicts patient relapse. *Proc Amer Assoc Cancer Res*, 1996; 37: 196
- 566 Millar JL, Millar BC, Steele JPC, Clutterbuck J, Catovsky D, Powles RL, Cox G, Forsen E. Liposomal vincristine treatment of human leukaemia in severe combined immunodeficient (SCID) mice. *Exp Haematol* 1997; 25: 853-853
- 567 Mitchell PLR, Treleaven J, GH Swansbury, Powles RL, S Ashley and TJ Powles. Secondary Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) following mitozantrone given as adjuvant therapy for breast cancer. (Poster Presentation) ASCO, Philadelphia, USA. May 1996
- 568 Powles RL, Noopur Raje, Clive Horton, Jayesh Mehta, Seema Singhal, Tamas Hickish, Christine Viner, Sarah Milan, Jennifer Treleaven, David Cunningham. Comparison of Interferon Tolerance after Autologous Bone Marrow or Peripheral Blood Stem Cell Transplants for Myeloma Patients who have Responded to Induction Therapy. *Leuk and Lymphoma* 1996; 21: 421-427
- 569 Raje N, Powles RL, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. *Br J Haematol* 1997; 97: 153-160
- 570 Mitchell PLR, Clutterbuck RD, Powles RL, De Lord C, Morilla R, Hiorns LR, Titley J, Catovsky D, and Millar J. Interleukin-4 Enhances the Survival of Severe Combined Immunodeficient Mice Engrafted With Human B-Cell Precursor Leukemia. *Blood* 1996; 87: (11): 4797-4803

- 571 Raje N, Powles RL. Advances in the Management of Myeloma. *Geriatric Medicine* 1996; 26: No.7: 49-51
- 572 Greenberg P, Advani S, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. *Bone Marrow Transplant* 1996; 18: 1057-1064
- 573 Millar BC, Millar JL, Bell JB, Raje N, Milan S, Mehta, Singhal S, Middleton GW, Shepherd V, Catovsky D, & Powles RL. The role of CD34+ cells in engraftment after high dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. *Bone Marrow Transplant* 1996; 18: 871-878.
- 574 Singhal S, Powles RL, Treleaven J, Horton C, Mehta J. Long term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five year follow up of a double blind randomized placebo controlled study. *Leuk Lymphoma*; 1997; 24: 301-307.
- 575 Mehta J, R.Powles, S.Singhal, G.Middleton, T.Eisen, R.Saso, S.Kulkarni,K.Wilson,A.Benjamin, J.Dent, P. Alton, S.Killick, P.Gravett, J. Treleaven. Induction of Graft-Versus-Host disease as immunotherapy of Leukemia relapsing after allografting: Single-center experience of 28 adults. *Bone Marrow Transplant* 1997; 19 (suppl):
- 576 Mehta J, Powles RL, Singhal S, Iveson T, & Catovsky D. Clinical and hematologic response of chronic lymphocytic and promlymphatic leukaemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukaemia. *Bone Marrow Transplant* 1996; 17: 371-377.
- 577 Singhal S, Powles RL, Horton C, Treleaven J, Mehta J. Idarubicin, high dose cytarabine and etoposide for induction of remission in acute myeloid leukaemia. Abstract: XIIIth Meeting of the International Society of Haematology (European & African Division), Istanbul, September 1995; No. 537
- 578 Singhal S, Powles RL, Treleaven J, Mehta J. Immunotherapy for acute leukaemia relapsing after allogeneic bone marrow transplantation. Abstract: XIIIth Meeting of the International Society of Haematology (European & African Division), Istanbul, September 1995; No. 564 MISSING
- 579 Glynne P, Powles RL, Steele J, Singhal S, Treleaven J, Tait D, Mehta J. Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukaemia. *Acta Oncologia* 1996; 35: 709-712.
- 580 Powles RL, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. *Bone Marrow Transplantation* 1997; 20: 435-443.
- 581 Singhal S, Powles RL, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Mehta J. Central nervous system relapse after bone marrow transplantation for acute leukaemia in first remission. *Bone Marrow Transplant* 1996; 17: 637-641.

- 582 Powles RL. Relapse after bone marrow transplantation: factors influencing incidence and treatment: 26th Congress of ISH, Singapore 1996: International Journal of Hematology 1996; (Suppl 1) S1-S202.
- 583 Mehta J, Powles RL, Treleaven J, Horton C, Shepherd V, Hale G, Waldmann Singhal S. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: Long Term Follow-Up: Leukaemia & Lymphoma 1997; 25: (5-6) 479-486.
- 584 Mehta J, Powles RL, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton R, Treleaven J. Early detection of patients at risk of death due to infections, haemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 1997; 19: 349-355. MISSING
- 585 Clutterbuck R, Newman A, Powles RL, Catovsky D, & Millar JL. Peripheral blood mobilization of haemopoietic cell populations in leukaemia-bearing severe combined immunodeficient (SCID) mice by granulocyte colony stimulating factor. Experimental Haematology 1996; 24 (9) 1143
- 586 Steele. J, Clutterbuck RD, Powles RL, Mitchell PLR, Catovsky D & Millar. Leukaemia cell engraftment in SCID mice and the biology of the human disease. Experimental Haematology 1996; 24 (9) 1125
- 587 Powles RL. The place of autologous stem cell transplantation in the total therapy of acute leukaemia and lymphoma. Chapter in Hematopoietic Stem Cell Therapy, Cambridge University Press. December 1997.
- 588 Kulkarni S, Powles RL, Field M, Dowding A, Mehta J, Singhal S, Treleaven J, Milan S, Raje N. Toxicity and Feasibility of short course consolidation chemotherapy following autografting in multiple myeloma. (Abstract) European Society for Medical Oncology, (ESMO) November 1-5, 1996. Annals of Oncology 1996; 7 (Suppl 5) 4090.
- 589 Parikh P, Powles RL, Advani S, Kulkarni S, Treleaven J, Raje N. Autografting in Myeloma Patients with Renal Impairment. Abstract: European Society for Medical Oncology (ESMO), November 1-5, Annals of Oncology 1996; 7 (Suppl 5) (4100)
- 590 Powles RL, Raje N, Horton C, Mehta J, Singhal S, Treleaven J, Complete Remission patients with myeloma - factors influencing subsequent outcome. Abstract: European Society for Medical Oncology (ESMO), November 1-5. Annals of Oncology 1996; 7 (suppl 5) 4110 INCOMPLETE
- 591 Raje N, Powles RL, Horton CAP, Mehta J, Singhal S, Kulkarni S, Middleton G, Treleaven J, Milan S. Comparison of marrow versus blood derived stem cells for autografting in previously untreated multiple myeloma. Abstract: European Society for Medical Oncology (ESMO) November 1-5. Annals of Oncology 1996; 7 (Suppl 5) (414P)
- 592 Powles RL, Singhal S, Treleaven J, Swansbury GJ, Min T, Horton C, Middleton G, Eisen T, Catovsky D, Mehta J. Effect of Karyotype abnormalities (including failure to obtain metaphases) on response to induction chemotherapy and survival in acute myeloid leukemia. Blood 1996; 88 (Supplement 1) 159b

- 593 Hamblin M, Swansbury GJ, Min T, Singhal S, Powles RL, Treleaven J, Mehta J. Sequential Transformation of Philadelphia positive acute Lymphoblastic Leukemia after autografting into Myelodysplasia and acute myeloid leukemia with no evolution of the original complex Karyotype. *Blood* 1996; 88: (Supplement 1): 160b
- 594 Kulkarni S, Powles RL, Eisen T, Treleaven J, Singhal S, Middleton G, Horton C, Mehta J. High-Dose Cytarabine and VP-16 with or without Idarubicin for relapsed acute leukemia. *Blood* 1996; 88: (Supplement 1) 174b
- 595 Saso R, Kulkarni S, Powles RL, Hiorns L, Swansbury GJ, Treleaven J, Singhal S, Catovsky D, Mehta J. Treatment of acute Promyelocytic leukemia: Single-Centre +experience of 54 Cytogenetically confirmed cases. *Blood* 1996; 88: (Supplement 1): 177b
- 596 Singhal S, Powles RL, J.Treleaven, R.Saso, S.Kulkarni, S.Long, A.Rowland, J.Mehta. Hematologic and Biochemical consequences of donating both marrow and blood cells within a week in normal donors. *Blood* 1996; 88: (Supplement 1) 242b.
- 597 Singhal S, Powles RL, B.Millar, V.Shepherd, C.Horton, J.Treleaven, J.Mehta, D.Catovsky. Variability in CFU-GM measurements and Correlation with CD34-positive cell yields from the Blood and Marrow of normal donors. *Blood* 1996; 88: (Supplement 1): 242b.
- 598 Zomas A, Saso R, Powles RL, Mackey H, Singhal S, Hamblin M, Treleaven J, Mehta J. Red Cells Fragmentation (Schistocytosis) after bone marrow transplantation: incidence and clinical significance. *Blood* 1996; 88 (Suppl 1): 260b
- 599 Mehta J, Powles RL, Singhal S, Riley U, Saso R, Wilson K, Eisen T, Middleton G, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Importance of infection prophylaxis. *Blood* 1996; 88 (Supplement 1):263b
- 600 Mehta J, Kelsey SM, Chu P, Powles RL, Singhal S, Hazel D, Newland AC, Treleaven J. Amphotericin B Lipid complex (ABLCL) for fungal sepsis in immunocompromised adults. *Blood* 1996; 88 (Supplement 1):264b.
- 601 Powles RL, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Hematopoiesis in acute myeloid leukemia patients in long-term remission and at relapse: influence of previous therapy. *Blood* 1996; 88 (Supplement 1): 270b
- 602 Powles RL, Milan S, Singhal S, Horton C, Treleaven J, Mehta J. An institution-based database of consecutive hemato-oncology patients: uses and potential integration with international transplant registries. *Blood* 1996; 88, (Supplement 1): 270b
- 603 Powles RL, Raje N, Kulkarni S, Eisen T, Middleton G, Field M, Mehta J, Singhal S, Treleaven J, Milan S. The feasibility of short course consolidation chemotherapy following high dose chemotherapy in multiple myeloma. *Blood* 1996; 88 (Supplement 1): 286b.
- 604 Raje N, Powles RL, Kulkarni S, Milan S, Middleton G, Eisen T, Treleaven J. Autografting in myeloma patients with renal impairment. *Blood* 1996; 88; (Supplement 1): 286.

- 605 Mehta J, Powles RL, Singhal S, Millar B, Shepherd V, Treleaven J. Cobe Spectra or Haemonetics MCS-3P for leukapheresis in patients with hematologic malignancies. *Blood* 1996; 88, (Supplement 1): 109a
- 606 Singhal S, Powles RL, J.Treleaven, S.Kalkarni, C.Horton, D.Tait, J.Mehta. Sequential High-Dose therapy of adult acute lymphoblastic leukemia: Blood cells autografts with maintenance therapy in first remission and allografting in second remission for relapsing patients. *Blood* 1996; 88, (Supplement 1): 125a
- 607 Raje N, Powles RL, Horton C, Kulkarni S, Eisen T, Middleton G, Treleaven J. Predictors of early relapse following autografting for Myeloma. *Blood* 1996; 88 (Supplement 1):130
- 608 Raje N, Powles RL, Horton C, Kulkarni S, Miller B, Shepherd V, Treleaven J. Comparison of marrow versus blood derived stem cells for autografting in previously untreated Myeloma. *Blood* 1996: 88 (Supplement 1): 131a
- 609 Treleaven J, Powles RL, Singhal S, Horton C, Kulkarni S, Hale G, Waldmann H, Mehta J. Autografting with CD52 Monoclonal Antibody-Perged marrow for acute Lymphoblastic Leukemia. *Blood* 1996; 88 (Supplement 1) 255a.
- 610 Mehta J, Powles RL, Singhal S, Middleton G, Eisen T, Saso R, Kulkarni S, Wilson K, Benjamin A, Dent J, Alton P, Killick S, Gravett P, Treleaven J. Induction of Graft-Versus-Host disease as immunotherapy for Leukemia relapsing after allografting: Single-Center experience of 28 adults. *Blood* 1996; 88, (Supplement 1):260a
- 611 Mehta J, Powles RL, Treleaven J, Horton C, Meller S, Pinkerton R, Singhal S. Acute Leukemia relapsing after bone marrow transplantation: The place of second grafts. *Blood* 1996; 88 (Supplement 1):260a
- 612 Middleton G, Powles RL, Singhal S, Horton C, Kulkarni S, Eisen T, Dent J, Treleaven J, Mehta J. Bone Marrow transplantation from HLA-mismatched family donors for acute myeloid Leukemia: 10-Year follow-up. *Blood* 1996; 88 (Supplement 1): 269a
- 613 Steele J, Mitchell P, Powles RL, DeLord C, Clutterbuck R, Catovsky D, Millar J. The SCID mouse model reflects the biology of human leukemia. *Blood* 1996; 88 (Supplement 1): 360a
- 614 Singhal S, Powles RL, Treleaven J, Saso R, Kulkarni S, Long S, Rowland A, B. Millar B, Shepherd V, Cabral S, Morton C, Field M, Mehta J. Cell Yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Blood* 1996; 88 (Supplement 1): 403a.
- 615 Mehta J, Powles RL, Singhal S, Horton C Meller S, Pinkerton R. Treleaven J. Early identification of patients at risk of death due to infection, Hemorrhage, or graft failure after allografting on the basis of the leukocyte counts. *Blood* 1996; 88 (Supplement 1): 417a.
- 616 Kulkarni S, Powles RL, Mehta J, Horton C, Treleaven J, Middleton G, Eisen T, Singhal S. Thalidomide for acute or chronic graft-versus host disease. *Blood* 1996; 88 (supplement 1): 609a.

- 617 Singhal S, Powles RL, Treleaven J, Horton C, Swanbury J, Kulkarni K, Mehta J. Single-Agent Melphalan conditioning for allografting in Leukemia: engraftment with potential preservation of fertility in women. *Blood* 1996; 88 (Suppl 10): 611a.
- 618 Wilson K, Powles RL, Treleaven J, Singhal S, Horton C, Tait D, Kulkarni S, Saso R, Alton P, Killick S, Mehta J. Allografting after Melphalan-total body irradiation for first remission acute myeloid Leukemia. *Blood* 1996; 88 (Suppl 10): 613a.
- 619 Powles RL, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Early Lymphocyte recovery after allografting for acute myeloid Leukemia and risk of relapse: identification of patient who may benefit from prophylactic immunotherapy. *Blood* 1996; 88: (Supplement 1): 681a
- 620 Mehta J, Powles RL, Millar B, Proctor H, Cabral S, Shepherd V, Treleaven J, Singhal S. A prospective, concurrent comparison of the Cobe Spectra and Haemonetics MCS-3P cell separators for leukapheresis after high-dose filgrastim in patients with haematologic malignancies. *J. Clin Apheresis* 1997; 12: 63-67
- 621 Steele J, Clutterbuck RD, Powles RL, Mitchell PLR, Horton C, Morilla R, Catovsky D, Millar JL. Growth of human T-cell lineage acute leukaemia in severe combined immunodeficiency (SCID) mice and non obese diabetic SCID mice. *Blood* 1997; 90 (No.5): 2015-2019.
- 622 Mehta J, Chu P, Powles RL, Kelsey S. Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies. *Drugs of Today* 1996; 32: (5): 417-421
- 623 Duncan N, Hewetson M, Powles RL, Raje N, Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. *Bone Marrow Transplant* 1996; 18: 1175-1178
- 624 Mehta J, Powles RL, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhal S. Outcome of acute leukaemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. *Bone Marrow Transplant* 1997; 19: 709-719
- 625 Zomas A, Saso R, Powles RL, Mackay H, Singhal S, Hamblin M, Treleaven J, Mehta J. Red cell fragmentation (schistocytosis) after bone marrow transplantation: incidence and clinical significance. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. *Bone Marrow Transplantation* (1997) Vol 19, Supplement 1.
- 626 Powles RL, Kulkarni S Raje N, Horton C, Milan S, Middleton G Eisen T, Sumpter K, Hill K, Singhal S, Mehta J, Treleaven J. Relapse following complete response in myeloma outcome predictors. Proceedings from 23rd Annual Meeting of the EBMT (Aix Les Bains, France). March 1997. *BMT* vol. 19 Suppl 1
- 627 Kulkarni S, Powles RL, Treleaven J, Matutes E, Hill M, Sumpter K, Dyer M, & Catovsky D. Autografting for T-cell prolymphocytic leukaemia. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. *Bone Marrow Transplantation* (1997) Vol 19, Supplement 1.
- 628 Mehta J, Powles RL, Singhal S, Riley U, Saso R, Wilson K, Eisen T, Middleton G, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic

- leukaemia: importance of infection prophylaxis. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 629 Hill M, Powles RL, Kulkarni S, Horton C, Mehta J, Singhal S, Treleaven J. Effect of body weight at transplant on outcome in adult myeloid leukaemia. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 630 Powles RL, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Early lymphocyte recovery after allogeneic allografting for acute myeloid leukaemia and risk of relapse. Identification of patients who may benefit from prophylactic immunotherapy. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 631 Powles RL, Singhal S, Treleaven J, Swansbury GJ, Min T, Horton C, Middleton G, Eisen T, Catovsky D, Mehta J. Effect of karyotype abnormalities (including failure to obtain metaphases) on response to induction chemotherapy and survival in acute myeloid leukaemia. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 632 Wilson K, Powles RL, Treleaven J, Singhal S, Horton C, Tait D, Kulkarni S, Saso R, Alton P, Killick S, Mehta J. Allografting after melphalan total body irradiation for first remission acute myeloid leukaemia. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 633 Middleton G, Powles RL, Singhal S, Horton C, Kulkarni S, Eisen T, Dent J, Treleaven J, Mehta J. Bone marrow Transplantation from HLA-mismatched family donors for acute myeloid leukaemia: 10 year follow up. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 634 Saso R, Kulkarni S, Powles RL, Hiorns L, Swansbury GJ, Treleaven J, Singhal S, Catovsky D, Mehta J. Treatment of acute promyelocytic leukaemia: single centre experience of 54 cytogenetically confirmed cases. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 635 Powles RL, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Hematopoiesis in acute myeloid leukaemia patients in long term remission and at relapse: influence of previous therapy. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19 Supplement 1.
- 636 Vaidya S, Meller S, Pinkerton R, Atra A, Horton C, Milan S, Treleaven J, Powles RL. Autologous BMT for 2nd remission childhood ALL. Long term follow up. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 637 Saso R, Zomas A, Hamblin M, Swansbury GJ, Min T, Singhal S, Powles RL, Treleaven J, Mehta J. Sequential transformation of Philadelphia positive acute lymphoblastic leukaemia after autografting into myelodysplasia and acute myeloid leukemia with no elevation of the

- original complex karyotype. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 638 Singhal S, Powles RL, Millar B, Shepherd V, Horton C, Treleaven J, Mehta J, Catovsky D. Variability in CFU-GM measurements and correlation with CD34-positive cell yields from the blood and marrow of normal donors. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 639 Singhal S, Powles RL, Treleaven J, Saso R, Kulkarni S, Long S, Rowland A, Millar B, Shepherd V, Cabral S, Morton C, Field M, Mehta J. Cell yields in a double blind randomized study of allogeneic marrow versus blood stem cell transplantation. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 640 Hamblin M, Powles RL, Treleaven J, Saso R, Singhal S, Middleton G, Kulkarni S, Cabral S, Mehta J. Defibrotide for refractory thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 641 Kulkarni S, Powles RL, Mehta J, Horton C, Treleaven J, Middleton G, Eisen T, Singhal S. Thiamidomide for acute or chronic graft-versus host disease. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 642 Mehta J, Powles RL, Singhal S, Middleton G, Eisen T, Saso R, Kulkarni S, Wilson K, Benjamin A, Dent J, Alton P, Killick S, Gravett P, Treleaven J. Induction of graft-versus-host disease as immunotherapy of leukaemia relapsing after allografting: single-centre experience of 28 adults. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 643 Sumpter K, Powles RL, Kulkarni S, Ramiah V, Raje N, Treleaven J. Oral idarubicin as a single agent therapy in patients with relapsed multiple myeloma post high dose chemotherapy. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 644 Kulkarni S, Powles RL, Mehta J, Raje N, Singhal S, Treleaven J. Allogeneic bone marrow transplantation for multiple myeloma. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 645 Raje N, Powles RL, Horton C, Kulkarni S, Eisen T, Middleton G, Treleaven J. Predictors of early relapse following autografting for myeloma. Proceedings from 23rd Annual Meeting of the EBMT (Aix-les Bains, France) March 1997. Bone Marrow Transplantation (1997) Vol 19, Supplement 1.
- 646 Singhal S, Powles RL, Treleaven J, Mehta J. Sensitivity of secondary acute myeloid leukaemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon a-2b. Bone Marrow Transplant, 1997; 19: 1151-1153
- 647 Millar B, Millar JL, Powles RL, & Catovsky D. Interferon and Interleukin-2

- + T-cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with Interferon $\alpha 2b$ (Intron A). *British Journal of Haematology* 1997; 98: 119-125.
- 648 Newman A, Clutterbuck R, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors Simvastatin, Lovastatin and Pravastatin on Leukaemic and normal bone marrow progenitors. *Leuk & Lymphoma* 1997; 24: 533-537
- 649 Mehta J, Powles RL, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. *Bone Marrow Transplant* 1997; 20: 129-135.
- 650 Powles RL, Horton C, Treleaven J, Singhal S, Leukocyte recovery and early treatment related mortality after bone marrow transplantation. *Blood* 1997; 89 (11); 4237-4238
- 651 Singhal S, Powles RL, Treleaven J, Horton C, Pinkerton CR, Meller S, & Mehta J. Cytomegaloviremia after autografting for leukaemia: clinical significance and lack of effect of engraftment. *Leukaemia* 1997; 11: 835-838
- 652 Middleton G, Powles RL. Interferon Alpha and B2 microglobulin in multiple myeloma Experimental approaches and novel Therapies, Munster, Germany Feb 22-26, 1997.
- 653 Millar JL, Clutterbuck RD, Newman A, Powles RL, and Catovsky D. Simvastatin inhibits the growth of HL60 human leukaemia in severe combined immuno-deficient (SCID) mice. *Br J Haematol* 1997; 97 (Suppl 1) 232 ; P61
- 654 De Lord C, Powles RL, Mehta J, Wilson K, Swansbury J, Treleaven J, Mellor S, Catovsky D. Familial acute myeloid leukaemia. *British Journal of Haematology* 1997; 97 (Suppl 1) 223; P59
- 655 Clutterbuck R, Newman A, Powles RL, Catovsky D, & Millar JL. G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia. *Bone Marrow Transplant* 1997; 20: 325-332.
- 656 Singhal S, Powles RL, Treleaven J, Rattenbury H and Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. *Leukemia and Lymphoma* 1997; 24: 539-543.
- 657 Mehta J, Powles RL, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton CR and Treleaven J. Early identification of patients at risk of death due to infections, haemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leucocyte count. *Bone Marrow Transplantation* 1997; 19: 349-355.
- 658 Raje N, Powles RL, Horton C, Millar B, Shepherd V, Middleton G, Kulkarni S, Eisen T, Singhal S, Treleaven J. Comparison of marrow vs. blood-derived stem cells for autografting in previously untreated multiple myeloma. *British Journal of Cancer* 1997;75: (11) 1684-1689.

- 659 Mehta J, Kelsey S, Chu P, Powles RL, Hazel D, Riley U, Evans C, Newland A, Treleaven J, & Singhal S. Amphotericin B lipid complex (ABLCL) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. *Bone Marrow Transplantation* 1997; 20: 39-43.
- 660 Mehta J, Powles RL, Singhal S, Riley U, Treleaven J and Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic leukaemia after allogeneic blood or marrow transplantation. *Leuk Lymphoma* 1997; 26: 83-88.
- 661 Powles RL and Treleaven J. Top 100 – Leukaemia. *GP Medicine* (Aug 1997) 2-4 MISSING
- 662 Saso R, Zomas A, Hamblin M, Swansbury GJ, Min T, Singhal S, Powles RL, Treleaven J, Mehta J. Sequential transformation of Philadelphia positive acute lymphoblastic leukaemia after autografting into myelodysplasia and acute myeloid leukemia with no elevation of the original complex karyotype. *Leukaemia and Lymphoma*, 1997; 26:625-628
- 664 Powles RL. Stem cell transplants for B-cell malignancies including multiple myeloma. Abstract: The 5th Asia-Pacific Congress on Bone Marrow Transplantation. September 19-20 1996; Souel, Korea
- 665 Keith Wheatley et al. Myeloma Trialists' Collaborative Group. The role of Interferon (IFN) as therapy for multiple myeloma: An overview of 24 randomised trials with over 4000 patients. *American Society of Clinical Oncology (ASCO)* 1998. (ongoing 2001)
- 666 Mehta J, Powles RL, Treleaven J, Kulkarni S, Horton C, Singhal S. infused during allogeneic and autologous bone marrow transplantation: An important modifiable factor influencing outcome. *Blood* 1997; 90: 3808-3810
- 667 Cunningham D, Powles RL, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J and Gore M. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. *Br. J Haem.* 1998; 102; 2: 495-502
- 668 Millar B, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D, Judson I, Treleaven J, Powles RL, Catovsky. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral stem cell rescue. *Bone Marrow Transplantation* (1998) 22 469-475
- 669 Farahet N, Morilla A, Owusu-Ankomah, Morilla R, Pinkerton CR, Treleaven JG, Matutes E, Powles RL and Catovsky D. Detection of minimal residual disease in B-Lineage acute lymphoblastic leukaemia by quantitative flow cytometry. *British Journal of Haematology* 1998; 101: 158-164
- 670 Hijiyanakis P, Mehta J, Milan S, Powles RL, Hinson J, Tait D. Melphalan, single fraction total body irradiation and allogeneic bone marrow transplantation for acute leukaemia Review of transplant related mortality. *Leuk Lymphoma* 1997 25; 565-572
- 671 Mateos P, Lafuente A, Rodriguez M, Kulkarni S, Mehta J, Singhal, Saso R, Gregory K, Dark G, Tait D, Treleaven J, Powles RL. Hepatic veno-occlusive disease (VOD) treated with recombinant tissue plasminogen activator (rt-PA). *Blood* 1997, Vol 90 No. 10 (Supple 1) 964

- 672 Hill ME, Powles RL, Kulkarni S, Horton C, Sumpter K, Mehta J, Singhal S, and Treleaven J. Influence of nutritional status on outcome following transplantation for AML. *Blood* 1997, Vol 90 No. 10 (Supple 1) 975
- 673 Powles RL, Treleaven J, Singhal S, Kulkarni S, Horton C, Tait D and Mehta J. Total therapy of acute myeloid leukaemia: 7 year follow-up. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1000
- 674 Singhal S, Powles RL, Treleaven J, Kulkarni, Horton C, Tait D and Mehta J. Sequential high dose therapy of acute lymphoblastic leukaemia in adult patients: Long term follow up. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1033
- 675 Powles RL, Kulkarni S, Mehta J, Treleaven J, Millar J, Shepherd V, Tait D, Antrum J, Neville F, Long S, Rowland A and Singhal S. A double blind randomised study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1118
- 676 Powles RL, Cunningham D, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicholson M, Johnson P, Treleaven J, Raymond J and Gore M. A randomised trial of maintenance Interferon following high dose chemotherapy in multiple myeloma. Results 5 1/2 years after accrual. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1588
- 677 Powles R, Cunningham D, Gore, Kulkarni S, Singhal S, Horton C, Milan S, Sastry P, Raje N, Treleaven J, Ramiah V and Mehta J. Long-term follow-up of myeloma patients treated with 140 mg/m² melphalan without autologous transplantation. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1589
- 678 Kulkarni S, Powles R, Mehta J, Horton C, Treleaven J, Meller S, Atra A, Pinkerton R and Singhal S. Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1673
- 679 Powles R, Singhal S, Treleaven J, Horton C, Meller S, Pinkerton CR, Atra A, Tait D and Mehta J. Second cancers after non-autologous bone marrow transplantation for hematologic malignancies: Single Center experience of 883 patients. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1674
- 680 Treleaven J, Powles RL, Singhal S, Kulkarni S, Tait D, Horton C and Mehta J. Long term outcome of patients who are alive and well two years after autografting for acute leukaemia. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1691
- 681 Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, and Singhal S. Long term outcome of patients who are alive and well two years after allografting for acute leukaemia. *Blood* 1997, Vol 90 No. 10 (Supple 1) 1692
- 682 Mehta J, Powles R, Treleaven J, Kulkarni S, Swansbury J, Hamblin M, Saso S, Killick S, Rege K and Singhal S. High dose cytarabine and etoposide for induction of remission in acute myeloid leukaemia: *Blood* 1997, Vol 90 No. 10 (Supple 1) 2259
- 683 Singhal S, Powles R, Kulkarni S, Treleaven J and Mehta J. Immunotherapy of acute leukaemia relapsing after allogeneic transplantation: The inseparability of GVHD and

- graft-vs-leukaemia and the problem of extramudullary relapse. *Blood* 1997, Vol 90 No. 10 (Supple 1) 2435
- 684 Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S and Covelli A. A phase 1 dose-finding study of PSC 833, a novel MDR reversing agent with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukaemia. *Blood* 1997, Vol 90 No. 10 (Supple 1) 2518
- 685 Powles RL, Catovsky D and Millar D. Interleukin 6 is a negative regulator of macrophage proliferation. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 3353
- 686 Saso R, Kulkarni S, Treleaven J, Killick S, Rege K, Mehta J, Singhal S, Morilla R, Atra A, Swansbury GJ, Powles RL and Catovsky D. Immunophenotypic and cytogenetic features of 10 patients with minimally differentiated acute myeloid leukaemia. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 3732
- 687 Clutterbuck R, Powles RL, Catovsky D, Jarman M, and Millar JL. Ketoconazole selectively inhibits the proliferation of acute myeloid leukaemia progenitor cells. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 3815
- 688 Killick S, Powles RL, Kulkarni, Matutes E, Atra A, Zomas S, Meller S, Hamblin M, Swansbury J, Horton C, Treleaven J and Catovsky D. Biphenotypic leukaemia: Eight year experience from the Royal Marsden Hospital. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 3832
- 689 Killick S, Kulkarni S, Powles RL, Matutes E, Saso R, Hamblin M, Rege K, Treleaven J, Meller S, Swansbury J, Horton C, and Catovsky D. Erythroleukaemia (AML M6): 18 year experience from the Royal Marsden Hospital. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 3833
- 690 Sumpter, K., Powles, R.L., Rage N, Kulkarni S, Ramieh V, Hill M, Horton C, Milan S, Mehta J, Singhal S, Rodriguez M, Mateos P, Laufente and Treleaven J. Oral Idarubicin as single agent therapy for patients with relapsed multiple myeloma. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4144
- 691 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Raje, N., Ramieh V, Gregory K, Dark G, Millar B, Shepherd V, Neville F, Antrum J, Horton C, Milan S and Mehta J. Comparison of equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with hematologic malignancies. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4226
- 692 Kulkarni, S., Powles, R., Mehta, J., Treleaven, J., Saso, R., Long, S., Rowland, A. and Singhal, S. Feasibility of donating both marrow and blood cells within a week in normal donors. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4227
- 693 Mehta, J., Powles, R., Cabral, S., Proctor, H., Millar, B., Shepherd, V., Kulkarni, S., Treleaven, J., Singhal, S., De Reys, S. A new automated apheresis system for the Cobe separator utilizing the platelet channel. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4240.

- 694 Wilson, P.C., Hill, M.E., Powles, R., Horton, C., Kulkarni, S., Treleaven J. The implications of cavity formation on chest x-ray in intensive haematological practice. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4442
- 695 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Sastry, P., Raje, N., Tait, D., Mehta, J. Allogeneic bone marrow transplantation for multiple myeloma. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4497
- 696 Mehta, J., Powles, R., Treleaven, J., Kulkarni, S., Singhal, S., Saso, R., Hamblin, M., Rege, K., Cunningham, D., Killick, S., Tait, D., Catovsky D. Bone marrow transplantation for chronic lymphocytic leukaemia. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4503
- 697 Mehta, J., Powles, R., Treleaven, J., Kulkarni, S., Singhal S. Peripheral blood stem cells autografts in acute myeloid leukaemia: Is relapse the only eventual outcome. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4568
- 698 Raje, N., Powles, R., Kulkarni, S., Ramieh, V., Sumpter, K., Horton, C., Mehta, J., Singhal, S., Treleaven, J. Plasma cell leukaemia: Outcome following infusional chemotherapy and autografts. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4577
- 699 Ramieh, V., Powles, R., Sumpter, K., Raje, N., Kulkarni, S., Hill, M., Gregory, K., Dark, G., Horton, C., Milan, S., Mehta, J., Singhal, S., Field, M., Neville, F., Antrum, J., Treleaven, J. A randomised trial of short course consolidation chemotherapy (RCP UKALL X) following high dose chemotherapy in multiple myeloma. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4578
- 700 Sumpter, K., Powles, R., Raje, N., Kulkarni, S., Ramieh, V., Hill, M., Horton, C., Milan, S., Mehta, J., Singhal, S., Rodriguez, M., Mateos, P., Laufente, A., Treleaven J. A single institution review of cases of AL amyloidosis. *Blood* 1997, Vol 90, No. 10 (Supple 1) part II: 4583.
- 701 Saso, R., Kulkarni, S., Killick, S., Rege, K., Mehta, J., Swansbury, J., Matutes, E., Atra, A., Morilla, R., Powles, R., Treleaven, J., Catovsky, D. Immunopenotypic and cytogenetic features in patients with minimally differentiated acute myeloid leukaemia (AML-M0). *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 27.
- 702 Saso, R., Kulkarni, S., Killick, S., Rege, K., Mehta, J., Swansbury, J., Matutes, E., Atra, A., Morilla, R., Powles, R., Treleaven, J., Catovsky D. Therapy of acute megakaryocytic leukaemia (AML-M7). *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 28
- 703 Treleaven, J., Powles, R., Singhal, S., Kulkarni, S., Tait, D., Horton, C., Mehta, J. Long-term outcome of patients who are alive and well two years after autografting for acute leukaemia. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 29
- 704 Mehta, J., Powles, R., Treleaven, J., Kulkarni, S., Singhal, S. Peripheral blood stem cell autografts in acute myeloid leukaemia: Is relapse the only eventual outcome? *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 30
- 705 Killick, S., Powles, R., Kulkarni, S. Matutes, E., Atra, A., Saso, R., Zomas, A., Treleaven, J., Hamblin, M., Swansbury, J., Horton, C., Catovsky, D. Biphenotypic leukaemia: Eight

- year experience from a single centre. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 31
- 706 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Mehta, J., Saso, R., Horton, C. Factors affecting blood component requirements after autograft for haematological malignancies. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 34
- 707 Powles, R., Kulkarni, S., Mehta, J., Treleaven, J., Millar, J., Shepherd, V., Tait, D., Antrum, J., Neville, F., Long, S., Rowland, A., Shaw, K., Singhal, S. A double blind randomised study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 124
- 708 Kulkarni, S., Powles, R., Singhal, S., Mehta, J., Treleaven, J., Shaw, K., Long, S., Rowland, A. Feasibility of donating both marrow and blood cells within a week in normal donors. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 148
- 709 Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Saso, R., Long, S., Rowland, A., Shaw, K., Millar, J., Shepherd, V., Cabral, S., Mehta, J. Comparison of cell yields in a single centre double blind, randomised study of allogeneic marrow vs. stem cell transplantation. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 149
- 710 Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Mehta J. Immunotherapy of acute leukaemia relapsing after allogeneic transplantation: the inseparability of GVHD and graft-vs-leukaemia and the problem of extramedullary relapse. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 245
- 711 Kulkarni, S., Powles, R., Mehta, J., Singhal, S., Horton, C., Treleaven, J. Transplants for haematological malignancies in patients above the age of 50 years. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 274
- 712 Mehta, J., Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Cunningham, D., Tait, D., Catovsky, D. Bone marrow transplantation for chronic lymphocytic leukaemia. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 275
- 713 Powles, R., Cunningham, D., Jameson, B., Tiley, C., Mehta, J., Milan, S., Hewitson, M. Randomised placebo-controlled evaluation of prophylactic fluconazole after bone marrow transplantation. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 504
- 714 Wilson, P.C., Powles, R., Hill, M.E., Horton, C., Kulkarni, S., Treleaven, J. The implications of cavity formation on chest x-ray in bone marrow transplant patients. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 532
- 715 Kulkarni, S., Powles, R., Singhal, S., Riley, U., Horton, C., Treleaven, J., Mehta, J. Outcome of bone marrow transplantation in patients with evidence of viral hepatitis. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 536
- 716 Kulkarni, S., Powles, R., Singhal, S., Treleaven, J., Horton, C., Meller, S., Pinkerton, C.R., Atra, A., Tait, D., Mehta, J. Second cancers after non-autologous bone marrow transplantation for hematologic malignancies: single center experience of 883 patients. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 563

- 717 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Raje, N., Ramieh, V., Gregory, K., Dark, G., Millar, B., Shepherd, V., Neville, F., Antrum, J., Horton, C., Milan, S., Mehta, J. Comparison of equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with hematologic malignancies. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 680
- 718 Powles, R., Cunningham, D., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicholson, M., Johnson, P., Treleaven, J., Raymond, J., Gore, M. A randomised trial of maintenance Interferon following high dose chemotherapy in multiple myeloma. Results 5 1/2 years after accrual of the last patient. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 733
- 719 Sumpter, K., Powles, R., Horton, C., Milan, S., Treleaven, J. Rate of reduction in serum paraprotein in patients with IgG multiple myeloma comparing VAMP like chemotherapy with high dose melphalan (HDM) as first line treatment. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 734
- 720 Powles, R., Gore, M., Cunningham, D., Kulkarni, S., Ramieh, V., Mehta, J. Long-term follow up of myeloma patients treated with 140 mg/m² melphalan without autologous transplantation. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 735
- 721 Raje, N., Kulkarni, S., Powles, R., Ramieh, V., Sastry, P., Gregory, K., Dark, G., Treleaven, J. Plasma cell leukaemia - Single Center study of 140 patients. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 736
- 722 Sumpter, K., Powles, R., Raje, N., Kulkarni, S., Ramieh, V., Hill, M., Horton, C., Milan, S., Mehta, J., Singhal, S., Treleaven, J. A single institution review of cases of AL amyloidosis. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 737
- 723 Kulkarni, S., Powles, R., Treleaven, J., Raje, N., Ramieh, V., Gregory, K., Dark, G., Horton, C., Milan, S. Response of Waldenstrom's Macroglobulinaemia (WM) and IgG myeloma (IgM-M) to infusional chemotherapy (CVAMP) and /or autograft. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 742
- 724 Treleaven, J., Al-Deen, A., Dearnaley, D., Powles, R. PBSC transplantation in patients receiving ablative doses of 186 HEDP for skeletal secondaries from prostate cancer. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 795
- 725 Lafuente, A., Mateos, P., Rodriguez, M., Kulkarni, S., Mehta, J., Singhal, S., Saso, R., Gregory, K., Dark, G., Treleaven, J., Powles, R. Hepatic veno-occlusive disease (VOD) treated with recombinant tissue plasminogen activator (rt-PA). *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 843
- 726 Gregory, K., Smith, I., Powles, R., Treleaven, J. CMV infection following bone marrow transplantation -sparing of the central nervous system. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 483
- 727 Middleton, G., Kulkarni, S., Treleaven, J., Antrum, J., Neville, F., Sage, D.A., Kallon, D., Powles, R. A detailed analysis of the clinical status of long term survivors of mis-matched bone marrow transplantation. *Bone Marrow Transplantation* 1998; vol 21 (supple 1) No. 566

- 728 Mehta, J., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Tait, D., Singhal, S. Long term outcome of patients who are alive and well two years after allografting for acute leukaemia. *Bone Marrow Transplantation* 1998; vol 21 (suppl 1) No. 26.
- 729 DeLord, C., Powles, R., Mehta, J., Wilson, K., Treleaven, J., Meller, S., Catovsky, D. Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation. *Br. J Haem.* 1998; 100: 577-560
- 730 Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukaemia on the basis of lymphocyte recovery early after transplantation. *Blood* 1998; vol 91: No. 9: pp. 3481-3486
- 731 Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Saso, R., Mehta, J. Long-term follow up of relapsed acute leukaemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft versus leukaemia, and the problem of extramedullary relapse. *Leuk Lymphoma* (1999) 32 (5-6): 505-12
- 732 Clutterbuck, R.D., Millar, B.C., Powles, R.L., Newman, A., Catovsky, D., Jarman, M., Millar, J.L. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. *Br. J Haem.* 1998; 102; 522-527
- 733 Millar, J.L., Millar, B.C., Powles, R., Steele J.P.C., Clutterbuck, R.D., Mitchell, P.L.R., Cox, G., Forssen, E., Catovsky, D. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. *Br. J Haem.* 1998; 102: 718-721
- 734 Zomas, A., Saso, R., Powles, R., Mackay, H., Singhal, S., Treleaven, J., Mehta, J. Red cell fragmentation (schistocytosis) after bone marrow transplantation. *Bone Marrow Transplantation* (1998) 22; 777-780.
- 735 Killick, S., Matutes, E., Powles, R., Treleaven, J., Kulkarni, S., Swansbury, J., Atra, A., Zomas, A., Hamblin, M., Catovsky, D. Outcome of Biphentotypic Acute Leukaemia: Results from a single centre study. *Haematologica* 1999; 84: 699-706
- 736 Powles, R., Mehta, J. Chapter In: *Leukaemia and Related Disorders. (Autologous Blood and Marrow Transplantation)*. Third Edition: Whitaker & Holmes (Eds) Blackwell Science. 1998 MISSING
- 737 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Saso, R., Horton, C., Killick, S., Tait, R., Mehta, J. Impact of previous high dose therapy on outcome after allografting for multiple myeloma. *Bone Marrow Transplantation* (1999) 23; 7: 675-680
- 738 DeLord, C., Treleaven, J., Shepherd, J., Saso, R., Powles, R. Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukemia. *BMT* (1999) 23: (5) 523-525
- 739 Kulkarni, S., Rodriguez, Lafuente, A., Mateos, P., Mehta, J., Singhal, S., Saso, R., Tait, D., Treleaven, J.G., Powles, R.. Recombinant tissue activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) *BMT* 1999 23; 8: 803-807 MISSING

- 740 Powles, R. Understanding Leukaemia and Related Cancers. (Foreword). Authors Tariq Mughal and John Goldman. (Blackwell Science).
- 741 Gregory, R.K., Powles, R., Treleaven, J.G., Smith, M.L., Mortimer, P.S., Wotherspoon, A., Riley, U. Systemic candidiasis with candida vasculitis due to *Candida kruzei* in a patient with acute myeloid leukaemia. *Bone Marrow Transplant* (1999) 23 (1) 103-4.
- 742 Sastry, P.S., Powles, R. Thalidomide for chronic GVHD. *Bone Marrow Transplantation* (1998) 22 (9): 933-4. MISSING
- 743 Talbot, D.C., Montes, A., Teh, W.L., Nandi, A., Powles, R. Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. *Hospital Medicine* 1998 59 (7) 580-1
- 744 Catovsky, D., Fraahat, N., Matutes, E., Powles, R., Pinkerton, C. Minimal residue disease in children with acute lymphoblastic leukaemia (letter). *Lancet* 1998 351 (9111):1287
- 745 Rege, K.P., Janes, S.L., Saso, R., Min, T., Swansbury, J., Powles, R.L., Treleaven, J.G. Secondary leukemia characterised by monosomy 7 occurring post autologous stem cell transplantation for AML. *Bone Marrow Transplantation* 1998 (8) 853-5 MISSING
- 746 Saso, R., Zomas, A., Hamblin, M., Dunlop, L., Swansbury, J., Min, T., Singhal, S., Powles, R., Treleaven, J., Mehta, J. Sequential Development of myelodysplasia and acute myeloid leukaemia but with no karyotypic evolution after autografting in a patient with Philadelphia positive acute lymphoblastic leukaemia. *Leuk Lymphoma* 1997 (5-6) 625-8. MISSING
- 747 Powles, R., Kulkarni, S., Mehta, J., Treleaven, J., Millar, B., Shepherd, V., Tait, D., Rowland, A., Long, S., Singhal, S. Pattern of immune reconstruction after allograft : results of double blind randomised trial of allogeneic bone marrow or peripheral blood stem cells transplantation. *Blood* 1998; 92 (supplement 1) Abstract No. 566
- 748 Kulkarni, S., Singhal, S., Powles, R., Neville, F., Shaw, K., Antrum, J., Rowland, A., Long, S., Field, M., Treleaven, J., Mehta, J. Donor Preference Assessment regarding bone marrow (BM) versus lenograstim mobilized peripheral stem cells (PBSC) for allograft. *Blood* 1998; 92 (supplement 1) Abstract No. 567
- 749 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Mehta, J., Saso, R., Horton, C. Factors affecting blood component requirement after autograft for haematological malignancies. *Blood* 1998; 92 (supplement 1) Abstract No. 1146
- 750 Mehta, J., Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Saso, R., Tait, D., Catovsky, D. Melphalan-TBI and T-cell-nondepleted allografts for chronic lymphocytic leukaemia: Long-term follow up shows excellent anti-leukaemic activity. *Blood* 1998; 92 (supplement 1) Abstract No. 1179
- 751 Kulkarni, S., Powles, R., Singhal, S., Treleaven, J., Horton, C., Mehta, J. Late pneumococcal infections in bone marrow transplant recipients: Is penicillin prophylaxis inadequate? *Blood* 1998; 92 (supplement 1) Abstract No. 1313

- 752 Saso, R., Kulkarni, S., Powles, R., Treleaven, J., Wilson, K., Swansbury, J., Sastry, P., Ramiah, V., Horton, C., Mehta, J., Catovsky, D. Secondary MDS/AML in patients treated for myeloma. *Blood* 1998; 92 (supplement 1) Abstract No. 1879
- 753 Powles, R., Kulkarni, S., Treleaven, J., Mehta, J., Singhal, S., Horton, C. Assessment of patients who are alive in first complete remission (CR) for more than 10 years following autograft for haematological malignancies. *Blood* 1998; 92 (supplement 1) Abstract No. 1881.
- 754 Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Tait, D., Mehta, J. Melphalan-TBI for allogeneic transplantation in acute myeloid leukaemia: Lack of veno-occlusive disease and hemorrhagic cystitis. *Blood* 1998; 92 (supplement 1) Abstract No. 2714
- 755 Mainwaring, P., Horton, C., Powles, R., Treleaven, J. Role of autologous transplantation in patient with multiple myeloma (MM) aged 65 years and over. *Blood* 1998; 92 (supplement 1) Abstract No. 1179
- 756 Rege, K., Hamblin, M., Powles, R., Atr, A., Treleaven, J., Swansbury, J., Catovsky, D. Disease features in acute myeloid leukaemia with t(8;21)(q22;q22) influence of age, complexity of karyotype immunophenotype and extramedullary leukaemia on event free survival. *Blood* 1998; 92 (supplement 1) Abstract No. 3873.
- 757 Sirohi, B., Powles, R., Treleaven, J., Ramiah, V., Horton, C., Mustafa, M., Kulkarni, S., Rage, N. Glomerular filtration rate (GFR) as a surrogate marker for transplant related morbidity (TRM) and overall outcome of multiple myeloma (MM) patients. *Blood* 1998; 92 (supplement 1) Abstract No. 4166
- 758 Mustafa, M., Powles, R., Treleaven, J., Horton, C., Sirohi, B. Total Therapy with VAMP/CVAMP+high dose melphalan and autograft for IgM lymphoplasmoid disease. *Blood* 1998; 92 (supplement 1) Abstract No. 4212
- 759 Sastry, P., Powles, R., Kulkarni, S., Horton, C., Ramiah, V., Sirohi, B., Treleaven, J. Total therapy for IgA Myeloma. *Blood* 1998; 92 (supplement 1) Abstract No. 4218.
- 760 Treleaven, J., Kulkarni, S., Powles, R., Singhal, S., Horton, C., Mehta, J. Transplantation for haematological malignancies in patients above the age of 50 years. *Blood* 1998; 92 (supplement 1) Abstract No. 4415
- 761 Kulkarni, S., Powles, R., Singhal, S., Riley, U., Horton, C., Treleaven, J., Mehta, J. Outcome of bone marrow transplantation in patients with evidence of viral hepatitis. *Blood* 1998; 92 (supplement 1) Abstract No. 4437.
- 762 Powles, R., Cunningham, D., Jameson, B., Tiley, C., Mehta, J., Milan, S., Hewitson, M. Randomized placebo controlled evaluation of prophylactic fluconazole after bone marrow transplantation. *Blood* 1998; 92 (supplement 1) Abstract No. 4453
- 763 Kulkarni, S., Powles, R., Mehta, J., Horton, C., Treleaven, J., Meller, S., Atr, A., Pinkerton, C., Singhal, S. Thalidomide in GVHD - S anti GVHD separable from the anti-angiogenesis. *Blood* 1998; 92 (supplement 1) Abstract No.4482

- 764 Kulkarni, S., Powles, R., Singhal, S., Treleaven, J., Horton, C., Ramiah, V., Saso, R., Sirohi, B., Sastry, P., Mehta, J. Second autografts for relapsed multiple myeloma: Is tandem autotransplantation better? *Blood* 1998; 92 (supplement 1) Abstract No. 4483
- 765 Saso, R., Kulkarni, S., Mitchell, P., Treleaven, J., Swansbury, J., Mehta, J., Powles, R., Ashley, S., Powles, T. Secondary MDS/AML following mitozantrone based therapy for breast carcinoma. *Blood* 1998; 92 (supplement 1) Abstract No. 4494.
- 766 Kulkarni S, Powles RL, Mehta J, Raje N, Singhal S, Horton C, Tait D, Treleaven J. Allogeneic bone marrow transplantation for multiple myeloma. *Blood* 1998; 92 (supplement 1) Abstract No. 4514
- 767 Powles, R., Kulkarni, S., Mehta, J., Treleaven, J., Tait, D., Horton, C., Shepherd, V., Millar, B., Rowland, A., Marsden, J., Long, S., Singhal, S., Shepherd, V., Millar, B., Rowland, A. Incidence and outcome of GVHD and its correlation with immune reconstitution in a double blind randomised single centre trial of PBSC versus bone marrow for allogeneic HLA identical sibling BMT. *Blood* 1998; 92 (supplement 1) Abstract No. 4524
- 768 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Mehta, J., Saso, R., Horton, C. Predictors of transfusion requirement beyond three months for AML autografts in first remission. *Blood* 1998; 92 (supplement 1) Abstract No.4580
- 769 Powles, R., Sirohi, B., Treleaven, J., Ramiah, V., Horton, C., Wilson, K., Raje, N. Impact of current treatment modalities including autografts on IgG multiple myeloma (MM). *Blood* 1998; 92 (supplement 1) Abstract No. 4596.
- 770 Singhal, S., Powles, R., Treleaven, J., Kulkani, S., Horton, C., Mehta, J. Long term outcome of adult acute leukaemia patients who are alive and well two years after allogeneic bone marrow transplantation from HLA identical siblings. *Leukemia & Lymphoma* 1998; Vol 00 pp 1-8.
- 771 Killick, S., Matutes, B., Powles, R. Acute erythroid leukaemia (M6): Outcome of Bone Marrow Transplantation. *Leukemia & Lymphoma* 1999; Vol 35; (1-2) pp 99-107.
- 772 Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. *Journal of Clinical Oncology*; 1998 vol 16; No. 12 pp 3832-3842
- 773 Sirohi, B., Powles, R., Mehta, J., Raje, N., Kulkarni, S., Ramiah, V., Saso, R., Horton, C., Bhagwati, N., Singhal, S., Treleaven, J. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. *British Journal of Haematology* 1999; 107: 656-666
- 774 Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Pandha, H., Bhagwati, N., Horton, C., Singhal, S., Mehta, J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. *Bone Marrow Transplantation* 2000; 25, (5) 533-539

- 775 Wang, J., Pandha, H.S., Treleaven, J., Powles, R. Metastatic extramedullary plasmacytoma of the lung. *Leukaemia & Lymphoma* 1999; 35: 423-425
- 776 Sirohi, B., Powles, R., Treleaven, J., Bhagwati, N., Kulkarni, S., Horton, C., Singhal, S., Mehta, J. A phase I-II study evaluating the feasibility of acute lymphoblastic leukaemia - type intensive consolidation chemotherapy (UKALLXA) after initial C-VAMP and high dose Melphalan autotransplantation in new patients with multiple myeloma. VII International Multiple Myeloma Workshop, Stockholm Sweden 1-5 September 1999.
- 777 Powles, R., Mawhorter, S., Williams, T. Liposomal Nystatin (Nyotran) vs Amphotericin B (Fugizone) in Empiric treatment of presumed fungal infection in neutropenic patients. Abstract: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco September 1999 MISSING
- 778 Schuster, M., Powles, R., Mawhorter, S., Williams, T. A randomized, double-blind comparison of liposomal nystatin (Nyotran) vs amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in febrile neutropenic patients. Abstract: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco September 1999.
- 779 Gahrton, G., Svensson, H., Bjorkstrand, B., Apperley, J., Carlson, K., Cavo, M., Ferrent, A., Fouillard, L., Gratecis, N., Gratwohl, A., Guilhot, F., Lambertenghi Deliliers, G., Ljungman, P., Masszi, T., Milligan, D.W., Powles, R., Reiffers, J., Samson, J.D., Stoppa, A.M., Vernant, J.P., Volin, L., Wallvik, J: for the European Group for Blood and Marrow Transplantation. Syngeneic transplanation in MM - a case matched comparison with autologous and allogeneic transplantation. *Bone Marrow Transplant* 1999, 24: 741-745
- 780 Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Sirohi, B., Tair, D., Horton, C., Rowland, A., Long, S., Millar, B., Shepherd, V., Singhal, S. More powerful graft-versus-tumor effects with blood derived stem cells? Significantly lower relapse after blood stem cell allografts in a randomized study comparing allogeneic blood versus marrow transplantation. *Blood*, 1999. No. 10, Supplement 1; No. 718.
- 781 Powles, R., Kulkarni, S., Treleaven, J., Hobbs, K., Sirohi, B., Bhagwati, N., Mehta, J., Singhal, S., Williams, T. Phase III randomized trial of Nyotran (liposomal nystatin) or amphotericin B for the empiric antifungal therapy in febrile neutropenic patients. *Blood*, 1999. No. 10, Supplement 1; No. 1528.
- 782 Singer, C.R.J., Taghipour, G., Boogaerts, M.A., Powles, R., Cordonnier, C., Schmitz, N., Holdstone, A.H.: the EBMT Working Party. Matched unrelated donor (MUD) bone marrow transplantation for adults and children with non-Hodgkins lymphoma and Hodgkin's lymphoma: Preliminary analysis of 56 cases reported to EBMT lymphoma registry. *Blood*, 1999. No. 10, Supplement 1; No. 2503
- 783 Sirohi, B., Powles, R., Treleaven, J., Singhal, S., Kulkarni, S., Parikh, P., Bhagwati, N., Horton, C., Mehta, J. The implications of compromised renal function at the time of presentation: A single centre study of 251 patients. *Blood*, 1999. No. 10, Supplement 1; No. 2566

- 784 Sirohi, B., Powles, R., Treleaven, J., Singhal, S., Parikh, P., Bhagwati, N., Horton, C., Kulkarni, S., Mehta, J. Light chain disease (LCD): A different form of myeloma compared with IgG disease. *Blood*, 1999. No. 10, Supplement 1; No. 2567
- 785 Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Bhagwati, N., Horton, C., Singhal, S., Mehta, J. High dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. *Blood*, 1999. No. 10, Supplement 1; No. 2578
- 786 Bhagwati, N., Powles, R., Sirohi, B., Treleaven, J., Horton, C., Tait, D., Mehta, J., Singhal, S., Kulkarni, S. Single center evaluation of long term follow up of ABMT/PBSCT for first remission adult ALL: potential for cure without excessive toxicity. *Blood*, 1999. No. 10, Supplement 1; No. 2586
- 787 Powles, R., Cunningham, D., Kulkarni, S., Sirohi, B., Gregory, R., Mehta, J., Singhal, S., Bhagwati, N., Treleaven, J., Fletcher, L., Fisher, T., O'Dea, S., Millar, B., Shepherd, V., Sampson, M., Watson, D., Penny, J. Combination of Ancestim (r-metHu stem cell factor, SCF) and filgrastim (r-metHu G-CSF) for peripheral blood stem cell (PBSC) collection in patients who have previously failed to mobilize with G-CSF alone. *Blood*, 1999. No. 10, Supplement 1; No. 2698
- 788 Sirohi, B., Powles, R., Sumpter, K., Kulkarni, S., Singhal, S., Bhagwati, N., Horton, C., Saso, R., Mehta, J., Treleaven, J. A comparison of kinetics of paraprotein clearance after infusional chemotherapy versus high-dose melphalan in previously untreated patients with IgG multiple myeloma. *Blood*, 1999. No. 10, Supplement 1; No. 4631
- 789 Powles, R., Kulkarni, S., Sirohi, B., Bhagwati, N., Mehta, J., Singhal, S., Treleaven, J., Neville, F., Hobbs, K., Indri Annesley, N., Gourlay, M.L., Barouki, F. Phase I/II evaluation of intravenous tresperimus (LF 08-0299) and methyprednisolone as first line therapy for acute graft versus host disease (GVHD) *Blood*, 1999. No. 10, Supplement 1; No. 4707
- 790 Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Mehta, J. Post transplant consolidation chemotherapy to eliminate minimal residual disease in myeloma patients after high-dose melphalan and autotransplantation: feasibility and tolerance. *Blood*, 1999. No. 10, Supplement 1; No. 4628
- 791 Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Sirohi, S., Tait, D., Horton, C., Rowland, A., Long, S., Millar, B., Shepherd, V., Mehta, J. A low CD34+ cell dose results in higher mortality and lower survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2×10^6 CD34+ cells/kg be considered the threshold? *Blood*, 1999. No. 10, Supplement 1; No. 4963
- 792 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Bhagwati, N., Mehta, J. Sequential high dose therapy of adult acute lymphoblastic leukaemia (ALL) with autotransplantation in first remission and salvage allogeneic transplantation in second remission : Long term follow-up. *Blood*, 1999. No. 10, Supplement 1; No. 4964
- 793 Sumpter, K., Powles, R., Raje, N., Ramiah, V., Kulkarni, S., Treleaven, J., Mainwaring, P. Oral Idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. *Leukaemia & Lymphoma* 1999, Vol 35 (5-6) pp 593-597

- 794 Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J. Long term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. *Bone Marrow Transplant* 1999, 23: 875-879.
- 795 Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Sirohi, B., Millar, B., Shepherd, V., Saso, R., Rowland, A., Long, S., Cabral, S., Horton, C., Mehta, J. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplantation* 2000 25: (5) 501-505.
- 796 Kulkarni, S., Powles, R., Treleaven, J., Riley, U., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Meller, S., Saso, R., Mehta, J. Chronic GVHD is associated with long-term risk of pneumococcal infections in bone marrow transplant patients. *Blood*, 2000, 95:(12) p3683-86
- 797 Kulkarni, A., Powles, R., Treleaven, J., Singhal, S., Horton, C., Sirohi, B., Bhagwati, N., Tait, D., Saso, R., Killick, Pinkerton, R., Atra, A., Meller, S., Mehta, J. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. *Bone Marrow Transplant* 2000 25,(4) 365-370
- 798 Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Raje, J., Horton, C., Singhal, S., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - A phase I/II feasibility and tolerance study of 17 patients. *Bone Marrow Transplant* 2000 25: (9) 949-956
- 799 Frassoni, F., Labopin, M., Powles, R., Mary, J.Y., Arcese, W., Bacigalupo, A., Bunjes, D., Gluckman, E., Ruutu, T., Schaefer, U.W., Sierra, J., Vernant, J.P., Willemze, R., de Witte, T., Gorin, N.C. for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Effect of centre on outcome of bone marrow transplantation for acute myeloid leukaemia. *Lancet* 2000, 355, (9213) 1393-1398
- 800 Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Millar, B., Shepherd, V., Rowland, A., Sirohi, B., Tait, D., Horton, C., Long, S., Singhal, S. Allogeneic blood and marrow stem cell transplantation in haematologic malignant disease: a randomised trial. *Lancet* 2000, 355: 1231-1237
- 801 Raje, N. and Powles, R. Autologous hematopoietic stem cell transplantation for multiple myeloma and AL amyloidosis. Chapter in *Clinical Bone Marrow and Blood Stem Cell Transplantation (Second Edition)*. Edited by Kerry Atkinson. Cambridge University Press. 2000, p 287
- 802 Mehta, J. and Powles, R. The future of blood and bone marrow transplantation. Chapter in *Clinical Bone Marrow and Blood Stem Cell Transplantation (Second Edition)*. Edited by Kerry Atkinson. Cambridge University Press. 2000, p 1447
- 803 Davies, S.M., Ramsay, N.K., Klein, J.P., Weisdorf, D.J., Bolwell, B., Cahn, J.Y., Camitta, B.M., Gale, R.P., Giral, S., Heilmann, C., Henslee-Downey, P.J., Herzig, R.H., Hutchinson, R., Keating, A., Lazarus, H.M., Milone, G.A., Neudorf, S., Perez, W.S.,

- Powles, R., Prentice, H.G., Schiller, G., Socied, G., Vowels, M., Wiley, J., Horowitz, M.M. et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. *Journal of Clinical Oncology* 2000 18: (2) 340-347
- 804 Saso, R., Kulkarni, S., Mitchell, P., Treleaven, J., Swansbury, J., Mehta, J., Powles, R., Ashley, S., Kuan, A., Powles, T. Secondary myelodysplastic syndrome/Acute myeloid leukaemia (MDS/AML) following mitoxantrone based therapy for breast carcinoma. *British Journal of Cancer*, 2000, (83): 91-94.
- 805 Bhagwati, N., Powles, R., Sirohi, B., Treleaven, J., Horton, C., Tait, D., Mehta, J., Singhal, S., Kulkarni, S. Single centre evaluation of long-term follow up of ABMT/PBSCT for first remission adult all: potential for cure without excessive toxicity. *Bone Marrow Transplantation*, 2000, (25): suppl 1, No. 11
- 806 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Horton, C., Saso, R., Singhal, S., Mehta, J., Treleaven, J. Central nervous system after stem cell transplantation (SCT) for acute leukaemia beyond first remission, *Bone Marrow Transplantation* (2000), Vol 25, uppl 1, No. 15
- 807 Powles, R., Kulkarni, S., Mehta, J., Treleaven, J., Millar, B., Shepherd, V., Rowland, A., Sirohi, B., Tait, D., Horton, C., Long, S., Singhal, S. Pattern of immune reconstitution after allograft: results of double blind randomized trial of allogeneic bone marrow or peripheral blood stem cells transplantation. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, No. 74
- 808 Powles, R., Kulkarni, S., Bhagwati, N., Mehta, J., Singhal, S., Sirohi, B., Treleaven, J., Neville, F., Inriannesley, N., Gourlay, M.L., Barouki, F. Phase III evaluation of intravenous tresperimus (LF 08-0299) and methylprednisolone as first line therapy for acute graft-versus-host disease. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, No. 98
- 809 Gahrton, G., Svensson, H., Apperley, J., Bacigalupo, A., Bjorkstrand, B., Blade, J., Cavo, M., Cornelissen, J., De Laurenzi, A., Facon, T., Ljungman, P., Michallet, M., Powles, R., Reiffers, J., Russell, N., Schaefer, U.W., Schattenberg, A., Tura, S., Verdonck, L.F., Vernant, J.P., Volin, L., deVries, T. Progress in allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, No. 140.
- 810 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Mehta, J., Sirohi, B., Barlow, C., Chau, I., Horton, C. Predictors of transfusion requirements beyond three months for AML autografts in first remission. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p214.
- 811 Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Sirohi, B., Bhagwati, N., Horton, C., Tait, D., Mehta, J. Delivery of intensive acute myeloid leukaemia curative care in real world environments: a single center experience of 92 population based patients with potential implications to future multi-center trials. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p214.

- 812 Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type intensive chemotherapy (ALL-IC). Bone Marrow Transplantation (2000), Vol 25, suppl 1, p252.
- 813 Kulkarni, S., Powles, R., Mehta, J., Singhal, S., Treleaven, J., Saso, R., Matutes, E., Dearden, C., Cunningham, D., Catovsky, D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p259.
- 814 Barlow, C., Powles, R., Chau, I., Horton, C., Treleaven, J., Mehta, J., Singhal, S., Kulkarni, S. Allograft beyond the age of 50 years: Matched pair analysis with cases transplanted at younger age. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p410.
- 815 Kulkarni, S., Powles, R., Mehta, J., Treleaven, J., Saso, R., Horton, C., Sirohi, B., Singhal, S. Thalidomide in GVHD - is anti GVHD effect separable from the antiangiogenesis. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p462.
- 816 Powles, R., Kulkarni, S., Treleaven, J., Hobbs, K., Sirohi, B., Bhagwati, N., Mehta, J., Singhal, S., Williams, T. Phase III randomized trial of nyotran (liposomal nystatin) or amphotericin for the empiric antifungal therapy in febrile neutropenic patients. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p616.
- 817 Powles, R., Kulkarni, S., Treleaven, J., Mehta, J., Singhal, S., Sirohi, S., Hobbs, K., Horton, C. Assessment of patients who are alive in first complete remission (CR) for more than 10 years following autograft for haematological malignancies. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p667.
- 818 Kulkarni, S., Powles, R., Singhal, S., Sirohi, B., Horton, C., Treleaven, J., Barlow, C., Chau, I., Swannie, H., Mehta J. Second autografts for relapsed multiple myeloma: is tandem autotransplantation better? Bone Marrow Transplantation (2000), Vol 25, suppl 1, p691.
- 819 Sirohi, B., Powles, R., Sumpter, K., Kulkarni, S., Singhal, S., Bhagwati, N., Saso, R., Horton, C., Mehta, J., Treleaven, J. A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p692.
- 820 Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Bhagwati, N., Horton, C., Singhal, S., Saso, R., Mehta, J. High dose chemotherapy (HDT) and autologous transplantation in myeloma patients aged 85 years and over: A case control comparison with younger patients. Bone Marrow Transplantation (2000), Vol 25, suppl 1, p693.
- 821 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Glomerular filtration rate (GFR) as a surrogate marker for transplantrelated toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high dose melphalan (HDM) 200mg/m². Bone Marrow Transplantation (2000), Vol 25, suppl 1, p694.
- 822 Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type intensive chemotherapy

- (ALL-IC) to eliminate minimal residual disease post autografting in multiple myeloma. A phase I/II feasibility and tolerance study of 17 patients. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p695.
- 823 Sirohi, B., Powles, R., Singhal, S., Bhagwati, N., Saso, R., Horton, C., Singal, S., Raje, N., Mehta, J., Treleaven, J. Bence-Jones (BJ) Myeloma: A different form of myeloma compared to IgG and IgA myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p696
- 824 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Metha, J., Horton, C., Sirohi, B., Swannie, H. Previous autograft adversely affects the outcome of allograft for myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p702.
- 825 Sirohi, B., Powles, R., Sumpter, K., Kulkarni, S., Singhal, S., Bhagwati, N., Saso, R., Horton, C., Mehta, J., Treleaven, J. A comparison of kinetics of paraprotein clearance: rapid decline of paraprotein after high dose Melphalan (HDM) versus infusional chemotherapy in previous untreated patients with IgG multiple myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p724.
- 826 Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Bhagwati, N., Horton, C., Singhal, S., Saso, R., Mehta, J. High dose chemotherapy (HDT) and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p725.
- 827 Sirohi, B., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Parikh, P., Bhagwati, N., Saso, R., Singhal, S., Raje, N. The implication of compromised and normal renal function at presentation in myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p726.
- 828 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Glomerular filtration rate (GFR) as a surrogate marker for transplant-related toxicity and overall outcome in patients of multiple myeloma (MM) homogeneously treated with high dose melphalan (HDM) 200 mg/m². *Bone Marrow Transplantation* (2000), Vol 25, Suppl 1, p727.
- 829 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Bence Jones (BJ) myeloma: A different form of myeloma compared to IgG and IgA myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p728.
- 830 Saso, R., Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Swansbury, J., Horton, C., Catovsky, D. Secondary MDS/AML in patients treated for multiple myeloma (MM). *Bone Marrow Transplantation* (2000), Vol 25, Suppl 1, p751.
- 831 Sirohi, B., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Parikh, P., Bhagwati, N., Saso, R., Raje, N., Mehta, J., Singhal, S. High dose chemotherapy and autologous stem cell transplant for metastatic neuroblastoma: A single center experience. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p72.
- 832 Powles, R., Cunningham, D., Kulkarni, S., Gregory, K., Sirohi, B., Mehta, J., Singhal, S., Bhagwati, N., Treleaven, J., O'Dea, S., Miller, B., Sampson, M., Watson, D., Penny, J.

- Combination of ancestim (r-metHu stem cell factor, SCF) and filgrastim (r-metHu G-CSF, G-CSF) for peripheral blood stem cell (PBSC) collection in patients who have previously failed to mobilize with G-CSF alone. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p816.
- 833 Saini, A., Kulkarni, S., Stephens, M., Powles, R., Cunningham, D. High dose chemotherapy and peripheral blood stem cell transplantation for lymphoma with reinfusion of low numbers of CD34+ cells. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p819.
- 834 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Sirohi, B., Millar, B., Shepherd, V., Neville, F., Swannie, H., Mehta, J. Randomized trial comparing equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with hematologic malignancies. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p833.
- 835 Swannie, H., Kulkarni, S., Powles, R., Treleaven, J., Horton, C. Bone Marrow (BM) and peripheral blood stem cell (PBSC) harvest for patients with acute myeloid leukaemia (AML) in first complete remission (CR): Predictors of proper timing to achieve maximum yield. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p838.
- 836 Swannie, H., Kulkarni, S., Powles, R., Treleaven, J., Chau, I., Barlow, C., Horton, C. Comparison of cell yields in granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cell (PBSC) harvest in various hematological malignancies. *Bone Marrow Transplantation* (2000), Vol 25, Supplement 1, P860
- 837 Sirohi, B., Powles, R., Sumpter, K., Singhal, S., Bhagwati, N., Saso, R., Mehta, J., Treleaven, J. A comparison of kinetics of paraprotein clearance: rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. *Bone Marrow Transplantation* (2000), Vol 25, suppl 1, p917.
- 838 Clutterbuck, R., Powles, R., Miller, J., Catovsky, D. Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage haemopoietic progenitor cells. *Experimental Haematology*, 2000, Vol 28(10) p1120-8.
- 839 Vaidya, S.J., Atra, A., Bahl, S., Pinkerton, C.R., Calvagna, V., Horton, C., Milan, S., Shepherd, V., Brian, C., Treleaven, J., Powles, R., Tait, D., Meller, S.T. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long term follow up. *Bone Marrow Transplantation* 2000, Vol 25: p599-603.
- 840 Sirohi, B., Powles, R., Treleaven, J., Kulkarni, S., Horton, C., Parikh, P., Bhagwati, N., Saso, R., Singhal, S., Raje, N., Mehta, J. The implication of compromised renal function at presentation in myeloma – similar outcome in patients who receive high-dose therapy (HDT): A single centre study of 251 previously untreated patients. *British Journal of Haematology* 2000, Vol 108; suppl 1: p21.
- 841 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Bence Jones (BJ) myeloma: A distinct entity compared to IgG and IgA myeloma. *British Journal of Haematology* 2000, 108; suppl 1: p32.

- 842 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Mehta, J., Singhal, S., Treleaven, J. Central nervous system relapse after stem cell transplantation(SCT) for acute leukemia beyond first remission. *British Journal of Haematology* 2000, Vol 108; suppl 1: p71.
- 843 Powles, R., Kulkarni, S., Treleaven, J. Singhal, S., Sirohi, B., Bhagwati, N., Horton, C., Tait, D., Mehta, J. Delivery of intensive acute myeloid leukaemia curative care in real world environments: A single center experience of 92 population based patients with potential implications to future multi-center trials. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p104 .
- 844 Sirohi, B., Sumpter, K., Powles, R., Kulkarni, S., Singhal, S., Bhagwati, N., Saso, R., Horton, C., Mehta, J., Treleaven, J. Kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose melphalan (HDM) compared to infusional chemotherapy in previously untreated patients with IgG myeloma. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p169.
- 845 Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Sirohi, B., Millar, B., Shepherd, V., Neville, F., Horton, C., Mehta, J., Cunningham, D. Comparison of equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with haematologic malignancies. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p191.
- 846 Powles, R., Kulkarni, S., Bhagwati, N., Mehta, J., Singhal, S., Sirohi, B., Treleaven, J., Neville, F., Indri Annesley, N., Gourlay, M.L., Barouki, F. Phase I/II evaluation of intravenous tresperimus (LF08-0299) and methylprednisone as first line therapy for acute graft-versus-host disease. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p194.
- 847 Sirohi, B., Powles, R., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Singhal, S., Raje, N., Mehta, J., Treleaven, J. Glomerular filtration rate as a surrogate marker for transplant-related toxicity and overall outcome in patients with multiple myeloma homogenously treated with high-dose melphalan. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p196.
- 848 Kulkarni, S., Powles, R., Mehta, J., Singhal, S., Treleaven, J., Saso, R., Matutes, E., Tait, D., Cunningham, D., Catovsky, D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p202.
- 849 Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Horton, C., Mehta, J., Singhal, S., Treleaven, J. Autotransplants for adult ALL in CR1. A single centre study of 75 patients. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p204.
- 850 Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Horton, C., Singhal, S., Saso, R., Mehta, J. High-dose therapy and autotransplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. 5th Annual Meeting of the European Haematology Association. *The Hematology Journal* 2000: Vol 1, suppl 1: p209.

- 851 Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Horton, C., Parikh, P., Bhagwati, N., Saso, R., Singhal, S., Raje, N., Mehta, J. Influence of renal dysfunction at presentation in myeloma-similar outcome in patients who receive high-dose therapy (HDT): A single centre study of 251 previously untreated patients. 5th Annual Meeting of the European Haematology Association. The Hematology Journal 2000: Vol 1, suppl 1: p209.
- 852 Sirohi, B., Powles, R., Kulkarni, S., Saso, R., Horton, C., Mehta, J., Singhal, S., Treleaven, J. CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukemia beyond first CR. 5th Annual Meeting of the European Haematology Association. The Hematology Journal 2000: Vol 1, suppl 1: p213.
- 853 Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Sirohi, B., Horton, C., Millar, J., Shepherd, V., Tait, D., Saso, R., Rowland, A., Long, S., Mehta, J. A low CD34+ cell dose results in higher mortality and poorer survival or marrow stem cell transplantation from HLA-identical siblings: Should CD34+ cells/kg be considered the maximum threshold? Bone Marrow Transplantation, 2000 Sep, 36(5) p489-96.
- 854 Zuha, R., Price, T., Powles, R., Treleaven, J. Paradoxical emboli after central venous catheter removal. Ann Oncol 11 (7) 855-6
- 855 Rege, K., Swansbury, J., Atra, A., Horton, C., Min, T., Dainton, M., Matutes, E., Durosini, M., Treleaven, J., Powles, R., Catovsky, D. Disease features in acute myeloid leukaemia with t(8;21) (q22;q22). Influence of Age, secondary Karyotype abnormalities, CD19 status, and extramedullary leukaemia on survival. Leukaemia & Lymphoma 2000; vol 40 (1-2) p67-77.
- 856 Sirohi, B., Powles, R., Treleaven, J., Kulkarni, S., Singhal, S., Mehta, J. Single center evaluation of autologous stem cell transplantation in first remission followed by maintenance chemotherapy in patients with acute lymphoblastic leukaemia. Poster Abstracts; Leukaemia 2000 (P003) p37.
- 857 Sirohi, B., Powles, R., Treleaven, J., Kulkarni, S., Singhal, S., Mehta, J. Central nervous system relapse after stem cell transplantation for acute leukaemia beyond first remission. Poster Abstracts; Leukaemia 2000 (P010) p40.
- 858 Powles, R., Sirohi, B., Treleaven, J., Singhal, S., Kulkarni, S., Lal, R., Riggs, A., Horton, C., Saso, R., Mehta, J. Continued first complete remission in multiple myeloma for over 10 years: A Series of "Operationally Cured" patients. Blood 2000: Vol 96(11), p515a.
- 859 Frassoni, F., Labopin, M., Arcese, W., Ruutu, T., Reiffers, J., Shaefers, U., Gluckman, E., McCann, S., Bunjes, D., Harousseau, J.L., Zander, A., Ringden, O., Willemze, R., Powles, R., De Witte, T., Bacigalupo, A.,. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for AML 1CR is significantly worse after 35 years. Implication for reducing the intensity of the conditioning regimen. Report of the Acute Leukaemia Working Party of EBMT. Blood 2000: Vol 96(11), p393a.
- 860 Powles, R., Sirohi, B., Treleaven, J., Singal, S., Cunningham, D., Gore, M., Kulkarni, S., Horton, C., Saso, R., Mehta, J. 15 year follow-up of myeloma patients receiving

140 mg/m² melphalan without hematopoietic stem cell or growth factor support as initial therapy. Blood 2000: Vol 96(11), p292b.

- 861 Powles, R., Sirohi, B., Treleaven, J., Millar, B., Singhal, S., Kulkarni, S., Saso, R., Horton, C., Hobbs, K., Murphy, K., Mehta, J. Collection of peripheral blood stem cells in newly-diagnosed myeloma patients without any prior cytoreductive therapy. Blood 2000: Vol. 96(11), p182a.
- 861 Sirohi, B., Powles, R., Treleaven, J., Singhal, S., Kulkarni, S., Saso, R., Riggs, A., Mehta, J. High-dose melphalan and autotransplantation in myeloma patients with severe renal dysfunction (creatinine clearance <20 ml/min/m²): High incidence of atrial fibrillation and treatment-related mortality. Blood 2000: Vol 96(11), p388a.
- 862 Powles, R., Kulkarni, S., Mehta, J., Singhal, S., Sirohi, B., Saso, R., Long, S., Rowland, A., Marsden, J., Horton, C., Millar, B., Treleaven, J. Pattern of immune reconstitution after allograft: Results of double blind randomised trial of allogeneic bone marrow or peripheral blood stem cells transplantation. Blood 2000: Vol 96(11), p182a.
- 863 Powles, R., Kulkarni, S., Mehta, J., Singhal, S., Sirohi, B., Saso, R., Horton, C. Leukaemia. Allogeneic bone marrow (BMT) or peripheral blood stem cell (PBSCT) transplant: early helper T-cell recovery results in better survival. Blood 2000: Vol 96(11), p197a.
- 864 Powles, R., Kulkarni, S., Sirohi, B., Mehta, J., Singhal, S., Hobbs, K., Saso, R., Treleaven, J. Single centre analysis of long-term outcome in patients who are alive beyond 10 year. After autograft for haematological malignancies. Blood 2000: Vol 96(11), p405a.
- 865 Kulkarni, S., Powles, R., Treleaven, J., Sirohi, B., Horton, C., Saso, R. Predictive model based on pre-conditioning parameters to predict the risk of treatment related mortality (TRM) in patients undergoing allogeneic hematopoietic-stem cell transplant (AHSCT) Blood 2000: Vol 96(11), p585a.
- 866 Powles, R., Mehta, J., Treleaven, J., Kulkarni, S., Sirohi, B., Tait, D., Singhal, S. Blood or BM for allogeneic transplantation from HLA-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. Blood 2000: Vol 96(11), p196a.
- 867 Treleaven, J., Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Saso, R., Horton, C., Mehta, J. Autografting and post-transplant maintenance chemotherapy in CR1 acute lymphoblastic leukaemia. Blood 2000: Vol 96(11), p427a.
- 869 Kulkarni, J., Powles, R., Cunningham, D., Sirohi, B., Cheung, B., Treleaven, J. Factors predicting failure to mobilize adequate CD34 positive cells (2x10⁸/kg) after priming with growth factors. Blood 2000: Vol 96(11), p519a.

- 868 Kulkarni, S., Powles, R., Treleaven, J., Sirohi, B., Millar, B., Horton, C., Cunningham, D. Comparison of lower doses of lenograstim and filgrastim and standard dose G-CSF for mobilization of peripheral blood stem cells in patients with haematologic malignancies. *Blood* 2000: Vol 96(11), p317b.
- 871 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Murphy, K., Conway, A., Cole, C., Saso, R., Singhal, S. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric anti-fungal therapy in immunocompromised patients with hematologic malignancies. *Blood* 2000: Vol 96(11), p24a.
- 872 Chau, I., Powles, R., Treleaven, J., Kulkarni, S., Horton, C. Outcome of bone marrow transplantation in patients with previous evidence of viral hepatitis – a matched pair analysis. *Blood* 2000: Vol 96(11), p188a.
- 873 Singhal, S., Powles, R., Henslee-Downey, P.J., Treleaven, J., Chiang, K.Y., Godder, K., Kulkarni, S., van Rhee, F., Meller, S., Pinkerton, C.R., Sirohi, B., Horton, C., Mehta, J. Haploidentical or autologous transplantation for advanced acute leukaemia? *Blood* 2000: Vol 96(11), p209a.
- 874 Singhal, S., Chiang, K.Y., Powles, R., Henslee-Downey, P.J., Treleaven, J., Godder, K., Kulkarni, S., van Rhee, F., Sirohi, B., Pinkerton, C.R., Meller, S., Mehta, J. Allogeneic transplantation from matched sibling or partially matched related donors for primary refractory acute leukaemia. *Blood* 2000: Vol 96(11), p210a.
- 875 Sirohi, B., Powles, R., Mehta, J., Treleaven, J., Pinkerton, C.R., Meller, S., Kulkarni, S., Saso, R., Horton, C., Singhal, S. Central nervous system relapse in acute leukaemia patients transplanted beyond the first remission. *Blood* 2000: Vol 96(11), p404a.
- 876 Kulkarni, S., Saso, R., Powles, R., Treleaven, J., Sirohi, B., Cheung, B., Horton, C. Results of allogeneic hematopoietic transplants in patients with chronic myeloid leukaemia (CML): Single centre evaluation of 141 patients. *Blood* 2000: Vol 96(11), p412a.
- 877 Chau, I., Powles, R., Treleaven, J., Sirohi, B., Kulkarni, S. Analysis of treatment outcome and long term survival in patients diagnosed with multiple myeloma \leq age of 35. *Blood* 2000: Vol 96(11), p759a.
- 878 Saini, A., Kulkarni, S., Norman, A., Stephens, M., Rao, S., Fisher, T., Powles, R., Cunningham, D. High-dose chemotherapy and peripheral blood stem cell transplantation for lymphoma with reinfusion of low numbers of CD34+ cells. *Blood* 2000: Vol 96(11), p796a.
- 879 Sirohi, B., Powles, R., Treleaven, J., Singhal, S., Kulkarni, S., Saso, R., Pinkerton, C.R., Meller, S., Vaidya, S., Murphy, K., Conway, A., Seybel, C., Cunningham, D., Mehta, J. Amphotericin B colloid dispersion (ABCD) for the treatment of proven or presumed fungal infections in immunocompromised patients with hematologic malignancies. *Blood* 2000: Vol 96(11), pp37b.

- 880 Saso, R., Kulkarni, S., Treleaven, J., Paneesha, R., Alvarez, C., Sirohi, B., Rudin, C., Foukanelli, D., Swansbury, J., Horton, C., Powles, R., Catovsky, D. Single centre evaluation of acute monocytic leukaemia (AML-M5). *Blood* 2000: Vol 96(11), p206b.
- 881 Powles, R., Kulkarni, S., Treleaven, J., Mehta, J., Singhal, S., Sirohi, B., Saso, R., Horton, C. Delivery of intensive acute myeloid leukaemia curative care in real world environments: A single centre experience of 96 population based patients with potential implications to future multi-centre trials. *Blood* 2000: Vol. 96(11), p216b.
- 882 Guppy, A., Cunningham, D., Webb, A., Norman, A., (Intr by Ray Powles): The value of surveillance CT scans to detect early relapses in the first year after complete response to induction chemotherapy in patients with aggressive non/hodgkins lymphoma. *Blood* 2000: Vol. 96(11), p223b.
- 883 Saso, R., Kulkarni, S., Cunningham, D., Ashley, S., Powles, R., Swansbury, J., Treleaven, J. Increased risk of secondary MDS/AML in patients treated for hodgkin disease. *Blood* 2000: Vol 96(11), p264b.
- 884 El-Nenaei, M., Sirohi, B., Powles, R., Treleaven, J., Brito-Babapule, V., Singhal, S., Mehta, J., Matutes, E., Swansbury, J., Saso, R., Catovsky, D. Deletions of 13q14 are associated with a high frequency of p53 deletions in newly-diagnosed patients with myeloma. *Blood* 2000: Vol. 96(11), p274b.
- 885 Powles, R., Sirohi, B., Treleaven, J., Singhal, S., Kulkarni, K., Chau, I., Saso, R., Horton, C., Lal, R., Mehta, J. Maximal response to infusional chemotherapy prior to autotransplantation influences outcome of patients with newly-diagnosed multiple myeloma. *Blood* 2000: Vol 96(11), p292b.
- 886 Sirohi, B., Saso, R., Powles, R., Treleaven, J., Mehta, J., Singhal, S., Kulkarni, S. Role of defibrotide (DT) and therapeutic plasma exchange (TPE) in the management of transplant associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): A single centre experience. *Blood* 2000, Vol. 96(11), p334b.
- 887 Cheung, B., Ackers, C., Powles, R., Rigg, A., Lal, R., Sirohi, B., Kulkarni, S. Allogeneic peripheral blood stem cell transplantation (PBSCT) for patients with multiple myeloma (MM)-single centre experience. *Blood* 2000: Vol. 96(11), p352b.
- 888 Apperley JF et al. Baby Paper. *Lancet*
(j.apperley@ic.ac.uk) phone 020 8 383 3237
- 889 *New England Journal of Medicine Letter*
- 890 Prescott, A.P., Collins, D.J., Dzik-Jurasz, A., Sirohi, B., Powles, R., & Leach, M. Localised 2D proton magnetic resonance spectroscopy and the study of systemic bone disease.

- 891 Powles, R. and Sirohi, B. Toward an Understanding of the causation, Treatment and Pathology of Myeloma, High Dose Therapy in Patients with Multiple Myeloma. *Oncology Spectrums*, Vol. 2 No. 2 (February 2001), pp.86-93.
- 892 Sirohi B, Powles R L, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, and Treleaven J. Glomerular filtration rate prior to high dose melphalan 200 mg/m² as a surrogate marker or outcome in patients with myeloma. *British Journal of Cancer* 2001; 85 (3):325-332.
- 893 Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bjorkstrand B, Blade J, Cornelissen J, De Laurenzi A, Facon T, Ljungman, Michallet M, Niederwieser D, Powles R, Reiffers N, Russell H, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemsen R, and Volin L for the European Group for Blood and Marrow Transplantation (EBMT). Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation Centres. *British Journal of Haematology*, 2001 209-216.
- 894 Murray P V, O'Brien M E R, Padhani A R, Powles R, Cunningham D, Jeanes A, Ashley S. Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. *Bone Marrow Transplantation* 2001; 27: 967-971.
- 895 Boriskin Y, Fuller K, Powles R, Vipond B, Caul O, Booth J, Butcher P. Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site trial. *Journal of Clinical Virology*, 24, (2002) 13-23
896. Sirohi, B., and Powles, R., : High-Dose Therapy in Patients with Multiple Myeloma: *Oncology Spectrums*, Volume 2 – Number 2: Pages 86-95.
897. Powles R, Mehta J, Kulkarni S, Treleaven J, Sirohi B, Horton C, Tait D, Marsden J, Long J, Singhal S (Sutton, UK): Blood or BM for allogeneic transplantation from Hla-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM: *Bone Marrow Transplantation*, Volume 27, Supplement 1: Page S8.
898. Powles, R., Kulkarni, S., Sirohi B, Saso R, Treleaven J, Horton C, Singhal S, Mehta J (Sutton,UK):Results of allogeneic transplant in patients with Chronic Myeloid Leukaemia (CML): single centre evaluation of 141 patients: *Bone Marrow Transplantation* 2001; 27: Supplement 1:Page S37.
899. Powles R, Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bjorkstrand B, Blade J, Cornelissen J, Laurenzi A de, Facon T, Hagman A, Ljungman P, Michallet M, Niederwieser D, Reiffers J, Russell N, Samson D, Schaefer U, Schattenberg A, Tura S, Verdonck J, Vernant J, Willemsen R, Volin L (Huddinge S): Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) compared to Bone Marrow transplantation (BMT) in multiple myeloma: *Bone Marrow Transplantation*, Volume 27, Supplement 1:Page S39

900. Powles R, Kulkarni S, Cunningham D, Cheung B, Sirohi B, Saso R, Treleaven J (Sutton, UK): Factors predicting CD34 yields above $2 \times 10^6/\text{kg}$ with growth factor mobilization: Bone Marrow Transplantation, Volume 27, Supplement 1:Page S58.
901. Gahrton G, Apperley J, Bacigalupo A, Björkstrand B, Blade J, Cavo M, Cornelissen J, Laurenzi A de, Facon T, Hagman A, Lalancette M, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russel N H., Samson D, Schaefer U W, Schattenberg A, Tura S, Verdonck J, Vernant J P, Willemze R, Volin L: An Overview of Allogeneic Transplantation in Multiple Myeloma: VIIIth International Myeloma Workshop, Banff Springs Hotel, Banff, Alberta, Canada: Pages S14.
902. Sirohi B, Powles R, Kulkarni S, Saso R, Treleaven J, Singhal S, Horton C, Mehta J: Rapid early response to infusional chemotherapy is an independent prognostic factor in newly-diagnosed IGG and IGA multiple myeloma: The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 35.
903. Powles J, Sirohi B, Kulkarni S, Treleaven J, Saso R, Horton C, Mehta J, Singhal S. A pilot trial of feasibility of collecting peripheral blood stem cells in newly-diagnosed myeloma patients before receiving infusional CVAMP chemotherapy: The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 97.
904. Roberts S, Powles R (2), Powles R, Horton C, Treleaven J, Kulkarni S: Transfusion requirement after autologous bone marrow (BM) or peripheral blood stem cells (PBSC) for AML in first complete remission (CR1): The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 209 .
905. Foukaneli T F, Powles R (2), Treleaven J (2), Kulkarni S (2), Sirohi B (3), Shepherd V (2), Horton C (2): Dose of PBSC after high dose melphalan is not a factor in outcome for newly diagnosed myeloma patients who has been induced with C-VAMP before autografting: The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 219.
906. Kulkarni S, Powles R, Sirohi B, Treleaven J, Tait D, Saso R, Horton C. Single centre analysis of allogeneic hematopoietic stem cell transplant for acute leukaemia in first complete remission: comparison of two single fraction dose schedules (9.5GY or 10.5GY): The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 182.
907. Kulkarni S, Powles R, Sirohi B, Treleaven J, Tait D, Saso R, Horton C.: Results of allogeneic transplant in patients with chronic myeloid leukaemia (CML): single centre evaluation of 141 patients – Royal Marsden Hospital experience over 20 years: The Hematology Journal, Volume 1 – Supplement 1 – June 2001: Page 99.
908. Sirohi B, Powles R, Kulkarni S, Saso R, Goyal S, Rudin C, Treleaven J. High-Dose Melphalan with Autologous Peripheral Stem Cell Rescue in Myeloma Patients with Severe Renal Dysfunction (Creatinine Clearance $<20\text{ml}/\text{min}/\text{m}^2$): High Incidence of Atrial Fibrillation and Treatment-Related Mortality. VIIIth International Myeloma Workshop, Banff Springs Hotel, Banff, Alberta, Canada, May 4-8, 2001, Abstracts, p145.

909. Powles R, Sirohi B, Kulkarni S, Saso R, Horton C, Goyal S, Singhal S, Mehta J, Treleaven J. Collection of Peripheral Blood Stem Cells in Newly-Diagnosed Myeloma Patients before Receiving Infusional CVAMP Chemotherapy. VIIIth International Myeloma Workshop, Banff Springs Hotel, Banff, Alberta, Canada, May 4-8, 2001, Abstracts, p152.
910. Sirohi B, Powles R, Kulkarni S, Saso R, Horton C, Goyal S, Rudin C, Treleaven J. Early Response to Infusional Chemotherapy is an Independent Prognostic Factor in Previously Untreated IgG and IgA Multiple Myeloma. VIIIth International Myeloma Workshop, Banff Springs Hotel, Banff, Alberta, Canada, May 4-8, 2001, Abstracts, p201.
911. Saso R, Treleaven J, Powles R, Sirohi B, Paneesha S, Alvarez C, Foukaneli T, Rudin C, Kulkarni S. Role of ABO-antigen mismatch in stem cell transplantation. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S83.
912. Kulkarni S, Powles R, Sirohi B, Saso R, Rudin C, Treleaven J, Horton C, Singhal S, Mehta J. Allogenic (Allo) or Autologous (Auto) Hematopoetic Stem Cell Transplant (HSCT) for advanced Acute Myeloid Leukaemia (AML). Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S86.
913. Powles R, Sirohi B, Kulkarni S, Mehta J, Singhal S, Bhagwati N, Saso R, Horton C, Treleaven J. Place of vincristine in maintenance of remission after autologous stem cell transplantation for first remission adult acute lymphoblastic leukaemia. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S88.
914. Powles R, Kulkarni S, Treleaven J, Mehta J, Singhal S, Saso R, Sirohi B, Horton C. Allogeneic Bone Marrow (BMT) or Peripheral Blood Stem Cell (PBSCT) Transplant: early helper T-cell recovery results in better survival. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S98.
915. Powles R, Sirohi B, Mehta J, Kulkarni S, Murphy K, Cheung B, Conway A, Saso R, Riggs A, Singhal S, Cunningham D, Treleaven J. Low-dose Amphotericin B Lipid Complex (ABLC) is safe and effective as empiric anti-fungal therapy in immunocompromised patients with hematologic malignancies. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S201.
916. Sirohi B, Powles R, Kulkarni S, Pinkerton R, Meller S, Murphy K, Wilgress A, Conway A, Seydel C, Mehta J, Singhal S, Treleaven J, Cunningham D. Amphotericin B Colloid Dispersion (ABCD) for the treatment of proven or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S204.
917. Sirohi B, Powles R, Kulkarni S, Riley U, Saso R, Treleaven J. Spectrum of fungal infections in patients with haematological malignancies in the last 5 years: royal marsden experience. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S209.
918. Malhotra A, Treleaven J, Powles R, Sirohi B, Atra A, Mellor S, Kulkarni S. Single centre evaluation of avascular necrosis following treatment for haematological

- malignancies. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S214.
919. Sirohi B, Powles R, Kulkarni S, Saso R, Mehta J, Singhal S, Horton C, Treleaven J. Early response to infusional chemotherapy is an independent prognostic factor in newly diagnosed IgG and IgA multiple myeloma. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S244.
920. Powles R, Sirohi B, Kulkarni S, Singhal S, Mehta J, Saso R, Horton C, Lal R, Treleaven J. Continued complete remission of patients with multiple myeloma beyond 10 years: are they "operationally cured"? Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S245.
921. Paneesha S, Powles R, Saso R, Alvarez C, Sirohi B, Rudin C, Foukaneli T, Horton C, Treleaven J, Kulkarni S. Single centre evaluation of patients with Plasma Cell Leukaemia (PCL). Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S245.
922. Sirohi B, Powles R, Kulkarni S, Chau I, Saso R, Lal R, Riggs A, Horton C, Treleaven J. Maximal response to infusional chemotherapy prior to autotransplantation influences outcome of patients with newly-diagnosed multiple myeloma. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S246.
923. Powles R, Sirohi B, Kulkarni S, Gore M, Saso R, Mehta J, Singhal S, Horton C, Treleaven J, Cunningham D. 15-year follow-up of myeloma patients, receiving 140 mg/m² melphalan without hematopoietic stem cell or growth factor support as initial therapy. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S246.
924. Sirohi B, Powles R, Kulkarni S, Parikh P, Mehta J, Singhal S, Saso R, Treleaven J. High Dose melphalan and autotransplantation in myeloma patients with severe renal dysfunction: high incidence of atrial fibrillation and treatment-related mortality. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S246.
925. Sankpal S, Powles R, Sirohi B, Treleaven J, Horton C, Saso R, Kulkarni S. Pathological fracture in the long bones at presentation – outcome in patients with multiple myeloma. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S250.
926. Powles R, Sirohi B, Kulkarni S, Millar B, Mehta J, Singhal S, Horton C, Murphy K, Fletcher L, Saso R, Treleaven J. Feasibility of collecting peripheral blood stem cells in previously untreated myeloma patients without any prior cytoreductive therapy. Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S251.
927. Kulkarni S, Powles R, Sirohi B, Horton C, Saso R, Mehta J, Singhal S, Treleaven J. Predictive model to assess the risk of Treatment Related Mortality (TRM) in patients undergoing Allogeneic Hematopoietic Stem Cell Transplant (AHSCT). Bone Marrow Transplantation, Volume 27, Supplement 1, March 2001, Page S280.

928. Kulkarni S, Powles R, Saso R, Sirohi B, Horton C, Mehta J, Singhal S, Tait D, Hyianakis D, Rudin C, Treleaven J. Single centre analysis of allogeneic hematopoietic stem cell transplant for acute leukaemia in first complete remission: comparison of two single fraction dose schedules (9.5Gy or 10.5Gy). *Bone Marrow Transplantation*, Volume 27, Supplement 1, March 2001, Page S309.
929. Sirohi B, Powles R, Kulkarni S, Treleaven J, Saso R, Singhal S, Mehta, J. Role of Defibratide (Dt) and Therapeutic Plasma Exchange (TPE) in the management of transplant associated thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS): a single centre Experience. *Bone Marrow Transplantation*, Volume 27, Supplement 1, March 2001, Page S314.
930. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. *Bone Marrow Transplantation*, 2001; 28:29-37.
931. Sirohi B, Powles R, Kulkarni S, Treleaven J, Singhal S, Saso R, Mehta J. High-dose melphalan with autotransplantation in Myeloma patients with severe renal dysfunction (GFR <20 ML/MIN/MS): High incidence of atrial fibrillation and treatment related mortality. *The Hematology Journal*, 24 June 2001, page 182.
932. Kulkarni S, Powles R, Sirohi B, Treleaven J, Tait D, Saso R, Horton C. Single Centre analysis of allogeneic hematopoietic stem cell transplant for acute leukaemia in first complete remission: comparison of two single fraction dose schedules (9.5GY or 10.5GY). *The Hematology Journal*, 24 June 2001, page 182.
933. Salooja N, Szydlo R M, Socie G, Rio B, Chatterjee R, Ljungman P, Van Lint T M, Powles R, Jackson G, Hinterberger-Fischer M, Kolb H J, Apperley J F. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. *The Lancet*. Vol. 358. Pages 271 to 276. July 28 2001.
934. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden Experience. *Seminars in Hematology*. Vol. 38. July 2001.
935. Sirohi B, Kulkarni S, Powles R. Some early Phase II trials in previously untreated multiple myeloma: The Royal Marsden Experience. *Seminars in Hematology*. Vol. 38. July 2001.
936. Sirohi B and Powles R. International Myeloma Grand Round. *The Lancet Oncology*, Vol 2 (9) 2001: 571-579.
937. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C, Bhagwati N, Horton C, Saso R, Singhal S, Parikh P. The Implication of compromised renal function at presentation in myeloma. *Medical Oncology*: vol 18(1) 2001: 39-50
938. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, Treleaven J. Glomerular filtration rate prior to high-dose melphalan 200

- mg/m² as a surrogate marker of outcome in patients with myeloma. *British Journal of Cancer*. Vol 83(3) August 2001, 325-332.
939. Powles R, B Sirohi, R Chopra, N Russel, H G Prentice. Assessment of Maximum Tolerated Dose (MTD) of FK463 in Cancer Patients Undergoing Haematopoietic Stem Cell Transplantation. 41st ICAAC Abstracts. 22-25 September 2001
940. Sirohi B, Powles R, S. Kulkarni, U. Riley. The Spectrum of Fungal Infections in Patients with Haematological Malignancies in the Last 5 years: Royal Marsden Experience. 41st ICAAC Abstracts. 22-25 September 2001
941. Mehta J, Powles R, Sirohi B, Atkinson K. Clinical Bone Marrow and Blood Stem Cell Transplantation – Third Edition. (In process of being written)
942. Singhal S, Powles R, Mehta J. Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood. *N Engl J Med*. 2001 May 24; 344(21)
943. Visani, G., Milligan, D., Leoni, F., Chang, J., Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Mallagola M, Pfister C. Combined action of PSCC 833 (Valspodar), a novel MDR reversing agent with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. *Leukemia*, 2001 May; 15(5)
944. Abdou Said M.H., Jadayel, D., Toon, M., Swansbury, J., Dainton MG, Jafewr Osman, Powles, R., and Catovsky, D. Incidence of MLL re-arrangement in acute myeloid leukaemia and CALM AF10 fusion in M4 type acute myeloblastic leukaemia. *Leukaemia and Lymphoma*, 2002 vol 43, pp.89-95.
945. Gahrton, G., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cavo, M., Cornelissen, J., de Laurenzi, A., Facon, T., Hagman, A., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russel, N.H., Samson, D., Schaefer, U.W., Schattenberg, A., Tura, S., Verdonck, L.F., Vernant, J.P., Willemze, R., Volin, L. for the European Group for Blood and Marrow Transplantation (EBMT). An update of allogeneic transplantation with peripheral blood stem cells (PBSCT) as compared to bone marrow (BMT) in multiple myeloma. To be presented at EBMT, March 2002.
- 945a Powles, R., Sirohi, B., El-Nenaei, M., Swansbury, J., Singhal, S., Treleaven, J., Saso, R., Kulkarni, S., Mehta, J., Goyal, S., Catovsky, D. Influence of chromosome 13 abnormalities on the likelihood of achieving complete remission (CR) in new patients treated with C-VAMP to maximum response. *Blood*, November 2001, vol. 98, pp. 164a-165a.
- 946 Powles, R., Sirohi, B., Singhal, S., Treleaven, J., Kulkarni, S., Goyal, S., Horton, C., Mehta, J. Using the original infusional inductions chemotherapy again as salvage therapy in myeloma patients relapsing after one autograft. *Blood*, November 2001, vol. 98, p.165a.
- 947 Powles, R., Sirohi, B., Morgan, G., Milligan, D., Yong, K., Cook, G., Williams, C., Ozaki, S., Kosaka, M., Goyal, S., Linch, D. A phase I study of the safety, tolerance,

- pharmokinetics, antigenicity and efficacy of a single intravenous dose of AHM followed by multiple doses of intravenous AHM in patients with multiple myeloma. *Blood*, November 2001, vol. 98, p.165a.
- 948 Powles, R., Sirohi, B., Kulkarni, S., Singhal, S., Mehta, J., Horton, C., Saso, R., Goyal, S., Lloyd, C., Treleaven, J. Relapse following complete remission: Outcome predictors in patients with secretory myeloma. *Blood*, November 2001, vol. 98, p.165a.
- 949 Powles, R., Singhal, S., Sirohi, B., Horton, C., Treleaven, J., Mehta, J. "Discontinuous complete remission": a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time. *Blood*, November 2001, vol. 98, p.166a.
- 950 Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Saso, R., Goyal, S., Horton, C., Mehta, S. The addition of weekly cyclophosphamide to infusional induction chemotherapy (Vincristine, Doxorubicin, Methylprednisolone) does not affect subsequent stem cell collection in patients with myeloma. *Blood*, November 2001, vol. 98, p.173a.
- 951 Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Horton, C., Saso, R., Tait, D., Hijiyanakis, P., Singhal, S., Mehta, J. Single centre of analysis of allogeneic hematopoietic stem cell transplant for acute leukaemia in first complete remission: Comparison of two single fraction dose schedules. *Blood*, November 2001, vol. 98, p.195a-196a.
- 952 Powles, R., Sirohi, B., Chopra, R., Russel, N., Prentice, G., Kulkarni, S., Rudin, C., Menon, A., Pac-Soo, A. Use of FK 463, a novel echinocandin analog in patients undergoing autologous or allogeneic stem cell transplantation for haematologic malignancies, a matched pair comparison for biochemical toxicity with historical controls. *Blood*, November 2001, vol. 98, p.208a.
- 953 Powles, R., Sirohi, B., Kulkarni, S., Treleaven, J., Rudin, C., Norman, A. Early total white blood cell (WBC) count recovery is an independent prognostic predictor for outcome and length of complete remission (CR) in newly diagnosed patients with acute myeloid leukaemia (AML) treated with intensive induction chemotherapy – a single centre study of 103 patients. *Blood*, November 2001, vol. 98, p.326a.
- 954 Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Singhal, S., Saso, R., Rudin, C., Horton, C., Mehta, J. Use of peripheral blood stem cells (PBSC) is likely to be associated with higher incidence of lung involvement in chronic graft vs. host disease (GVHD) following allogeneic hematopoietic stem cell transplant (AHSCT). *Blood*, November 2001, vol. 98, p.397a.
- 955 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Mehta, J. 20-year follow-up of allogeneic bone marrow transplantation with Cyclophosphamide-TBE and Cyclosporine for acute myeloid leukaemia in first complete remission. *Blood*, November 2001, vol. 98, p.165a.

- 956 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J. High-dose melphalan and second autografts for myeloma relapsing after one autograft: Results equivalent to tandem autotransplantation. *Blood*, November 2001, vol. 98, p.402a.
- 957 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Horton, C., Saso, R., Tait, D., Singhal, S. Does donor-recipient ABO-incompatible protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukaemia? *Blood*, November 2001, vol. 98, p.407a.
- 958 Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Mehta, J. Enhancement of the anti-tumour efficacy of allogeneic transplantation with the use of blood-derived stem cells: 5-year follow-up of a prospective study comparing marrow and blood allografts. *Blood*, November 2001, vol. 98, p.419a.
- 959 Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Mehta, J. The effect of CD34+ cell doses on long-term overall and disease-free survival after allogeneic blood or marrow stem cell transplantation for hematologic malignancies: More is better. *Blood*, November 2001, vol. 98, p.420a.
- 960 Powles, R., Milan, S., Horton, C., Sirohi, B., Treleaven, J., Singhal, S., Mehta, J. The Royal Marsden Hospital leukaemia-myeloma database: An "Operations Research" resource for assessing clinical outcomes and planning new drug trials. *Blood*, November 2001, vol. 98, p.426a.
- 961 Sirohi, B., Powles, R., Kulkarni, S., Saso, R., Ahmed, T., Rao, S., Treleaven, J. Early high resolution computed tomography (HRCT) scans allow for prompt diagnosis and more efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. *Blood*, November 2001, vol. 98, p.504a.
- 962 Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Saso, R., Riley, U., Rudin, C., Horton, C., Mehta, J., Singhal, S. Predictors of CMV Reactivation following allogeneic hematopoietic stem cell transplant (HSCT) for haematological malignancies. *Blood*, November 2001, vol. 98, p.552a.
- 963 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Rudin, C., Horton, C., Saso, R., Heming, D., Mehta, J. Hyperleukocytosis in patients with newly-diagnosed acute myeloid leukaemia: Clinical implications and consequences of leukapheresis to reduce the tumour burden. *Blood*, November 2001, vol. 98, p.588a.
- 964 Powles, R., Sirohi, B., Mehta, J., Treleaven, J., Horton, C., Kulkarni, S., Saso, R., Bowen, A., Norman, A., Singhal, S. Reduced relapse rates in newly-treated myeloma patients by using peripheral blood stem cells over bone marrow as the source of stem cells for autologous transplantation: Single-centre experience of 435 patients treated with 200 mg/m² Melphalan. *Blood*, November 2001, vol. 98, p.684a.

- 965 Powles, R., Sirohi, B., Mehta, J., Treleaven, J., Kulkarni, S., Horton, C., Saso, R., Menon, A., Macey, D., Singhal, S. Does the number of infused CD34+ cells affect the long-term outcomes of myeloma patients treated with high-dose Melphalan and autotransplantation? *Blood*, November 2001, vol. 98, p.685a.
- 966 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Saso, R., Horton, C., Heming, D., Mehta, J. Implication of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly-diagnosed myeloma. *Blood*, November 2001, vol. 98, p.686a.
- 967 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Saso, R., Kulkarni, S., Horton, C., Tait, D., Mehta, J. The impact of consolidation chemotherapy on the outcome of autotransplantation for acute myeloid leukaemia in first remission: Single-centre experience of 118 adult patients. *Blood*, November 2001, vol. 98, p.690a.
- 968 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Swansbury, G.J., Min, T., Kulkarni, S., Saso, R., Tait, D., Singhal, S. Impact of Cytogenetics on the outcome of autotransplantation for acute myeloid leukaemia in first remission: Is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? *Blood*, November 2001, vol. 98, pp.716a-717a.
- 969 Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Mehta, J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose Melphalan and autotransplantation in myeloma. *Blood*, November 2001, vol. 98, p.816a.
- 970 Kulkarni, S., Powles, R., Sirohi, B., Treleaven, J., Saso, R., Singhal, S., Rudin, C., Goyal, S., Horton, C., Earl, J., Mehta, J. Combination of tissue plasminogen activator (rt-PA) and low dose Heparin with or without Defibrotide for the treatment of clinically suspected hepatic veno-occlusive disease (HVOD) following allogeneic hematopoietic stem cell transplant (AHSCT) for hematological malignancies. *Blood*, November 2001, vol. 98, p.853a.
- 971 Powles, R., Sirohi, B., Kulkarni, S., Singhal, S., Treleaven, J., Saso, R., Rudin, C., Horton, C., Mehta, J. High dose ara-C (HDara) as a part of the first course of treatment for De Novo AML patients above the age of 50 yr. *Blood*, November 2001, vol. 98, p.219b.
- 972 Powles, R., Sirohi, B., Kulkarni, S., Treleaven, J., Rudin, C., Gatt, A., Horton, C., Bishop, L. Hyperleukocytosis (HL) in new patients with acute lymphoblastic leukaemia (ALL) – current implications in a background of modern induction therapy. *Blood*, November 2001, vol. 98, p.219b.
- 973 Goyal, S., Powles, R., Rudin, C., Sirohi, B., Kulkarni, S., Horton, C., Treleaven, J. Immunoglobulin D (IgD) myeloma does not carry a poor prognosis if treated with a modern infusional chemotherapy followed by high dose treatment: A series of 12 patients. *Blood*, November 2001, vol. 98, p.308b.

- 974 Powles, R., Sirohi, B., Chopra, R., Fitzgerald, C., Russel, N., Prentice, G., McCullough, H., Pac-Soo, A., Koblingner, S. Assessment of maximum tolerated dose (MTD) and pharmacokinetics (PK) of FK463 in neutropenic patients after haematopoietic stem cell transplantation. *Blood*, November 2001, vol. 98, p.361b.
- 975 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Horton, C., Tait, D., Kulkarni, S., Saso, R., Mehta, J. Melphalan-total body irradiation and allogeneic transplantation from HLA-identical siblings for acute myeloid leukaemia in first remission: Higher relapse after marrow-derived stem cell grafts compared to blood despite similar chronic graft-versus-host disease. *Blood*, November 2001, vol. 98, p.381b.
- 976 Kulkarni, S., Powles, R., Cunningham, D., Sirohi, B., Treleaven, J., Rudin, C., Saso, R., Singhal, S., Mehta, J., Matutes, E., Catovsky, D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. *Blood*, November 2001, vol. 98, p.393b.
- 977 Powles, R., Sirohi, B., Singhal, S., Goyal, S., Treleaven, J., Lloyd, C., Kulkarni, S. 200 mg/m² Melphalan as initial therapy in multiple myeloma: A key to rapid achievement of complete remission. *Blood*, November 2001, vol. 98, p.397b.
- 978 Powles, R., Sirohi, B., Frassoni, F., Singhal, S., Labopin, M., Michallet, M., Blaise, D., Reiffers, J., Meloni, G., Rio, B., Horton, C., Kulkarni, S., Mehta, J. Bone marrow or peripheral blood stem cell autotransplantation for acute myeloid leukaemia in first remission? A matched-pair analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant Group (EBMT). *Blood*, November 2001, vol. 98, pp.397b-398b.
- 979 Sirohi, B., Powles, R., Kulkarni, S., Menon, A., Ahmed, T., Saso, R., Goyal, S., Rudin, C., Treleaven, J. Feasibility of administering high-dose Melphalan (HDM) with autotransplantation in myeloma patients on dialysis. *Blood*, November 2001, vol. 98, p.399b.
- 980 Powles, R., Sirohi, B., Singhal, S., Treleaven, J., Kulkarni, S., Horton, C., Mehta, J. The role of maintenance therapy after autotransplantation in adult acute lymphoblastic leukaemia. *Blood*, November 2001, vol. 98, p.689a.
- 981 Singhal, S., Powles, R., Henslee-Downey, P.J., Chiang, K.Y., Treleaven, J., Godder, K., Kulkarni, S., van Rhee, S., Sirohi, B., Pinkerton, C.R., Meller, S., Mehta, J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukaemia. *Bone Marrow Transplantation*, 15.01.02. *BMA* (2002) 29, pp.291-295.
- 982 Mehta, J., Powles, R., Treleaven, J., Swansbury, G.J., Kulkarni, S., Saso, R., Min, T., Singhal, S. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukaemia receiving high-dose cytarabine-based induction chemotherapy. *Leukaemia and Lymphoma*, 1999, Vol. 34 (5-6), pp.553-560.

- 983 Condie, A., Powles, R., Hudson, C., Shepherd, V., Bevan, S., Yuille, M., and Houlston, R. Analysis of the Fanconi anaemia complementation Group A gene in acute myeloid leukaemia. *Leukaemia and Lymphoma*, 2002, Vol. 43, (9), pp1849-1853
- 984 Sirohi, B., Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Sankpal, S., Rudin, C., Saso, R., and Mehta, J. Clinical implications and consequences of leukapheresis to reduce tumour burden in newly-diagnosed patients with hyperleukocytosis (HL) and acute myeloid leukaemia. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p18.
- 985 Powles, R., Sirohi, B., Mehta, J., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Rudin, C., Horton, C., and Singhal, S. Impact of the number of infused CD34+ cells on the long-term outcome of myeloma patients treated with high dose melphalan and autotransplantation. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p38.
- 986 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Horton, C., and Mehta, J. Outcome of autotransplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy (CC). *British Journal of Haematology*, 2002, Vol.117, suppl 1, p38.
- 987 Powles, R., Sirohi, B., Mehta, J., Kulkarni, S., Treleaven, J., Goyal, S., Sankpal, S., Rao, S., Saso, R., and Singhal, S. Reduced relapse rates in newly-treated myeloma patients by using peripheral blood stem cells over home marrow as the source of stem cells for autologous transplantation: single centre experience of 435 patients treated with 200 mg/m² melphalan (HDM). *British Journal of Haematology*, 2002, Vol.117, suppl 1, p40.
- 988 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Goyal, S., Horton, C., and Mehta, J. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p51.
- 989 Sirohi, B., Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Sankpal, S., Mehta, J., Saso, R., Lloyd, C., Horton, C., Goyal, S. Implication of impaired renal function at the time of initiation of infusional chemotherapy including cyclophosphamide (C-VAMP) in patients with newly diagnosed myeloma. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p64.
- 990 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Horton, C., and Mehta, J. Use of infusional chemotherapy (C-VAMP) for patients who relapse after original C-VAMP and high-dose therapy (HDT). *British Journal of Haematology*, 2002, Vol.117, suppl 1, p65.
- 991 Sirohi, B., Powles, R., Goyal, S., Sankpal, S., Horton, C., Kulkarni, S., Macey, D., Rudin, C., and Treleaven, J. Relapse following complete remission outcome predictors in patients with secretory myeloma. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p65.

- 992 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Rudin, C., Mehta, J. Administration of weekly cyclophosphamide as part of infusional induction chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell collection in patients with myeloma. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p65.
- 993 Powles, R., Sirohi, B., El-Naenaei, M., Swansbury, J., Treleaven, J., Goyal, S., Kulkarni, S., Sankpal, S., Saso, R., Catovsky, D. Paradoxical increased complete emission (CR) rate in patients with chromosome 13 abnormalities in new patients treated with C-VAMP to maximum response. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p67.
- 994 Powles, R., Singhal, S., Sirohi, B., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Rudin, C., Saso, R., Rao, S., Mehta, J. "Discontinuous complete remission"; a new endpoint to evaluate the success of therapy in keeping myeloma patients disease free for extended periods of time. *British Journal of Haematology*, 2002, Vol.117, suppl 1, p67.
- 995 Kulkarni, S., Powles, R., Sirohi, B., Saso, R., Treleaven, J., Horton, C., Singhal, S., Mehta, J. The use of peripheral blood stem cells (PBSC) is likely to be associated with higher incidence of lung involvement in chronic graft vs. host disease (GVHD) following allogeneic haematopoietic stem cell transplant (AHSCT). 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, Vol 29, suppl 2, p173.
- 996 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Horton, C., Mehta, J. Use of infusional chemotherapy (C-VAMP) for patients who relapse after original C-VAMP and high dose therapy (HDT). 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, Vol 29, suppl 2, p96.
- 997 Powles, R., Sirohi, B., Chopra, R., Russel, N., Prentice, G., Kulkarni, S., Goyal, S., Herring, D., Pac-Soo, A., Koblingner, S. Use of FK 463, a novel echinocandin analog in patients undergoing stem cell transplantation (SCT) for hematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls. 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, Vol 29, suppl 2, p247.
- 998 Powles, R., Milan, S., Sirohi, B., Horton, C., Kulkarni, S., Singhal, S., Sankpal, S., Goyal, S., Mehta, J. The Royal Marsden Hospital Leukemia-Myeloma database: a research resource for planning new drug trial in Europe and the US. 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, Vol 29, suppl 2, p250.
- 999 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Goyal, S., Horton, C., Mehta, J. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. 28th EBMT

- Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29, suppl 2, p12.
- 1000 Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Goyal, S., Sankpal, S., Rao, S., Saso, R., Metha, J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29, suppl 2, p103.
- 1001 Rao, S., Powles, R., Sirohi, B., Goyal, S., Sankpal, S., Horton, C., Kulkarni, S., Macey, D., Rudin, C., Treleaven, J. Relapse following complete remission: Outcome predictors in patients with secretory myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p99.
- 1002 Powles, R., Sirohi, B., Mehta, J., Kulkarni, S., Treleaven, J., Goyal, S., Rao, S., Saso, R., Singhal, S. Reduced relapse rates in newly-treated myeloma patients by using peripheral blood stem cells over bone marrow as the source of stem cells for autologous transplantation; single-center experience of 435 patients treated with 200 mg/m² melphalan. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p69.
- 1003 Kulkarni, S., Powles, R., Sirohi, B., Horton, C., Treleaven, J., Saso, R., Reiley, J., Mehta, J., Singhal, S. Predictors of CMV reactivation following allogeneic hematopoietic stem cell transplant (HSCT) for haematological malignancies. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002 Vol 29; suppl 2, p132.
- 1004 Powles, R., Sirohi, B., El-Nenaei, M., Swansbury, J., Treleaven, J., Goyal, S., Kulkarni, S., Sankpal, S., Saso, R., Catovsky, D. Paradoxical increased complete remission (CR) rate in patients with chromosome 13 abnormalities in new patients treated with C-VAMP to maximum response. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol. 29; suppl 2, p103.
- 1005 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Horton, C., Mehta, J. Outcome of autotransplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy (CC). 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p73.
- 1006 Powles, R., Sirohi, B., Goyal, S., Treleaven, J., Sankpal, S., Lloyd, C., Rudin, C., Kulkarni, S. Intensive treatment with high-dose melphalan as initial therapy in newly-diagnosed patients with multiple myeloma: key to attain rapid complete remission (CR). 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p97.
- 1007 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkarni, S., Saso, R., Goyal, S., Sankpal, S., Horton, C., Lloyd, C., Mehta, J. Implications of impaired renal function at the time of initiation of induction chemotherapy including cyclophosphamide (C-

- VAMP) in patients with newly-diagnosed myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p100.
- 1008 Powles, R., Sirohi, B., Mehta, J., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Rudin, C., Horton, C., Singhal, S. Impact of the number of infused CD34+ cells on the long-term outcome of myeloma patients treated with high-dose melphalan and autotransplantation. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p102.
- 1009 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Swansbury, J., Min, T., Kulkarni, S., Saso, R., Rudin, C., Goyal, S., Singhal, S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: Is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p75.
- 1010 Powles, R., Sirohi, B., Kulkarni, S., Treleaven, J., Rudin, C., Goyal, S., Sankpal, S., Horton, C., Bishop, L. Hyperleukocytosis (HL) in new patients with acute lymphoblastic leukemia (ALL) – impact of supportive care in a background of modern induction therapy. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p113.
- 1011 Powles, R., Singhal, S., Sirohi, B., Treleaven, J., Kulkarni, S., Rudin, C., Saso, R., Mehta, J. Enhancement of the anti-tumor efficacy of allogeneic transplantation with use of blood-derived stem cells: 5-year follow-up of a prospective study comparing marrow and blood allografts. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p227.
- 1012 Powles, R., Singhal, S., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Goyal, S., Mehta, J. Effect of CD34+ cell doses on long-term overall and disease-free survival after allogeneic blood or marrow stem cell transplantation for hematologic malignancies: more is better. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p113.
- 1013 Powles, R., Sirohi, B., Treleaven, J., Horton, C., Sankpal, S., Goyal, S., Rudin, C., Saso, R., Kulkarni, S. Early recovery of total white cell (WC) count is an independent prognostic predictor for outcome and length of CR in newly-diagnosed patients with AML treated with intensive induction chemotherapy – A single center study of 103 patients. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p78.
- 1014 Sirohi, B., Powles, R., Kulkarni, S., Goyal, S., Sankpal, S., Rao, S., Riley, U., Treleaven, J. Early high-resolution computed tomography (HRCT) scans allow prompt diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p244.

- 1015 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Singhal, S. Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p77.
- 1016 Powles, R., Singhal, S., Sirohi, B., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Rudin, R., Saso, R., Rao, S., Mehta, J. "Discontinuous complete remission": a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p99.
- 1017 Kulkarni, S., Powles, R., Sirohi, B., Saso, R., Horton, C., Treleaven, J., Singhal, S., Rudin, C., Sankpal, S., Mehta, J. Combination of tissue plasminogen activator (rt-PA) and low dose heparin with or without defibrotide (DF) for the treatment of clinically suspected hepatic veno-occlusive disease (HVOD) following allogeneic hematopoietic stem cell transplant (AHSCT). 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p112.
- 1018 Sirohi, B., Powles, R., Kulkarni, S., Treleaven, J., Singhal, S., Sankpal, S., Rudin, C., Saso, R., Mehta, J. Clinical implications and consequences of leukapheresis to reduce tumor burden in newly-diagnosed patients with hyperleukocytosis (HL) and acute myeloid leukemia. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p79.
- 1019 Sirohi, B., Powles, R., Frassoni, F., Bacigalupo, A., Singhal, S., Labopin, M., Michallet, M., Blaise, D., Reiffers, J., Meloni, G., Rio, B., Horton, C., Kulkarni, S., Mehta, J. Bone marrow or peripheral blood stem cell autotransplantation (PBSCT) for acute myeloid leukemia in first remission? A matched-pair analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant group (EBMT). 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p69.
- 1020 Powles, R., Sirohi, B., Chopra, R., Fitzgerald, C., Russel, N., Prentice, G., McCullough, H., Pac-Soo, A., Koblingner, S. Assessment of maximum tolerated dose (MTD) and pharmacokinetics (PK) of FK463 used for anti-fungal prophylaxis in neutropenic patients after hematopoietic stem cell transplantation. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002 Vol 29; suppl 2, p38.
- 1021 Gahrton, G., Apperley, J., Bacigalupo, A., Njorkstrand, B., Blade, J., Cavo, M., Cornelissen, J., De Laurenti, A., Facon, T., Hagman, A., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N., Samson, D., Schaefer, U., Schattenberg, A., Tura, S., Verdonck, L., Vernant, J., Willemze, R., Volin, L. An update of allogeneic transplantation with peripheral blood stem cells (PBSCT) as compared to bone marrow (BMT) in multiple myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002 Vol 29; suppl 2, p13.

- 1022 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Sankpal, S., Goyal, S., Kulkarni, S., Saso, R., Horton, C., Mehta, J. Allogeneic transplantation with melphalan-total body irradiation from HLA-identical siblings for AML in first remission: higher relapse rates with marrow-derived stem cell grafts compared to blood despite similar chronic graft-versus-host disease. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p72.
- 1023 Kulkarni, S., Powles, R., Cunningham, D., Sirohi, B., Rudin, C., Saso, R., Treleaven, J., Reiley, U., Singhal, S., Mehta, J., Matutes, E., Catovsky, D. Allogeneic and autologous hematopoietic stem cell transplantation for chronic lymphocytic leukemia. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p165.
- 1024 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Sankpal, S., Goyal, S., Saso, R., Rudin, C., Mehta, J. Administration of weekly cyclophosphamide as part of infusional induction chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell collection in patients with myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002 Vol 29; suppl 2, p96.
- 1025 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Saso, R., Goyal, S., Sankpal, S., Macey, D., Mehta, J. 20-year follow-up of allogeneic bone marrow transplantation with cyclophosphamide - TBI and cyclosporine for acute myeloid leukemia in first complete remission. 28th EBMT Annual Meeting, Montreux, Switzerland. Bone Marrow Transplantation, 2002, Vol 29; suppl 2, p223.
- 1026 Sirohi, B., Powles, R., Singhal, S., Goyal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. 20-Year Follow-Up of Allogeneic Bone Marrow Transplantation with Cyclophosphamide-TBI and Cyclosporine for Acute Myeloid Leukaemia in First Complete Remission. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p24.
- 1027 Sirohi, B., Powles, R., Singhal, S., Goyal, S., Kulkarni, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Does the Number of Infused CD34 Cells Affect the Long-Term Outcome of Myeloma Patients Treated with High-Dose Melphalan and Autotransplantation? 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p42.
- 1028 Powles, R., Sirohi, B., Singhal, S., et al. Enhancement of the Anti-Tumour Efficacy of Allogeneic Transplantation with the Use of Blood-Derived Stem Cells: 5-Year Follow-Up of a Prospective Study Comparing Marrow and Blood Allografts. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p53.
- 1029 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Saso, R., Mehta, J. The Effect of CD34 Cell Doses on Long-Term Overall and Disease-Free Survival after Allogeneic Blood or Marrow Stem Cell Transplantation for Haematologic Malignancies: More is Better. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p54.

- 1030 Sirohi, B., Powles, R., Singhal, S., Kulkarni, S., Treleaven, J., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. The Addition of Weekly Cyclophosphamide to Infusional Induction Chemotherapy (Vincristine, Doxorubicin, Methylprednisolone) Does Not Affect Subsequent Stem Cell Collection in Patients with Myeloma. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p54.
- 1031 Sirohi, B., Powles, R., Singhal, S., Horton, C., Mehta, J., Frassoni, F., Bacigalupo, A., Labopin, M., Michallet, M., Blaise, D., Reiffers, J., Meloni, G., Rio, B. Bone Marrow or Peripheral Blood Stem Cell Autotransplantation for AML in First Remission? A Matched-Pair Analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant Group (EBMT). 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p55.
- 1032 Powles, R., Milan, S., Sirohi, B., Singhal, S., Horton, C., Mehta, J. The Royal Marsden Hospital Leukaemia/Myeloma Database (Fergus Maclay Database): a research resource for planning new drug trials in Europe and the US. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p85.
- 1033 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Hyperleukocytosis in patients with newly-diagnosed acute myeloid leukaemia: clinical implications and consequences of leukapheresis to reduce the tumour burden. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p157.
- 1034 Powles, R., Sirohi, B., Kulkarni, S., Treleaven, J., Goyal, S., Sankpal, S., Saso, R., Horton, C. Early recovery of total white cell (WBC) count is an independent prognostic predictor for outcome in new patients with AML treated with intensive induction therapy – single centre study of 103 patients. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p1 57.
- 1035 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Saso, R., Kulkarni, S., Horton, C., Goyal, S., Sankpal, S., Mehta, J. High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p174.
- 1036 Sirohi, B., Powles, R., Goyal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Saso, R., Horton, C. Early high resolution CT (HRCT) scans allow for prompt diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. The Hematology Journal, Vol 3, suppl 1, p213.
- 1037 Powles, R., Singhal, S., Sirohi, B., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Discontinuous Complete Remission: a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods

- of time. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, Vol 3, suppl 1, p331.
- 1038 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Treleaven, J., Horton, C., Saso, R., Mehta, J. Relapse following complete remission: outcome predictors in patients with secretory myeloma. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, Vol 3, suppl 1, p332.
- 1039 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Upfront 200mg/m² melphalan as initial therapy in multiple myeloma: a key to rapid achievement of complete remission. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, Vol 3, suppl 1, p340.
- 1040 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Reduced relapse rates in new myeloma patients by using PBSCs over bone marrow as source of stem cells for autotransplantation: single-centre experience of 435 patients treated with 200mg/m² melphalan. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, (3), suppl 1, 341.
- 1041 Powles, R., Sirohi, B., El-Nenei, M., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J., Catovsky, D. Paradoxically increased complete remission (CR) rate with chromosome 13 abnormalities in patients treated with C-VAMP to maximum response. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, (3): suppl 1, 341.
- 1042 Powles, R., Sirohi, B., Singhal, S., Kulkarni, S., Goyal, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Practical guide to using the original infusional induction chemotherapy again as salvage therapy in myeloma patients relapsing after one autograft. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, (3): suppl 1, 341.
- 1043 Sirohi, B., Powles, R., Singhal, S., Goyal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Implications of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly-diagnosed myeloma. 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, (3): suppl 1, 342.
- 1044 Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Saso, R., Kulkarni, S., Horton, C., Goyal, S., Sankpal, S., Mehta, J. Outcome of autotransplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy (CC). 7th Congress of EHA, 6-9th June 2002, Florence, Italy. *The Hematology Journal*, (3): suppl 1, 353.
- 1045 Sirohi, B., Powles, R., Singhal, S., Goyal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Horton, C., Saso, R., Mehta, J. Implications of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly-diagnosed myeloma. 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, (29): suppl 2, 100.

- 1046 Sirohi, B., Powles, R., Goyal, S., Treleaven, J., Kulkarni, S., Sankpal, S., Saso, R., Horton, C. Early high resolution CT (HRCT) scans allow for prompt diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised patients with haematologic malignancies. 28th EBMT Annual Meeting, Montreux, Switzerland. *Bone Marrow Transplantation*, 2002, (29): suppl 2, 244.
- 1047 Condie, A., Powles, R.L., Hudson, C.D., Shepherd, V., Bevan, S., Yuille, M.R., Houlston, R. Analysis of the Fanconi anaemia complementation Group A gene in acute myeloid leukaemia. *Lymphoma and Leukaemia*, 2002, 43(9): 1849-1853.
- 1048 Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Tait, D., Singhal, S., Mehta, J. The role of post-transplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukaemia. *Blood*, 2002, 100(5): 1641-1647
- 1049 Almeida Parra, J., Bargou, R., Barlogie, B., Drach, J., Einsele, H., Emmerich, B., Freund, M., Harousseau, J.L., Kienast, J., Ludwig, H., Ponisch, W., Powles, R., Shaughnessy, J., Straka, C. Summary to the Workshop on Multiple Myeloma, Spitzingsee, Germany, January 18th – 20th 2002. *Onkologie* (only available in German).
- 1050 Powles, R., Sirohi, B., Kulkarni, S., Treleaven, J., Rudin, C., Sankpal, S., Goyal, S., Horton, C., Millar, B., Saso, R., Singhal, S., Mehta, J. Peripheral blood stem cells. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? *Bone Marrow Transplantation*, 2002, 30, 479-484.
- 1051 El-Nenaei, M.O., Gruszka-Westwood, A.M., A’Hern, R., Matutes, E., Sirohi, B., Powles, R., Catovsky, D. Gene Abnormalities in multiple myeloma: the relevance of TP53, MDM2 and CDKN2A. Submitted to *Blood* (in November 2002).
- 1052 Mitchell, P., Lee, F-T., Hall, C., Rigopoulos, A., Smyth, F., Hekman, A-M., van Schijndel, G., Powles, R., Brechbiel, M., Scott, A. Targeting primary Philadelphia chromosome – positive human B-cell precursor leukaemia engrafted SCID mice using radio-labelled anti-CD19 monoclonal antibodies. Submitted to *The Journal of Nuclear Medicine* (in October 2002).
- 1053 Sirohi B., Powles R., Mehta J., Kulkarni S., Sankpal S., Treleaven J., Rudin C., Horton C., Singhal S. Prognostic Factors at the Time of Single Autotransplantation in 451 Myeloma Patients Treated with 200 mg/m² Melphalan: Results Equivalent to Tadem Autotransplantation. *Blood*, 2002;100 (11):180a.
- 1054 Powles R., Kulkarni S., Sirohi B., Treleaven J., Saso R., Sankpal S., Mehta J., Singhal S., Horton C. Predictive Model Based on Day 7 Parameters To Predict the Risk of Treatment Related Mortality (TRM) in Patients Undergoing Allogeneic Hematopoietic-Stem Cell Transplant (AHSCT). *Blood*, 2002;100 (11):111a-112a.

- 1055 Sirohi B., Powles R., Singhal S., Kulkarni S., Sankpal S., Treleaven J., Horton C., Saso R., Mehta J. Long-Term Outcome of Myeloma Patients Treated with an Elective Single Autograft with Follow-Up (5 Years): Results Comparable to Tandem Autotransplantation.) *Blood*, 2002;100 (11): 179a – 180a.
- 1056 Sirohi B., Powles R., Singhal S., Kulkarni S., Saso R., Horton C., Sankpal S., Treleaven J., Patel G., Mehta J. Total Cumulative Dose of Cyclophosphamide Administered during Induction Infusional Chemotherapy (C-VAMP) Is an Independent Prognostic Marker in New Patients with Myeloma. *Blood*, 2002;100 (11): 392b.
- 1057 Sirohi B., Powles R., Singhal S. Kulkarni S., Stephens M., Mehta J. Feasibility of Administering Infusional Induction Chemotherapy(C-VAMP) in Myeloma Patients over the Age of 70 Years. *Blood*, 2002;100 (11):392b.
- 1058 Powles R., Sirohi B., Singhal S., Kulkarni S., Patel G., Sankpal S., Brennan J., Stephens M., Treleaven J., Mehta J. Tolerability of High-Dose Melphalan 200 mg/m² in Patients with Myeloma and Leukaemia over the Age of 65 Years: A Single-Centre Study of 42 Patients. *Blood*, 2002;100 (11):480a.
- 1059 Powles R., Sirohi B., Singhal S., Kulkarni S., Horton C., Treleaven J., Sankpal S., Mehta J. Leukocyte Count on Day 14 of Infusional Chemotherapy with C-VAMP in New Patients with Multiple Myeloma: Predictor of Early Mortality. *Blood*, 2002;100 (11):381b.
- 1060 Powles R., Kulkarni S., Sirohi B., Treleaven J., Saso R., Horton C., Singhal S., Mehta J. Results of Allogeneic Transplant in Patients with Chronic Myeloid Leukaemia (CML): Single Centre Evaluation of 141 Patients-Royal Marsden Hospital Experience over 20 Years. *Blood*, 2002;100 (11):331b – 332b.
- 1061 Bhawna S., Powles R., Kulkarni S., Carr-Smith H.D., Sankpal S., Patel G., Singhal S., Iqbal J., Bradwell A.R., . Mehta J.. Serum Free Light Chain Assessment in Myeloma Patients Who Are in Complete Remission by Immunofixation. *Blood*, 2002;100 (11):383b.
- 1062 Powles R., Kulkarni S., Sirohi B., Treleaven J., Saso R., Sankpal S. Singhal S., Horton C., Mehta J. Is Clinical Graft-vs. Host Disease (GVHD) Essential for the Benefit of Allogeneic Bone Marrow Transplant (BMT)? *Blood*, 2002;100 (11):447b.
- 1063 Mehta J., Powles R., Sirohi B., Kulkarni S., Treleaven J., Zomas A., Singha S. Poor Outcome of Autotransplantation in Acute Myeloid Leukemia Patients Not Attaining Complete Remission with 1 Cycle of Induction Chemotherapy: Identifying Candidates for an Alternative-Donor Allograft in First Remission. [3392] : Poster Session: Clinical Results in Autologous Stem Cell Transplantation in Leukemia, Hodgkin[ssquote]s Disease and non-malignant disorders. *Blood*, 2002;100 (11):860a.

- 1064 Mehta J., Powles R., Sirohi B., Treleaven J., Kulkarni S., Singhal S. Excellent Results of Unpurged Autotransplantation in First-Remission Acute Myeloid Leukemia with t(8;21), inv(16), and t(15;17) [3391]. Clinical Results in Autologous Stem Cell Transplantation in Leukemia, Hodgkin's Disease and non-malignant disorders. *Blood*, 2002;100 (11):860a.
- 1065 Powles R., Mehta J., Sirohi B., Kulkarni S., Treleaven J., Singhal S. 7-year Follow-Up of a Randomized Study of Allogeneic Marrow Versus Blood Stem Cell Transplantation: Lower Relapse and Higher Disease-Free Survival with Blood. [1668]: Poster Session: Allogeneic Related Stem Cell Transplantation. *Blood*, 2002;100 (11):431a.
- 1066 Singhal S., Powles R., Sirohi B., Kulkarni S., Treleaven J., Mehta J. CD34+ Cell Dose Based upon Ideal Body Weight (IBW) Is a Better Predictor of Transplant-Related Mortality (TRM) and Disease-Free Survival (DFS) Than That Based upon Actual Body Weight (ABW). [1667]: Poster Session: Allogeneic Related Stem Cell Transplantation I. *Blood*, 2002;100 (11):430a.
- Raymond Powles, B. Sirohi, S. Singhal, S. Kulkarni, C. Horton, J. Treleaven, J. Mehta. 10-year Survival in Myeloma: A New Endpoint for Testing Potentially Curative Strategies? [1555] Poster Session: Novel Therapies, Supportive Care and Prognostic Factors for Myeloma. *Blood*, 2002;100 (11):400a – 401a
- 1068 Powles R., Cavenagh J.D., Sirohi B., Blood, 2002;100 (11):180a. Oakervee H., Singhal S., Bishop L., Horton C., Kulkarni S., Barnett M., Dyer P., Rintala T., Mehta J. Upfront Collection of Peripheral Blood Stem Cells (PBSC) in New Patients with Myeloma Receiving Minimal or No Prior Cytoreductive Therapy: Comparison of Two Regimes from Royal Marsden Hospital and St. Bartholomew's Hospital. [3270] : Poster Session: Development of Cell Therapies. *Blood*, 2002;100 (11):828a.
- 1069 Powles R., Sirohi B., Lawrence D., Kulkarni S., Hollis H., Heming D., Sankpal S., Patel G., Singhal S., Treleaven J. Mehta J. An Open, Randomized, Controlled, Phase II, Single Centre, Two-Period Cross Over Study To Compare the Quality of Life (QoL) and Toxicity Experienced on PEG Interferon (P-IFN) with Interferon- α 2b (IFN) in Patients with Multiple Myeloma (MM) Maintained on a Steady Dose of IFN. [1561] Poster Session: Novel Therapies, Supportive Care and Prognostic Factors for Myeloma. *Blood*, 2002;100 (11):402a.
- 1070 Sirohi B., Powles R., Singhal S., Kulkarni S., Sankpal S., Treleaven J., Saso R., Horton C., Stephens M., Mehta J. 200 mg/m² Melphalan (HDM200) and Salvage Autotransplantation in Myeloma Patients Relapsing after a Preceding Autograft. [1680] : Poster Session: Clinical Results in Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, 2002;100 (11):434a.
- 1071 Powles R., Sirohi B., Singhal S., Kulkarni S., Treleaven J., Mehta J. Predictors of Length of First Complete Remission in New Patients with Secretory Myeloma. [2381]. : Poster Session: Myeloma Biology II. *Blood*, 2002;100 (11):605a.

- 1072 Powles R., Kulkarni S., Sirohi B. Treleaven J., Saso R., Sankpal S., Horton C., Singhal S., Mehta. HLA- Matched Sibling Allograft for Acute Myeloid Leukaemia (AML) in Second Complete Remission (CR2): Potential for Reversal of Remission. [3368) Poster Session: Allogeneic Related Stem Cell Transplantation II. Blood, 2002;100 (11):853a.
- 1073 Kulkarni S., Powles R., Sirohi B., Brennan J., Treleaven J., Saso R., Sankpal S., Ortin M., Mehta J., Singhal S., Horton C. (3351) Single Centre Evaluation of Thyroid Function Abnormalities following Haematopoietic Stem Cell Transplant (HSCT). Blood 2002;100 (11): 849a.
- 1074 Powles R, Sirohi B and Kulkarni S. Scientific evidence and expert clinical opinion for the investigations and management of hyperleukocytosis in adults. Chemotherapy book, Chapter 3, July 2002, pg 33-50.
- 1075 Powles R, Sirohi B and Kulkarni S. scientific evidence and expert clinical opinion for the investigations and management of compressive syndromes in adults. Chemotherapy book, Chapter 4, July 2002, pg 51-54.
- 1076 Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S Mehta J. Response to chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplantation 2002; 30 (10): 673-9.
- 1077 Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D., Singhal, S. Does donor-recipient ABO-incompatible protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukaemia? Bone Marrow Transplantation 2002; 29 (10): 853-9.
- 1078 Powles, R., Raje, N. High Dose Treatment Plus Interferon for Multiple Myeloma. Presentation In Focus. The Alpine Meeting , Arosa, Switzerland 1996; 1 (1): 11
- 1079 L Fouillard, M Labopin, A Gratwohl, R Powles, A Bacigalupo, G Bego, V Chesnel and N C Gorin. Outcome of 5651 hematopoietic stem cell transplants for hematological malignancies carried out in Europe in 1993: a reliability study of the registry. On behalf of the European Group for Blood and Marrow Transplantation (EBMT) (2002) 30, 637-643.
- 1080 Sirohi B, Powles R, Singhal S, Kuklarni S, Rudin C, Horton C, Das M, Saso R, Treleaven J, and Mehta J. Predictors of length of first complete remission in new patients with seretory myeloma. Abstact (80). presented at the British Society for Haematology, Glasgow U.K. 7-9th April, 2002. BJH, Vol 121, Supplement 1 May 2003

- 1081 Powles R, Sirohi B, Lawrence D, Kulkarni S, Rudin C, Heming D, Hollis H, Das M, Treleaven J, and Horton C. An open, randomised, phase II, single centre, two period cross over study to compare the quality of life (QoL) and toxicity experienced on PEG interferon (P-IFN) with Interferon-alpha2b (IFN) in patients with myeloma maintained on a steady dose of IFN. Abstract (85) presented at the British Society for Haematology, Glasgow U.K. 7-9th April, 2002. *BJH*, Vol 121, Supplement 1 May 2003.
- 1082 Sirohi B, Powles R, Singhal S, Kulkarni S, Rudin C, Saso R, Treleaven J, Horton C, and Mehta J. Long-term outcome of myeloma patients treated with an elective single autograft with follow up (5 years): results comparable with tandem autotransplantation. Abstract (115) presented at the British Society for Haematology, Glasgow U.K. 7-9th April, 2002. *BJH*, Vol 121, Supplement 1 May 2003.
- 1083 Sirohi B, Powles R, Singhal S, Kulkarni S, Rudin C, Treleaven J, Saso R, Horton C, and Mehta J. Prognostic factors at the time of autotransplantation with 200 mg/m² melphalan : a single-centre study of 451 myeloma (MM) patients. Abstract (247) presented at the British Society for Haematology, Glasgow U.K. 7-9th April, 2002. *BJH*, Vol 121, Supplement 1 May 2003.
- 1084 Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevances of TP53, MDM2, and CDKN2A. *Haematologica* 88: 529-537, 2003.
- 1085 Paul Mitchel, MBBS, Fook-Thean Lee, PhD², Cathrine Hall, BSc², Angela Rigopoulos, MSc², Fiona E. Smyth, BSc², Anne-Marie Hekman, PhD³, Gijs M van Schijndel, PhD⁴, Ray Powles PhD⁵. Targeting Primary Human Ph⁺ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies. *Leukemia Xenografts*. Mitchell et al. 1105.
- 1086 S Kulkarni, R Powles, B Sirohi, J Treleaven, R Saso, C Horton, A Atra, M Ortin, C Rudin, S Goyal, S Sankpal. Graft-Versus-Host Disease. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. *Bone Marrow Transplantation* (2003) 32, 165-170.
- 1087 Brian GM Durie¹, Robert A Kyle², Andrew Belch³, William Bensinger⁴, Joan Blade⁵, Mario Boccadoro⁶, J Anthony Child⁷, Raymond Comenzo⁸, Ben Djulbegovic¹, Dorotea Fantl⁹, Gosta Gahrton¹⁰, Jean Luc Harousseau¹¹, Vania Hungria¹², Douglas Joshua¹³, Heinz Ludwig¹⁴, Jayesh Mehta¹⁵, Angelina Rodrique Morales¹⁶, Gareth Morgan¹⁶, Amara Nouel¹⁷, Martin Oken¹⁸, Raymond Powles¹⁹, David Roodman²⁰, Jesus San Miguel²¹, Kazuyuki Shimizu²², Seema Singhal¹⁵, Bhawna Sirohi¹⁹, Peter Sonneveld²³, Guido Tricot²⁴ and Brian Van Ness²⁵. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation¹. *The Hematology Journal* (2003) 4, 379-398.